{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### NLP Research Internship Assignment Biomedical Text Analysis\n",
    "*data_extraction_starter.ipynb*"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2023-10-03T11:05:31.381492815Z",
     "start_time": "2023-10-03T11:05:31.217977579Z"
    }
   },
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "[nltk_data] Downloading package stopwords to /home/mahshy/nltk_data...\n",
      "[nltk_data]   Package stopwords is already up-to-date!\n",
      "[nltk_data] Downloading package punkt to /home/mahshy/nltk_data...\n",
      "[nltk_data]   Package punkt is already up-to-date!\n"
     ]
    }
   ],
   "source": [
    "# Import necessary libraries\n",
    "from Bio import Entrez\n",
    "import ssl\n",
    "import nltk\n",
    "nltk.download('stopwords')\n",
    "nltk.download('punkt')\n",
    "import re\n",
    "from nltk.corpus import stopwords\n",
    "from nltk.tokenize import word_tokenize\n",
    "from nltk.stem import PorterStemmer\n",
    "from nltk.stem import WordNetLemmatizer\n",
    "\n",
    "# Bypass SSL certificate verification\n",
    "ssl._create_default_https_context = ssl._create_unverified_context"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2023-10-03T11:36:57.568361552Z",
     "start_time": "2023-10-03T11:36:57.538918524Z"
    }
   },
   "outputs": [],
   "source": [
    "# Function to fetch abstracts from PubMed using MeSH terms\n",
    "def fetch_abstracts(term, max_results=100000):\n",
    "    \"\"\"\n",
    "    Fetch abstracts from PubMed based on search terms.\n",
    "    \n",
    "    Parameters:\n",
    "    term (str): Search term or MeSH term for querying PubMed.\n",
    "    max_results (int): Maximum number of results to fetch.\n",
    "    \n",
    "    Returns:\n",
    "    list: A list of abstracts fetched from PubMed.\n",
    "    \"\"\"\n",
    "    \n",
    "    # Provide contact email for Entrez\n",
    "    Entrez.email = \"info@toxgensolutions.eu\"\n",
    "    \n",
    "    # Perform the search query using Entrez\n",
    "    handle = Entrez.esearch(db=\"pubmed\", term=term, retmax=max_results)\n",
    "    \n",
    "    # Read search results\n",
    "    record = Entrez.read(handle)\n",
    "    handle.close()\n",
    "    \n",
    "    # Extract PubMed IDs from the search results\n",
    "    id_list = record[\"IdList\"]\n",
    "    \n",
    "    # Check if search returned results\n",
    "    if not id_list:\n",
    "        print(\"No results found.\")\n",
    "        return []\n",
    "    \n",
    "    # Fetch abstracts based on PubMed IDs\n",
    "    handle = Entrez.efetch(db=\"pubmed\", id=id_list, rettype=\"abstract\", retmode=\"text\")\n",
    "    \n",
    "    # Read and split the abstracts\n",
    "    abstracts = handle.read().split(\"\\n\\n\")\n",
    "    handle.close()\n",
    "    \n",
    "    return abstracts"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2023-10-03T11:37:54.411543142Z",
     "start_time": "2023-10-03T11:36:58.225722540Z"
    }
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "First 5 abstracts:\n",
      "\n",
      "1. 1. Int J Cancer. 2023 Oct 3. doi: 10.1002/ijc.34745. Online ahead of print.\n",
      "\n",
      "2. Immune landscape of vulvar cancer patients treated with surgery and adjuvant \n",
      "radiotherapy revealed restricted T cell functionality and increased IL-17 \n",
      "expression associated with cancer relapse.\n",
      "\n",
      "3. Gies S(1), Melchior P(2), Stroeder R(3), Tänzer T(1), Theobald L(1), Pohlers \n",
      "M(1), Glombitza B(1), Sester M(4), Solomayer EF(3), Walch-Rückheim B(1).\n",
      "\n",
      "4. Author information:\n",
      "(1)Center of Human and Molecular Biology (ZHMB), Institute of Virology, Saarland \n",
      "University, Homburg, Saar, Germany.\n",
      "(2)Department of Radiation Oncology, Saarland University Medical Center, \n",
      "Homburg, Saar, Germany.\n",
      "(3)Department of Obstetrics and Gynecology, Saarland University Medical Center, \n",
      "Homburg, Saar, Germany.\n",
      "(4)Department of Transplant and Infection Immunology, Saarland University, \n",
      "Homburg, Saar, Germany.\n",
      "\n",
      "5. For vulvar cancers, radiotherapy is targeting cancer cells, but also affects the \n",
      "host immune system. As this may affect treatment outcome, in this prospective \n",
      "study, we characterized the individual T cell immune milieu induced by surgery \n",
      "and adjuvant radio +/- chemotherapy (aRT) systemically in the blood of vulvar \n",
      "cancer patients and found increased frequencies of Interleukin (IL)-17-producing \n",
      "CD4+ and CD8+ T cells after aRT while frequencies of Th1 and perforin-producing \n",
      "CD8+ killer cells were strongly diminished. Phenotypic characterization revealed \n",
      "enhanced expression of the ectonucleotidase CD39 on Th17 and Tc17 cells as well \n",
      "as CD8+ perforin+ cells after aRT. Furthermore, the aRT cohort exhibited \n",
      "increased proportions of Programmed Cell Death Protein (PD-1) expressing cells \n",
      "among Th1 and CD8+ perforin+ cells, but not among Th17 and Tc17 cells. High \n",
      "post-therapeutic levels of Th17 and Tc17 cells and low proportions of Th1 and \n",
      "CD8+ perforin+ cells expressing PD-1 was associated with reduced recurrence free \n",
      "survival on follow-up. In conclusion, our study defines individual \n",
      "therapy-induced changes in the cellular immune milieu of patients and their \n",
      "association with cancer relapse. Our results may help to explain differences in \n",
      "the individual courses of disease of vulvar cancer patients and suggest PD-1 and \n",
      "IL-17 as targets for immunotherapy in vulvar cancer.\n"
     ]
    }
   ],
   "source": [
    "# Define the search term, e.g., \"Cancer Immunotherapy\"\n",
    "search_term = \"Cancer Immunotherapy\"\n",
    "\n",
    "# Fetch abstracts using the search term\n",
    "abstracts = fetch_abstracts(search_term)\n",
    "\n",
    "# Display first 5 abstracts for quick inspection (optional)\n",
    "print(\"First 5 abstracts:\\n\")\n",
    "for i, abstract in enumerate(abstracts[:5]):\n",
    "    print(f\"{i+1}. {abstract}\\n\")"
   ]
  },
  {
   "cell_type": "markdown",
   "source": [
    "## Cleaning and preprocessing data"
   ],
   "metadata": {
    "collapsed": false
   }
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "outputs": [],
   "source": [
    "\n",
    "# remove meta data out of text\n",
    "def remove_metadata(text):\n",
    "    return [line for line in text if not re.match(r'^\\d+\\.',line)]\n",
    "\n",
    "\n",
    "# Tokenization, stopwords removal, and stemming\n",
    "stemmer = PorterStemmer()\n",
    "stop_words = set(stopwords.words('english'))\n",
    "\n",
    "def preprocess_text(text):\n",
    "    # remove special characters and extra spaces\n",
    "    cleaned_text = re.sub(r'[^a-zA-Z0-9\\s]', '', text)\n",
    "\n",
    "    # Convert text to lowercase\n",
    "    cleaned_text = cleaned_text.lower()\n",
    "    \n",
    "     # Tokenize the text into words\n",
    "    tokens = nltk.word_tokenize(cleaned_text)\n",
    "    \n",
    "    # Remove stopwords\n",
    "    tokens = [stemmer.stem(word) for word in tokens if word.lower() not in stop_words]\n",
    "    \n",
    "    # Join the words back into a cleaned text\n",
    "    cleaned_text = ' '.join(tokens)\n",
    "    return cleaned_text\n",
    "\n",
    "# select introduction out of test \n",
    "def select_introduction(abstracts):\n",
    "    cleaned_abstracts = []\n",
    "    for abstract in abstracts:\n",
    "        if abstract[:12] == 'INTRODUCTION':\n",
    "            cleaned_abstracts.append(abstract)\n",
    "    return cleaned_abstracts\n",
    "\n"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-10-03T11:37:54.418606881Z",
     "start_time": "2023-10-03T11:37:54.417057512Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "outputs": [
    {
     "data": {
      "text/plain": "['immun landscap vulvar cancer patient treat surgeri adjuv radiotherapi reveal restrict cell function increas il17 express associ cancer relaps',\n 'gie s1 melchior p2 stroeder r3 tnzer t1 theobald l1 pohler m1 glombitza b1 sester m4 solomay ef3 walchrckheim b1',\n 'author inform 1center human molecular biolog zhmb institut virolog saarland univers homburg saar germani 2depart radiat oncolog saarland univers medic center homburg saar germani 3depart obstetr gynecolog saarland univers medic center homburg saar germani 4depart transplant infect immunolog saarland univers homburg saar germani',\n 'vulvar cancer radiotherapi target cancer cell also affect host immun system may affect treatment outcom prospect studi character individu cell immun milieu induc surgeri adjuv radio chemotherapi art system blood vulvar cancer patient found increas frequenc interleukin il17produc cd4 cd8 cell art frequenc th1 perforinproduc cd8 killer cell strongli diminish phenotyp character reveal enhanc express ectonucleotidas cd39 th17 tc17 cell well cd8 perforin cell art furthermor art cohort exhibit increas proport program cell death protein pd1 express cell among th1 cd8 perforin cell among th17 tc17 cell high posttherapeut level th17 tc17 cell low proport th1 cd8 perforin cell express pd1 associ reduc recurr free surviv followup conclus studi defin individu therapyinduc chang cellular immun milieu patient associ cancer relaps result may help explain differ individu cours diseas vulvar cancer patient suggest pd1 il17 target immunotherapi vulvar cancer',\n '2023 author intern journal cancer publish john wiley son ltd behalf uicc',\n 'doi 101002ijc34745 pmid 37786948',\n '2 biorxiv 2023 sep 2220230919558537 doi 10110120230919558537 preprint',\n 'nsd1 support cell growth regul autophagi hpvneg head neck squamou cell carcinoma',\n 'topchu bychkov gursel makhov p boumber',\n 'head neck squamou cell carcinoma hnscc sixth common cancer worldwid despit advanc therapeut manag immunotherapi fiveyear surviv rate head neck cancer remain 66 diagnos case better definit driver hpvneg hnscc target point tumor vulner could lead signific clinic advanc nsd1 histon methyltransferas catalyz histon h3 lysin 36 dimethyl h3k36me 2 mutat inactiv nsd1 link improv outcom hnscc studi show nsd1 induc h3k36me 2 level hnscc deplet nsd1 reduc hnscc cell growth vitro vivo also find nsd1 strongli promot activ aktmtorc1 signal pathway nsd1 deplet hnscc induc autophag gene program activ caus accumul p62 lc3bii protein decreas autophag signal protein ulk1 protein mrna level reflect signal defect knockdown nsd1 disrupt autophag flux hnscc cell taken togeth data identifi posit regul aktmtorc1 signal autophagi novel nsd1 function hnscc suggest nsd1 may valu therapeut target cancer',\n 'doi 10110120230919558537 pmcid pmc10541623 pmid 37786686',\n '3 front immunol 2023 sep 15141264929 doi 103389fimmu20231264929 ecollect 2023',\n 'revalid attraction4 studi realworld set multicent retrospect propens score match studi china',\n 'dai y1 liu y1 gong z2 l3 wang l2 yang w3 qiu p4 zhang f1 yuan x1 cheng h5 qiu h1',\n 'author inform 1depart oncolog tongji hospit affili tongji medic colleg huazhong univers scienc technolog wuhan hubei china 2depart oncolog xiangyang central hospit affili hospit hubei univers art scienc institut oncolog hubei univers art scienc xiangyang hubei china 3depart oncolog first peopl hospit tianmen tianmen hubei china 4depart oncolog jingzhou central hospit jingzhou hubei china 5institut patholog tongji hospit affili tongji medic colleg huazhong univers scienc technolog wuhan hubei china',\n 'background immunecheckpoint inhibitor ici combin chemotherapi success use clinic trial treat advanc gastric cancer howev efficaci safeti firstlin immunotherapi combin chemotherapi chines patient unknown method multicent retrospect studi includ patient human epiderm growth factor receptor2 her2 neg advanc gastric cancer treat firstlin chemotherapi chemotherapi ici januari 2019 decemb 2022 propens score match use compar progressionfre surviv pf overal surviv object respons rate advers reaction cohort result propens score match 138 patient balanc baselin characterist includ chemotherapi combin treatment group median followup durat 1690 month median pf 853 month 95 confid interv ci 777928 combin treatment group 597 month 95 ci 456737 chemotherapi group median surviv durat 1705 month 95 ci 14181992 combin treatment group 1646 month 95 ci 12991993 chemotherapi group pf subgroup analysi reveal age 65 year women eastern cooper oncolog group perform statu 1 nonsignet ring cell carcinoma esophagogastr junction liver metastasi periton metastasi massiv ascit one metastat organ combin platinumbas chemotherapi correl treatment benefit incid advers event grade 3 compar group conclus studi confirm attraction4 trial result compar chemotherapi firstlin ici combin chemotherapi prolong pf improv overal surviv patient her2neg advanc gastric cancer',\n 'copyright 2023 dai liu gong wang yang qiu zhang yuan cheng qiu',\n 'doi 103389fimmu20231264929 pmcid pmc10541969 pmid 37786611',\n 'conflict interest statement author declar research conduct absenc commerci financi relationship could constru potenti conflict interest',\n '4 front oncol 2023 sep 15131245506 doi 103389fonc20231245506 ecollect 2023',\n 'low radiotherapi dose suitabl brain metastas sclc compar high dose',\n 'xu l1 zhang k1 han h2 sun h3 yuan y4 wang j15 zhao l1 wang p1',\n 'author inform 1depart radiat oncolog tianjin medic univers cancer institut hospit nation clinic research center cancer key laboratori cancer prevent therapi tianjin clinic research center cancer tianjin china 2hubei key laboratori tumor microenviron immunotherapi colleg basic medic scienc china three gorg univers yichang china 3depart radiat oncolog cancer centern clinic research center cancercanc hospit shenzhen hospit chines academi medic scienc peke union medic colleg shenzhen china 4depart anesthesia tianjin medic univers cancer institut hospit nation clinic research center cancer key laboratori cancer prevent therapi tianjin clinic research center cancer tianjin china 5depart radiat oncolog tianjin cancer hospit airport hospit tianjin china',\n 'object studi design evalu suitabl radiotherapi dose sclc patient bm method retrospect analysi perform among 121 patient prognosi bm sclc admit hospit 2013 2023 receiv first line chemotherapi 80 patient receiv trt chemotherapi chi squar method use compar categor data univari surviv analysi estim kaplan meier method logrank use compar surviv curv group multivari prognost analysi made cox proport hazard model io ilc two group low dose high dose analyz propens score match psm result patient median followup time 186 month rang 630857 2year io ilc rate 154 703 respect cerebr necrosi occur 2 patient univari analysi relat io extracrani diseas control p0023 higher dsgpa 2 p0016 immunotherapi p0049 lowdosep0030 wbrtsib p0009 significantli associ increas surviv rate psm 2year io low dose n49 significantli higher high dose n49 p0025 2year ilc significantli improv p0267 dsgpa 2 subgroup io low dose group significantli higher high dose group p0019 dsgpa 2 subgroup 2year ilc low dose group significantli inferior high dose group p0044 conclus ilc improv along increas radiotherapi dose high dose inferior io compar low dose significantli improv ilc radiotherapi bed 56gi patient dsgpa2 subgroup high dose brought better ilc benefit',\n 'copyright 2023 xu zhang han sun yuan wang zhao wang',\n 'doi 103389fonc20231245506 pmcid pmc10541991 pmid 37786509',\n 'conflict interest statement author declar research conduct absenc commerci financi relationship could constru potenti conflict interest',\n '5 ibrain 2022 feb 10811522 doi 101002ibra12017 ecollect 2022 spring',\n 'research progress antiaminobutyr acid b receptor enceph case report paraneoplast associ enceph treatment analysi',\n 'lv yk1 zhang hq1 zhang j1',\n 'author inform 1depart neurolog affili hospit zunyi medic univers zunyi china',\n 'enceph one common diseas neurolog earli diagnosi appropri treatment essenti autoimmun enceph ae gener refer type enceph mediat autoimmun mechan gradual consid import caus revers enceph caus noninfecti factor occur children adolesc adult clinic character multifoc diffus brain damag person chang seizur cognit impair overal good effect immunotherapi accord clinic featur patient blood cerebrospin fluid test neuroelectrophysiolog cranial imag treatment prognosi ae broadli divid specif antigen antibodyrel ae nonspecif antigen antibodi relat ae develop ae research antineuron antibodi found provid import refer diagnosi treatment ae understand knowledg ae import discov new diseas deepen understand immunopatholog mechan exist central nervou system diseas antiaminobutyr acid b gabab receptor enceph type ae diseas rare ae often develop clinic manifest margin enceph accompani obviou seizur statu epilepticu patient tumor mainli smallcel carcinoma prompt diagnosi earli immunotherapi necessari tumor treatment result complet partial neurolog improv patient',\n '2022 author ibrain publish affili hospit zunyi medic univers ahzmu wileyvch gmbh',\n 'doi 101002ibra12017 pmcid pmc10528969 pmid 37786417',\n 'conflict interest statement author declar conflict interest',\n '6 front bioeng biotechnol 2023 sep 15111288806 doi 103389fbioe20231288806 ecollect 2023',\n 'editori role extracellular vesicl ev pathogenesi diagnosi therapeut deliveri treatment theranost applic cancer',\n 'shahbazi r123 kalishwaral k4 paul mk56 anto rj4',\n 'author inform 1divis hematologyoncolog depart medicin indiana univers school medicin indianapoli unit state 2indiana univers melvin bren simon comprehens cancer center indianapoli unit state 3brown center immunotherapi indiana univers school medicin indianapoli unit state 4rajiv gandhi centr biotechnolog thiruvananthapuram india 5depart pulmonari critic care medicin david geffen school medicin univers california lo angel lo angel ca unit state 6depart microbiolog kasturba medic colleg manip academi higher educ manip karnataka india',\n 'doi 103389fbioe20231288806 pmcid pmc10541950 pmid 37786406',\n 'conflict interest statement author declar research conduct absenc commerci financi relationship could constru potenti conflict interest',\n '7 nanoscal 2023 oct 3 doi 101039d3nr03199c onlin ahead print',\n 'cascad nanoplatform regul tumor microenviron combin cancer therapi',\n 'hu x12 zhao w1 li r1 chai k1 shang f3 shi s1 dong c1',\n 'author inform 1depart comprehens cancer therapi shanghai east hospit school medicin shanghai key laboratori chemic assess sustain school chemic scienc engin tongji univers shanghai 200092 china shishuotongjieducn 2school medicin shanghai univers shanghai 200444 china 3colleg aeronaut engin binzhou univers binzhou 256603 china',\n 'recent disulfiram dsf antialcohol drug attract increas biomed interest due anticanc effect howev anticanc activ dsf cuiidepend extrem unstabl sever hinder clinic translat herein report fabric multifunct nanoplatform mcdgf improv stabil diethyldithiocarbam dtc main metabolit dsf modifi aryl boron ester group form prodrug dq also realiz situ gener cudtc2 reli cascad reaction deliv cudq induc immunogen cell death icd power enhanc immun respons cytotox lymphocyt ctl infiltr dendrit cell well cell furthermor graft glucos oxidas gox decompos glucos thu starv cancer cell provid h2o2 product cudtc2 importantli h2o2 significantli promot polar macrophag antitumor subtyp nanocarri mesopor polydopamin mpda also display good phototherm therapeut effect nanoplatformintegr chemotherapi starvat therapi phototherm therapi immunotherapi synergist stimul ctl activ m1 macrophag polar taken togeth asprepar nanoplatform could regul tumor immun microenviron elimin cancer combin cancer therapi offer promis strategi cancer treatment promot clinic applic dsf breast cancer',\n 'doi 101039d3nr03199c pmid 37786260',\n '8 int j radiat oncol biol phi 2023 oct 11172se9 doi 101016jijrobp202306666',\n 'hyperfraction reirradi local recurr thorac tumor',\n 'butler ss1 raclin t1 lau b1 raja n1 chin al1 skinner l1 diehn m1 loo bw jr1 vitzthum l1',\n 'author inform 1depart radiat oncolog stanford univers school medicin stanford ca',\n 'purposeobject patient local recurr thorac tumor second primari within previous irradi volum hyperfraction reirradi rert may mitig late toxic compar convent fraction clinic outcom extens studi herein report institut experi thorac hyperfraction reirradi materialsmethod identifi 26 case among 23 patient treat rert either primari metastat thorac tumor 60 gy 50 fraction twice daili 5 week use highli conform imag guid rt motion manag nineteen patient dosimetri data avail primari outcom grade g2 higher toxic rate per ctcaev50 secondari endpoint 12month local control lc progress free surviv pfsdetermin treat physician andor multidisciplinari tumor boardand overal surviv os result median followup 13 month half nonsmal cell lung cancer 958 ultracentr tumor 577 singl prior thorac rt cours 385 115 115 receiv concurr chemotherapi immunotherapi target agent respect minimum median interv rt cours 10 395 month respect 947 reirradi plan overlap 80 isodos volum median os pf 13 10 month respect crude 12month lc 731 recurr first recurr occur local 6 546 region 3 273 distantli 8 727 patient g2 g3 toxic rate 308 769 respect one g3 atrial fibril one g5 pneumon use american radium societi guidelin thorac reirradi 105 met dose volum constraint recommend conclus definit hyperfraction thorac rert well toler promis local control g3 toxic rare patient counsel low potenti risk lifethreaten toxic consensu guidelin dose constraint may difficult meet reirradi set cohort rate sever toxic low despit exceed put constraint patient',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306666 pmid 37786208',\n '9 int j radiat oncol biol phi 2023 oct 11172se80 doi 101016jijrobp202306825',\n 'clinic outcom thorac radiotherapi extensivestag smallcel lung cancer era immunotherapi retrospect analysi',\n 'zhang c1 zhou z2 deng l1 bi n1 wang w1 xiao z1 wang j2 jr wl1 wang x1 zhang t3 lv j1',\n 'author inform 1depart radiat oncolog nation cancer centern clinic research center cancercanc hospit chines academi medic scienc peke union medic colleg beij china 2depart radiat oncolog nation cancer centern clinic research center cancercanc hospit chines academi medic scienc cam peke union medic colleg pumc beij china 3depart radiat oncolog nation cancer centern clinic research center cancercanc hospit chines academi medic scienc peke union medic colleg beij beij china',\n 'purposeobject chemoimmunotherapi shown signific benefit extensivestag smallcel lung cancer essclc prolong overal surviv os nearli 245 month compar platinumbas chemotherapi alon howev thorac radiotherapi trt allow use previou trial retrospect studi aim evalu safeti effici trt essclc patient era immunotherapi materialsmethod retrospect review essclc patient treat chemoimmunotherapi 2017 2021 center patient accept consolid salvag trt includ overal surviv progressionfre surviv pf local progressionfre surviv lpf distant progress freesurviv dpf calcul use kaplanmei method toxic record base ctcae 50 scale result final enrol 30 patient studi median followup time 260 month 95 confid interv 182338 month 26867 patient undergon firstlin chemotherapi immunotherapi 4133 undergon immunotherapi secondlin agent 23766 patient achiev crprsd initi systemat therapi patient treat trt median dose 51 gy 24602 gy median interv trt immunotherapi 35 day median os 26 month 95 confid interv 178342 month median pf 8 month 95 confid interv 53107 month 2year os pf dpf 514 214 274 respect 18 month lpf 596 g3 radiationrel advers event except 267 g3 esophag g12 pneumon report 8267 patient conclus trt welltoler effect select essclc patient modern era immunotherapi prospect trial still need evalu combin trt immunotherapi patient essclc',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306825 pmid 37786186',\n '10 int j radiat oncol biol phi 2023 oct 11172se79 doi 101016jijrobp202306823',\n 'surviv analysi patient local advanc nonsmal cell lung cancer receiv neoadjuv immunotherapi',\n 'yuji y1 xu y2',\n 'author inform 1depart radiat oncolog shanghai pulmonari hospit affili tongji univers shanghai china 2depart radiat oncolog shanghai pulmonari hospit tongji univers school medicin shanghai china',\n 'purposeobject pacif studi immunoconsolid therapi great surviv benefit patient local advanc nonsmal cell lung cancer progress concurr chemoradiotherapi howev clear evid earlier immunotherapi intervent obtain better surviv benefit patient progress concurr sequenti chemoradiotherapi purpos retrospect studi explor impact earli intervent immunotherapi surviv materialsmethod patient treat concurr sequenti chemoradiotherapi immunotherapi lansclc septemb 2019 decemb 2021 elig timetoev data assess use kaplanmei estim cox proport hazard model use prognost factor analys result accord time immunotherapi use 60 patient la nonsmal cell lung cancer divid neoadjuv group consolid group 30 patient group patient complet concurr sequenti chemoradiotherapi median followup time neoadjuv consolid group 20 18 month neoadjuv group 4 patient die 15 patient develop tumor progress 5 patient distant metastasi consolid group 5 patient die 15 patient develop tumor progress 4 patient distant metastasi median pf neoadjuv group consolid group 19 month 15 month p 0703 group reach median os 1year 2year pf rate 729 633 410 481 1year 2year os rate 930 933 744 766 diseas control rate dcr neoadjuv consolid group 90 littl differ incid advers respons two group conclus earlier immun intervent may result treatment effect similar observ pacif trial suggest benefit immunotherapi could extend broader popul',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306823 pmid 37786182',\n '11 int j radiat oncol biol phi 2023 oct 11172se79 doi 101016jijrobp202306822',\n 'handcraft radiom deep learn radiom predict radiat pneumon nsclc patient treat immunotherapi follow thorac radiotherapi',\n 'yuan z1',\n 'author inform 1depart radiolog hubei cancer hospit tongji medic colleg huazhong univers scienc technolog wuhan pr china wuhan china china',\n 'purposeobject previou studi shown nsclc patient previous receiv immun checkpoint inhibitor ici underw thorac intens modul radiotherapi higher risk acut radiat pneumon rp studi aim establish machin learn model use handcraft radiom hcr deep learningbas radiom dlr clinic characterist improv predict symptomat radiat pneumon rp grade 2 statu nsclc patient treat immunotherapi follow thorac radiotherapi materialsmethod studi retrospect collect data 61 nsclc patient meet requir studi enrol 61 patient 35 develop symptomat grade 2 rp defin 3 region interest roi plan ct imag includ gross tumor volum gtv plan tumor volum ptv ptvgtv calcul mean dose v5 v10 v20 v30 within tlgtv volum gtv ptv total lung total 516 handcraft radiom featur 512 deep featur extract 3 roi person correl analysi least absolut shrinkag select oper lasso use reduc dimens featur hcr model dlr model fusion model across differ roi machin learn classifi built compar result multiclassifi model model ptv logist regress lr classifi show better predict roi differ machin learn algorithm base ptv lr hcr dlr model better perform area curv auc 095 95 confid interv ci 08931 train cohort 087 95 ci 06981 test cohort higher hcr model auc 086 95 ci 075509 train cohort 082 95 ci 06241 test cohort result fusion model hcr dlr 7 clinic characterist includ n clinic stage age smoke radiotherapi alonecombin v30 demonstr best distinguish perform auc 099 95 ci 09701 train cohort 091 95 ci 07841 test cohort conclus combin hcr dlr clinic characterist underw machin learn algorithm improv predict symptomat rp nsclc patient treat ici follow thorac radiotherapi',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306822 pmid 37786181',\n '12 int j radiat oncol biol phi 2023 oct 11172se78 doi 101016jijrobp202306820',\n 'attempt reduc lung dosevolum era radiotherapi combin immunotherapi',\n 'yin x1',\n 'author inform 1shandong cancer hospit jinan shandong china',\n 'purposeobject immunotherapi era safeti thorac radiotherapi especi pneumonia concern clinic patient incid pneumonia keynot 799 higher pacif gemstone301 incid pneumonia relat v20 gy studi aim explor reduc lung dose immunotherapi plu concurr chemoradi therapi ccrt materialsmethod prospect select 32 patient treat imrt untreat local advanc stage iii nsclc receiv immunochemotherapi first cycl treatment complet first ctbase simul second cycl treatment patient receiv ccrt plu ici patient receiv second radiotherapi locat 10 20 fraction radiotherapi initi second treatment plan base ct imag plan1 plan2 volum chang gross tumor volum gtv primari secondari ct scan compar dosevolum paramet lung volum v5 gy v20 gy v30 gy heart volum v30 gy plan2 compar plan1 result compar first second ct scan mean volum gtv decreas 34 dosevolum paramet total lung heart significantli lower plan1among v20 gy v30 gy total lung statist differ z 2068 p 0039 z 3008 p 0003 respect decreas 31 33 respect addit v20 resect 10fraction radiotherapi less 20th v20 gy 251 263 respect meanwhil treatmentrel pneumon one case 5 grade 3 higher pneumon pneumon reliev symptomat treatment conclus mode immunotherapi plu ccrt time reduct measur process radiotherapi effect reduc lung dosevolum v20 gy decreas pulmonari toxic twocycl induct therapi follow radiotherapi may potent treatment candid',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306820 pmid 37786179',\n '13 int j radiat oncol biol phi 2023 oct 11172se77e78 doi 101016jijrobp202306818',\n 'predict lymphopenia surviv baselin absolut lymphocyt count irradi dose immun cell patient nonsmal cell lung cancer treat concurr chemoradiotherapi',\n 'yang g1 yoon hi2 lee jg1 kim j3 kim j1 kim kh1',\n 'author inform 1depart radiat oncolog yonsei cancer center heavi ion therapi research institut yonsei univers colleg medicin seoul korea republ south korea 2depart radiat oncolog yonsei cancer center yonsei univers colleg medicin seoul korea republ south korea 3depart radiat oncolog yonsei univers colleg medicin seoul korea republ south korea',\n 'purposeobject studi aim investig effect effect dose immun cell edic combin preradiotherapi rt absolut lymphocyt count alc treatmentrel lymphopenia rt treatment outcom patient local advanc nonsmal cell lung cancer nsclc subgroup analysi patient receiv consolid immunotherapi also conduct materialsmethod august 2008 decemb 2021 517 patient local advanc nsclc treat definit concurr chemoradiotherapi crt retrospect analyz patient serial completebloodcount test pre duringcrt sever lymphopenia defin alc 05x109cellsl rt edic calcul accord mean dose lung heart total bodi patient group accord high low edic prert alc assess correl radiat induc lymphopenia surviv outcom result 517 elig patient patient receiv weekli paclitaxel carboplatin 903 195 patient 377 receiv consolid immunotherapi follow crt median radiat dose 63 gy iqr 60645 deliv 30 fraction optim cutoff valu edic prert alc predict sever lymphopenia 289 gy 203x109cellsl respect high risk group defin edic 289 gy prert alc 203x109cellsl low risk group edic 289 gy prert alc 203x109cellsl intermedi group edic 289 gy prert alc 203x109cellsl edic 289 gy prert alc 203x109cellsl incid sever lymphopenia rt high intermedi low risk group 901 771 523 respect p0001 risk group independ predictor progressionfre surviv pf p0001 overal surviv os p0001 highrisk group higher incid locoregion distant recurr p0001 subset patient treat consolid immunotherapi risk group predict sever lymphopenia p 0001 pf p 0004 os p 0012 conclus studi demonstr combin edic prert alc predictor sever lymphopenia rt recurr surviv patient local advanc nsclc receiv crt moreov combin edic prert alc may serv potenti biomark benefit mainten immunotherapi',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306818 pmid 37786176',\n '14 int j radiat oncol biol phi 2023 oct 11172se73e74 doi 101016jijrobp202306809',\n 'initi report random trial compar convent vs novel treatment plan techniqu amelior immunosuppress lung sbrt',\n 'wijesooriya k1 larner jm1 read pw2 showalt tn3 lum l2 conaway m2 nguyen c2 lain d4 thakur a2 romano k1 mclaughlin c5 jr emj6 luminai c1 wood s2 cousin df1 chen j2 muller da1 dutta sw7 nesbit ea6 ward ka1 sander j6 chavi y8 asar e6',\n 'author inform 1depart radiat oncolog univers virginia charlottesvil va 2univers virginia charlottesvil va 3depart radiat oncolog univers virginia charlottesvil va univers virginia charlottesvil va 4univers virginia charlottesvil va unit state 5univers virginia depart radiat oncolog charlottesvil va 6univers virginia depart radiat oncolog charlottesvil va 7depart radiat oncolog emori univers atlanta ga 8univers virginia health system charlottesvil va unit state',\n 'purposeobject sbrt highli effect earlystag nonsmal cell lung cancer radiat therapi rt known modul immun system contribut gener antitumor cell stimul cell infiltr tumor howev antitumor activ offset radiationinduc immunosuppress rii result lower tumor control surviv lymphocyt highli radiosensit rii mean destroy exist well newli creat cytotox helper lymphocyt hypothes optim rt treatment plan consid circul blood lymphat critic organ risk oar may mitig rii materialsmethod conduct irb approv nci fund clinic trial 50 earlystag lung cancer patient treat sbrt alon 2020 2023 investig abil reduc rii reduc dose circul blood lymphat aid predict algorithm sbrt plan adher treatment paramet rtog 0813 central rtog 0915 peripher patient random two arm experiment optim rii reduc dose blood lymphat rich organ versu standard sbrt plan without optim rii peripher blood sampl collect baselin end tx 4 week 6 month post tx patient baselin absolut lymphocyt count alc less 05x109 cellsl inelig trial data acquir blood cell type well lymphocyt sub popul cd3 cd4 cd8 cd19 cd56 two sampl ttest use determin statist signific cohort time point result standard arm alc reduct 28 one week post tx nadir 4 week 34 reduct absolut percentag reduct alc baselin optim arm compar standard arm end treatment point 13 p 003 4 week 12 p 008 6 month 15 p 01 three time point togeth 13 p 0001 alc recoveri appear faster optim arm radiat induc suppress blood cell type also reduc optim arm respect standard arm rel percentag alc 34 wbc 47 rbc 46 platelet 40 monocyt 100 neutrophil 62 4week mark averag percentag reduct integr dose v5 volum receiv 5 gy dose optim compar standard plan aorta 26 41 heart 8 33 vena cava 32 52 spine 51 81 lymph node 35 57 total lung itv 16 1 bodi 10 14 conclus first time shown possibl reduc rii statist signific manner compar standard care via optim rt plan use predict model implic increas efficaci immunotherapi preserv exist tumor reactiv cell immun system enhanc antitumor activ reduc hospit improv surviv',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306809 pmid 37786124',\n '15 int j radiat oncol biol phi 2023 oct 11172se72 doi 101016jijrobp202306805',\n 'efficaci safeti pd1pdl1 inhibitor combin radiotherapi patient brain metastas caus nonsmal cell lung cancer multicent retrospect analysi',\n 'wang x1',\n 'author inform 1henan cancer hospit zhengzhou henan china',\n 'purposeobject investig efficaci safeti pd1pdl1 inhibitor plu radiotherapi patient brain metastas bm nonsmal cell lung cancer nsclc materialsmethod 234 elig patient divid pd1pdl1 inhibitor plu intracrani radiotherapi bmrt group immunotherapi nonbmrt group 144 patient bmrt group divid patient receiv extracrani radiotherapi nsclc extrart group nonextrart group accord lung immun prognost index lipi patient stratifi good intermedi poor group toxic assess common terminolog criteria advers event ctcae 50 kaplanmei method logrank test use analyz intracrani progressionfre surviv ipf overal surviv os result median ipf 116 month vs 99 month p 0001 median os 173 month vs 146 month p 0029 signific differ bmrt group nonbmrt group meanwhil median ipf 157 month vs 105 month p0001 median os 202 month vs 151 month p 0024 extrart group longer nonextrart group median ipf 129 month vs 104 vs 84 month p 0001 median os 201 month vs 167 month vs 126 month p 0025 longer good group intermedi group poor group lipi conclus data suggest signific differ ipf os without radiotherapi patient bm nsclc safeti profil lipi help predict prognosi bm nsclc',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306805 pmid 37786101',\n '16 int j radiat oncol biol phi 2023 oct 11172se72e73 doi 101016jijrobp202306807',\n 'improv predict chemoradi immun checkpoint blockad efficaci dynam btmb combin ctdna unresect local advanc nsclc',\n 'wang y1 yang y1 zhang t2 wang j2 wang l3 bi n1',\n 'author inform 1depart radiat oncolog nation cancer centern clinic research center cancercanc hospit chines academi medic scienc peke union medic colleg beij china 2depart radiat oncolog nation cancer centern clinic research center cancercanc hospit chines academi medic scienc cam peke union medic colleg pumc beij china 3depart radiat oncolog nation cancer centercanc hospit shenzhen hospit chines academi medic scienc peke union medic colleg shenzhen china',\n 'purposeobject consolid durvalumab definit chemoradi therapi crt becom new standard care patient unresect local advanc nonsmallcel lung cancer lansclc howev fraction patient benefit current decisionmak procedur limit accuraci bloodbas tumor mutat burden btmb promis biomark whether btmb alon combin circul tumor dna ctdna predict efficaci definit crt immun checkpoint inhibitor ici patient lansclc remain unclear materialsmethod cohort studi enrol patient diagnos unresect lansclc 2018 2022 patient assign cohort receiv definit crt alon intens modul radiat therapi volumetr modul arc therapi prescrib dose 60 gy concurr sequenti two cycl platinumbas doublet chemotherapi cohort b undergo definit crt immunotherapi peripher blood specimen collect crt subject nextgener sequenc panel analyz ctdna btmb dynam chang btmb btmb calcul btmb level crt minu baselin btmb level potenti correl identifi spearman correl test express r coeffici timedepend receiv oper characterist curv area curv auc employ evalu predict power differ model surviv result total 73 lansclc patient includ 70 959 stage iii 3 stage ii 41 thirtysix patient 493 assign cohort treat crt alon 37 507 cohort b receiv crt ici patient crt ici cohort b show significantli improv overal surviv os p 001 progressionfre surviv pf p 002 crt alon baselin btmb cutoff valu 4 22 predict outcom p 010 patient increas btmb btmb 0 crt significantli wors os pf p 001 decreas stabl btmb btmb 0 btmb independ ctdna level crt p 076 r 004 patient divid 3 group base btmb postcrt ctdna btmb 0detect ctdna vs btmb 0detect ctdna vs btmb 0undetect ctdna signific surviv differ observ pairwis comparison 3 group p 005 model btmb combin postcrt ctdna statu exhibit optim predict power os auc 080 pf auc 075 outperform factor respect valid cohort b well conclus dynam btmb btmb combin postcrt ctdna statu novel effect biomark model predict surviv outcom lansclc patient treat crt ici outperform individu featur',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306807 pmid 37786099',\n '17 int j radiat oncol biol phi 2023 oct 11172se70 doi 101016jijrobp202306801',\n 'plasma exosom mirna respons biomark immunotherapi extensivestag smallcel lung cancer',\n 'wang b1 chen j2 fan m1',\n 'author inform 1depart radiat oncolog fudan univers shanghai cancer center shanghai china 2depart oncolog shanghai medic colleg fudan univers shanghai china',\n 'purposeobject immunotherapi combin chemotherapi becom firstlin standard treatment patient extensivestag smallcel lung cancer essclc reliabl biomark stratifi true respond immunotherapi effect unknown urgent identifi novel biomark clinic exosom mirna consid play role intercellular commun among immun cell interact immun cell tumor cell purpos studi explor possibl use plasmaderiv exosom mirna potenti biomark identifi respons immunotherapi essclc materialsmethod march 2020 septemb 2021 24 patient essclc receiv pdl1 inhibitor enrol tumor assess conduct everi two treatment cycl accord recist 11 plasma sampl patient collect administ pdl1 inhibitor baselin everi four cycl occurr diseas progress plasma exosom isol ultracentrifug total rna extract mirna profil analyz small rna nextgener sequenc follow differenti express analysi result 24 patient 15 underw immunotherapi mainten complet four cycl pdl1 inhibitor plu chemotherapi order identifi biomark better respons immunotherapi five respond patient achiev pr four nonrespond patient achiev pd tumor assess within eight cycl mainten phase includ differenti express analysi surprisingli hsamir320c hsamir320d hsamir320 show trend increas express nonrespond compar respond baselin significantli downregul posttreat plasma exosom compar pretreat sampl respond conclus exosom mirna profil discord respond nonrespond antipdl1 treatment hsamir320c hsamir320d hsamir320 identifi potenti biomark predict efficaci immunotherapi patient essclc',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306801 pmid 37786053',\n '18 int j radiat oncol biol phi 2023 oct 11172se68e69 doi 101016jijrobp202306797',\n 'surviv outcom oligometastat vs polymetastat extensivestag small cell lung cancer follow consolid thorac radiotherapi',\n 'verma n1 ninia jg1 hayman tj1 housri n1 peter gw1 knowlton ca1 campbel am1 park hsm1',\n 'author inform 1depart therapeut radiolog yale school medicin new ct',\n 'purposeobject patient limit metastat burden metastasisdirect radiotherapi shown associ improv os certain type cancer howev prior trial includ patient essclc yet clear patient oligometastat essclc improv outcom polymetastat essclc ctrt materialsmethod identifi patient treat ctrt essclc 20132020 singl institut oligometastat diseas defin time diagnosi three fewer organ distant diseas organ three fewer metastat lesion patient consid polymetastat kaplanmei estim logrank test multivari cox proport hazard regress use compar os progressionfre surviv pf local recurrencefre surviv lrf new metastasisfre surviv nmf oligometastat polymetastat essclc patient undergo ctrt result among 70 includ patient 36 defin oligometastat patient receiv platinumdoublet chemotherapi ct immunotherapi given 7 194 oligometastat patient 5 147 polymetastat patient p 056 median followup time 382 month multivari cox regress analysi show oligometastat diseas vs polymetastat diseas diagnosi associ improv os hazard ratio hr 044 95 ci 025078 p 0005 1year os 861 vs 469 2year os 471 vs 151 pf lrf nmf significantli differ cohort among oligometastat patient pleural involv hr 244 95 ci 102583 p 0046 lung involv hr 493 95 ci 102239 p 0047 associ inferior os among 26 36 722 oligometastat patient neither pleural bilater lung involv 1year os 885 2year os 583 conclus observ oligometastat essclc patient treat ctrt especi without pleural bilater lung involv superior os polymetastat diseas encourag enrol nrg lu007raptor random trial determin impact complet incomplet consolid rt 5 site essclc especi oligometastat diseas',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306797 pmid 37786002',\n '19 int j radiat oncol biol phi 2023 oct 11172se655 doi 101016jijrobp2023062084',\n 'radioimmun respons model radiotherapi plan heterogen dose distribut',\n 'cho yb1 yoon n2 scott jg3',\n 'author inform 1depart radiat oncolog taussig cancer institut cleveland clinic cleveland oh 2adelphi univers garden citi ny 3cleveland clinic cleveland oh',\n 'purposeobject order model immun respons tumor patient radiotherapi cancer characterist numer model preliminari applic present materialsmethod immun respons model 4 set ordinari differ equat ode function biomed variabl includ amount tumor antigen natur releas tumor activ cytotox tlymphocyt ctl radiat immun suppress tumor volum use immunotherapi drug effect heterogen radiat dose distribut also consid hyperbol tangent function account immunogen respons tissu highli heterogen dose distribut intent modul spatial fraction radiotherapi boundari behavior model investig tumor differ biomed characterist differ treatment condit develop model appli tumor volum chang mous 67nr tumor radiat 10 gy full half volum tumor clinic patient treat sarcoma three time 4 year result tumor growth exponenti earli phase slow time increas immun respons eventu reach equilibrium condit known termin tumor volum tumor littl immun suppress capabl isc even lack radiat treatment breakingthrough equilibrium tumor grow exponenti happen isc larger bifurc threshold analyt calcul propos model tumor isc close bifurc threshold show complex growth behavior depend treatment condit care consid optim treatment tumor volum chang 30 day period mous model well model full dose irradi reduc tumor volum faster first 10 day half volum irradi reduc tumor volum faster later stage due improv immun respons model tradit linear quadrat model tumor volum patient retreat three time 4 year also accur estim conclus propos immun respons model capabl estim tumor volum respons full partial volum irradi consid complex immun characterist tissu',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023062084 pmid 37785944',\n '20 int j radiat oncol biol phi 2023 oct 11172se654e655 doi 101016jijrobp2023062083',\n 'radioimmun respons spatial fraction radiotherapi vmat lattic plan',\n 'cho yb1 guo b2 xia p2 campbel sr2 yu js3 suh jh4 scott jg5',\n 'author inform 1dep radiat oncolog taussig cancer institut cleveland clinic cleveland oh 2depart radiat oncolog taussig cancer institut cleveland clinic cleveland oh 3cleveland clinic lerner colleg medicin case western reserv univers cleveland oh 4depart radiat oncolog taussig cancer center cleveland clinic cleveland oh 5dept radiat oncolog taussig cancer institut cleveland clinic cleveland oh',\n 'purposeobject evalu radioimmun respons spatial fraction radiotherapi sfrt larg tumor use vmat lattic techniqu term tumor volum irradi dose fraction scheme sfrt materialsmethod eleven patient treat sfrt singl institut retrospect replan deliv 15gi singl fraction use lattic techniqu high dose region defin multipl sphere diamet 125 15cm vertex space 30 40cm insid gtv vmat plan multipl arc develop sfrt four palli fraction regimen 200cgi x 12 eqd2 24gi ab 10gi 400cgi x 5 233gi 600cgi x 3 24gi 800cgi x2 24gi four definit regimen 200cgi x 24 eqd2 48gi 400cgi x 10 467gi 600cgi x 6 48gi 800cgi x 4 48gi consid radiotherapi follow sfrt linear quadrat lq model compar radioimmun ri respons model activ cytotox lymphocyt tumor immun suppress capabl immunotherapi drug consid tumor regrowth time trt time tumor regrowth origin volum treatment model compar measur benefit achiev applic sfrt result averag volum gtv studi 776cc rang 582944cc three differ sfrt plan 2d grid techniqu convent collim 2d grid step shoot imrt 3d lattic develop patient lattic plan consid studi sinc produc compar dose modul insid tumor lattic significantli reduc skin critic organ dose radioimmun respons model alway expect longer trt lq model palli regimen trt ri model longer lq model 14599 151106 172124 175128 day fraction scheme lattic plan 15gi deliv palli treatment differ becom 259153 315233 367276 375285 day benefit sfrt ri respons 1020 day interestingli ri respons invers proport tumor volum cur dose consid differ trt drastic chang 25998 46072858 118089857 1512013275 day 20744 44904117 1725421710 3517745317 day benefit sfrt ri respons appear larger larg tumor hypofraction definit regimen conclus benefit sfrt signific larg tumor hypo fraction definit regimen radioimmun respons model consid appar lq model radioimmun respons model may help guid develop success treatment scheme larg tumor volum',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023062083 pmid 37785943',\n '21 int j radiat oncol biol phi 2023 oct 11172se65e66 doi 101016jijrobp202306791',\n 'use mri radiom predict efficaci immunotherapi brain metastasi patient small cell lung cancer',\n 'shi x1 wang p2 li y1 xu j1 yu j3 teng f4',\n 'author inform 1depart radiat oncolog shandong provinci key laboratori radiat oncolog shandong cancer hospit institut shandong first medic univers shandong academi medic scienc jinan shandong china 2shandong cancer hospit institut cheeloo colleg medicin shandong univers jinan china 3shandong cancer hospit shandong univers jinan shandong china 4depart radiat oncolog shandong cancer hospit institut shandong first medic univers shandong academi medic scienc jinan shandong china',\n 'purposeobject immunecheckpoint inhibitor ici combin chemotherapi wide use firstlin treatment small cell lung cancer sclc patient howev efficaci ici patient brain metastas bm sclc limit effect factor predict efficaci develop valid model predict intracrani efficaci ici patient bm sclc use mri radiom materialsmethod studi collect 101 sclc patient bm treat ici clinic characterist pretreat magnet reson imag mri collect seventi case collect hospit train cohort 31 case collect anoth hospit independ valid cohort brain metastat lesion contour itksnap softwar 3748 radiom featur captur intra peritumor textur pattern extract primari endpoint studi intracrani overal respons rate orr intraclass correl coeffici icc random forest rf model use select radiom featur top 10 select radiom featur adopt build prognost model use logist regress area curv auc receiv oper characterist roc chosen metric assess model perform also perform nomogram base multivari logist regress model includ radiom clinic featur predict ici intracrani efficaci result clinic characterist includ number treatment line concurr brain radiotherapi ten intratumor signatur one peritumor signatur found significantli associ ici intracrani efficaci predictor contain individu predict nomogram includ radiom signatur clinic featur model show favor discrimin cindex 086195 ci 07790943 auc 086195 ci 0778 0944 train cohort cindex 081295 ci 06470978 auc 081295 ci06460979 test cohort conclus radiom featur pretreat mri imag predict intracrani efficaci sclc patient bm pretreat radiom may allow earli predict benefit expedit aggress treatment highrisk patient explor predictor outcom larger seri patient',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306791 pmid 37785933',\n '22 int j radiat oncol biol phi 2023 oct 11172se65 doi 101016jijrobp202306790',\n 'use mri radiom predict efficaci immunotherapi brain metastasi patient nonsmal cell lung cancer',\n 'xu j1 wang p2 li y1 shi x1 yu j3 teng f4',\n 'author inform 1depart radiat oncolog shandong provinci key laboratori radiat oncolog shandong cancer hospit institut shandong first medic univers shandong academi medic scienc jinan shandong china 2shandong cancer hospit institut cheeloo colleg medicin shandong univers jinan china 3depart radiat oncolog shandong provinci key laboratori radiat oncolog shandong cancer hospit institut shandong first medic univers shandong academi medic scienc jinan shandong china shandong cancer hospit institut shandong first medic univers shandong academi medic scienc jinan shandong china 4depart radiat oncolog shandong cancer hospit institut shandong first medic univers shandong academi medic scienc jinan shandong china',\n 'purposeobject despit immun checkpoint inhibitor ici proven effect patient advanc nsclc controversi therapeut respons seen brain metastat lesion robust biomark predict benefit regimen evalu util novel imag biomark radiom distinguish nsclc patient brain metastas bm benefit ici like progress despit therapi materialsmethod onehundr seventyfour nsclc patient bm treat ici june 2019 june 2022 identifi collect patient clinic outcom pretreat mri imag imag split train test set brain metastat lesion contour itksnap softwar 3748 radiom featur captur intra peritumor textur pattern extract primari endpoint studi intracrani progressionfre surviv ipf secondari object progressionfre surviv pf overal surviv os use least absolut shrinkag select oper lasso cox regress model build radiom signatur orr base support vector machin svm model construct clinicalradiom nomogram crn multivari cox regress analysi perform evalu effect factor ipf perform kaplanmei surviv analysi logrank test assess prognost valu featur result identifi 174 patient fit criteria avail mri imag 122 patient treat center divid train set 52 patient treat anoth center divid test set intratumor radiom signaturesir peritumor radiom signaturespr crn show favor predict effect orr area receiv oper curv auc ir 0845 95 ci 07760914 pr 0799 95 ci07200879 crn0907 95 ci 08550959in train set ir 0809 95 ci 06930926 pr 0749 95 ci06160883 crn088895 ci07980979 test set kaplanmei analys show significantli longer ipf highcrn group versu lowcrn group p 0001 crn also found significantli associ pf p 0001 os conclus radiom biomark pretreat mri imag nsclc patient bm predict ipf ici pretreat radiom may allow earli predict benefit expedit aggress treatment highrisk patient addit valid imag biomark warrant',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306790 pmid 37785932',\n '23 int j radiat oncol biol phi 2023 oct 11172se637 doi 101016jijrobp2023062041',\n 'realworld treatment pattern older adult local advanc scchn use seermedicar',\n 'zhou sq1 ng c2 wang r2 gasior g2 schrader d2 baliga s3 fox d2',\n 'author inform 1genesi research hoboken nj 2genentech inc south san francisco ca 3the ohio state univers columbu oh',\n 'purposeobject roughli 5067 patient squamou cell carcinoma head neck scchn present local advanc la diseas 65 relaps initi therapi standard care la scchn definit therapi dt combin surgeri radiat therapi rt without platinumbas chemotherapycetuximab chemo shown optim long term diseas control publish analys character recent realworld treatment tx pattern older adult la scchn us materialsmethod use surveil epidemiolog end result seermedicar databas linkag cancer registri claim data identifi patient diagnos la scchn first cancer 2010 2017 initi relev tx tx initi date defin index date continu enrol medicar part b 12 month preindex death 12 month postindex use clinic guidelin regard time frequenc treatment build algorithm use medicar claim categor initi tx nondt nonsurg dt concomit chemort ccrt chemotherapi rtccrt surgic dt surgeri rtccrt prior chemo result identifi 1052 older adult la scchn median age 73 year 37 femal 81 nonhispan white whose initi treatment start median 26 day initi diagnosi 610 patient receiv dt initi tx 233 patient subsequ tx 38 receiv immunotherapycontain regimen io common subsequ tx surgeri 77 chemotherapi 36 rt 34 median time next tx ttnt differ dt categori primari tumor site tabl 1 conclus descript analysi provid updat tx pattern older adult la scchn us novel fda approv decad found larg proport 42 patient receiv dt regimen realworld set despit known benefit la scchn roughli quarter patient requir subsequ tx avail io low due approv 2017 find suggest need novel therapi improv outcom la scchn',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023062041 pmid 37785899',\n '24 int j radiat oncol biol phi 2023 oct 11172se629 doi 101016jijrobp2023062022',\n 'determin optim sequenc immunotherapi lymph node irradi among patient cancer propens score match analysi',\n 'taparra k1 benevent r2 gimmen m2 kekumano k3 pollom e4',\n 'author inform 1stanford cancer institut stanford ca 2harvard medic school boston 3harvard univers cambridg 4depart radiat oncolog stanford univers school medicin stanford ca',\n 'purposeobject immunotherapi lymph node irradi lni essenti cancer treatment modal combin optim sequenc enhanc tumor respons poorli understood lni deplet radiosensit itrel immun cell lni also provid immunostimulatori effect shed tumor neoantigen microenviron aim 1 assess lni sequenc pattern among patient common cancer 2 evalu propens score ps match overal surviv os first lni first treatment 3 compar os cancer site materialsmethod ps match retrospect cohort studi conduct use nation cancer databas primari endpoint os time diagnosi death patient age 18 year breast gi pancrea colorect liver gu prostat kidney bladder lung lymphoma melanoma oral caviti cancer includ patient underw lni incomplet treatment time exclud follow lni first compar lni follow lni first ps perform 11 match standard mean differ cutoff 01 covari balanc ps match age stage comorbid index facil type upfront lymph node surgeri unadjust kaplanmei km estim logrank test assess os multivari cox proport hazard cph model adjust patient demograph compar first versu lni first adjust hazard ratio ahr 95 confid interv 95 ci model stratifi cancer site result total 23238 patient treat lni includ 88 patient underw first median interquartil rang iqr age followup 57 4866 year 39 2753 month respect cancer includ 74 breast 8 oral caviti 6 gi 5 lymphoma 4 lung 2 gu 1 melanoma median iqr week treatment 7 413 first 8 417 lni first unadjust analysi os significantli inferior lni first overal p0001 breast p0001 gi p 004 lymphoma p 0003 oral caviti cancer p 005 signific differ os gu lung melanoma ps match adjust cph analysi lni first significantli higher risk death overal ahr 32 95 ci 3034 compar first ps match cancer stratifi analys found os significantli inferior lni first breast ahr 15 95 ci 1218 gi ahr 12 95 ci 1114 gu ahr 13 95 ci 1018 lymphoma ahr 18 95ci 1326 oral caviti cancer aor 13 95 ci 1115 conclus ps match analys reveal superior os patient receiv first lni breast gi gu lymphoma oral caviti cancer find suggest import intact immun system prior futur prospect studi warrant valid find',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023062022 pmid 37785878',\n '25 int j radiat oncol biol phi 2023 oct 11172se61 doi 101016jijrobp202306780',\n 'associ proton pump inhibitor use sever pneumon stage iii nonsmallcel lung cancer treat primari chemoradi adjuv durvalumab',\n 'sun gy1 edward dm1 miller sr1 elliott da1 hamstra da2 chen ac3 green m1 bryant ak1',\n 'author inform 1depart radiat oncolog univers michigan ann arbor mi depart radiat oncolog veteran affair ann arbor health system ann arbor mi 2depart radiat oncolog baylor colleg medicin houston tx 3depart radiat oncolog baylor colleg medicin houston tx depart radiat oncolog michael e debakey veteran affair medic center houston tx',\n 'purposeobject prior studi suggest gut microbiom chang induc longterm acidreduc medic use could modul immunotherapi efficaci toxic assess relationship baselin acidreduc medic use proton pump inhibitor ppi h2 antagonist h2a treatmentrel toxic efficaci larg cohort stage iii nonsmallcel lung cancer nsclc patient treat without immunotherapi materialsmethod patient unresect stage iii nsclc treat primari concurr chemoradi without adjuv durvalumab 2015 2021 identifi veteran affair va system defin baselin acidreduc medic use va nonva pharmaci record year prior radiat start number prescript cumul durat therapi quantifi use multivari cox model adjust potenti baselin confound stratifi adjuv durvalumab use estim associ ppi h2a use subsequ sever pneumon progressionfre surviv overal surviv pneumon determin grade manual chart review result includ 1994 patient stage iii nsclc treat primari chemoradi 1005 50 receiv adjuv durvalumab 1064 53 receiv ppi 1030 52 receiv h2a overal sampl baselin use ppi associ increas risk grade 35 pneumon adjust hazard ratio ahr 153 95 ci 112210 p 0008 found signific durvalumabtr patient ahr 167 95 ci 110254 p 0016 patient treat without durvalumab ahr 134 95 ci 082220 p 02 higher number ppi prescript associ increas risk sever pneumon ahr 138 per 5 prescript 95 ci 103185 p 003 longer durat ppi trend toward signific ahr 104 per 90 day 95 ci 100109 p 0066 ppi use associ wors os durvalumabtr patient ahr 130 95 ci 105161 p 0016 patient without durvalumab use ahr 099 95 ci 086114 p 09 ppi use associ progressionfre surviv either cohort signific associ baselin h2a use pneumon pf os either cohort seen conclus ppi h2a associ increas risk treatmentrel pneumon inferior os stage iii nsclc patient treat chemoradi immunotherapi associ observ among patient treat chemoradi alon associ found ppi use cancer progress work warrant confirm find immunotherapytr cohort',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306780 pmid 37785836',\n '26 int j radiat oncol biol phi 2023 oct 11172se603e604 doi 101016jijrobp2023061970',\n 'combin radiotherapi chemotherapi immunotherapi firstlin treatment de novo metastat nasopharyng carcinoma dualcent retrospect analysi',\n 'l1 xiang x1 lan f2 chen p1 lei l1 zou t1 wu r3 zhang j1',\n 'author inform 1nation cancer centern clinic research center cancercanc hospit shenzhen hospit chines academi medic scienc peke union medic colleg shenzhen china 2nation cancer centern clinic research center cancercanc hospit shenzhen hospit chines academi medic scienc peke union medic colleg shenzhen guangdong china 3depart radiat oncolog nation cancer centern clinic research center cancercanc hospit chines academi medic scienc peke union medic colleg beij china',\n 'purposeobject local region radiotherapi combin system chemotherapi significantli improv prognosi patient metastat nasopharyng carcinoma npc immunochemotherapi becom firstlin treatment initi metastat npc studi evalu safeti efficaci local region radiotherapi combin immunochemotherapi firstlin treatment metastat npc materialsmethod patient histolog proven de novo metastat npc receiv immunotherapi chemotherapi follow localregion radiotherapi includ 2 cancer center toxic treatment respons assess use ctcae 50 recist 11 respect overal surviv os progress free surviv pf analyz use kaplanmei method result 2019 2021 total 16 patient retrospect analyz median age 445yearold rang 1676 patient 3 metastat lesion account 588 bone metastasi common metastat site chemotherapi regimen paclitaxelgemcitabin cisplatin toripalimab camrelizumab sintilimab use immunotherapi patient complet local region radiotherapi 6996gi primari nasopharyng tumor posit lymph node 6006gi highrisk region 505445gi lowrisk region seven patient underw radiotherapi metastat lesion median followup 205 month rang 638 month twoyear os 100 three patient experienc distant progress oneyear 2year pf rate 938 767 respect combin chemotherapi immunotherapi overal respons rate orr 937 complet respons cr 63 end radiotherapi orr 100 nine patient 563 achiev cr radiotherapi relat acut sever grade 3 higher toxic dermat 116 63 mucos 216 125 immunotherapi relat hypophys capillari hyperplasia 63 63 respect longterm toxic observ conclus locoregion radiotherapi provid promis efficaci modest toxic patient metastat nasopharyng carcinoma receiv immunochemotherapi',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023061970 pmid 37785819',\n '27 int j radiat oncol biol phi 2023 oct 11172se602 doi 101016jijrobp2023061966',\n 'glitter gold examin cost effect analys radiat oncolog',\n 'mutsaer a1 tan vs2 youssef a3 nguyen t2 suchit a4 boldt g5 palma da2 zaric g6 qu m2 louie av1',\n 'author inform 1depart radiat oncolog odett cancer centr sunnybrook health scienc centr univers toronto toronto canada 2divis radiat oncolog western univers london health scienc centr london canada 3durham region cancer centr oshawa canada 4western univers london canada 5depart radiat oncolog western univers london canada 6ivey busi school western univers london canada depart epidemiolog biostatist western univers london canada',\n 'purposeobject cost effect analys cea provid data health polici decis resourc constrain environ import radiat oncolog infrastructur deliveri cost increas indic expand purpos studi systemat review methodolog qualiti trend cea involv radiotherapi rt materialsmethod systemat review perform cost effectivenessutil studi involv rt queri pubm embas incept septemb 2020 nonenglish review abstract costonli studi exclud independ review screen abstract studi demograph econom paramet methodolog detail result screen 1652 abstract 214 met criteria first public 1995 half n 113 53 publish 2014 author institut north america n 128 60 europ n 49 23 asia n 30 14 report us n 143 67 major util decis model n 164 77 healthcar payer perspect n 171 80 finit time horizon n 108 50 public span 96 uniqu journal commonli intern journal radiat oncolog biolog physic n 35 16 treatment intent cur 171 studi diseas site includ breast n 34 16 genitourinari n 31 14 gastrointestin n 31 14 rt mostli use primari treatment n 144 67 follow adjuv n 70 33 neoadjuv n 10 5 emerg topic includ stereotact rt n 45 21 immunotherapi n 6 3 oligometastasi n 4 2 heavi particl n 23 11 rt compar rt n 136 64 surgeri n 43 20 drug n 14 7 observ n 31 17 incomplet report common miss element includ analysi perspect n 13 6 time horizon n 38 18 discount util n 71 33 cost n 54 25 willingnesstopay threshold n 59 28 furthermor 27 studi perform sensit analys 36 evalu increment costeffect ratio 60 explicitli util recogn report guidelin conflict interest statement found 63 sponsor statement 59 25 industri sponsor outcom paramet obtain primari author institutiontri data sourc 33 includ random trial rct n 20 9 retrospect data n 20 9 popul data n 9 4 remaind util secondari sourc includ rct n 71 33 retrospect data n 35 16 metaanalys n 11 5 outcom includ qualiti adjust life year n 158 74 lifeyear n 30 14 toxic n 2612 31 util author gener util literatur deriv 49 match diseas clinic context conclus cea increasingli common rt report methodolog rigor must improv greater use publish guidelin improv data qualiti decis maker',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023061966 pmid 37785817',\n '28 int j radiat oncol biol phi 2023 oct 11172se594e595 doi 101016jijrobp2023061949',\n 'outcom patient treat reirradi recurr head neck cancer use pencil beam scan proton therapi',\n 'krc rf1 mend w2 molitori jk2 ferri mj2 mehra r3 papadimitri j4 hatten k4 taylor r5 wolf j5 bentzen sm6 sun k6 regin wf jr2 tran pt2 witek me7',\n 'author inform 1depart radiat oncolog univers maryland medic center baltimor md 2depart radiat oncolog univers maryland school medicin baltimor md 3univers maryland cancer center baltimor md unit state 4univers maryland baltimor md 5depart otorhinolaryngolog head neck surgeri univers maryland school medicin baltimor md 6divis biostatist bioinformat univers maryland greenebaum cancer center depart epidemiolog public health univers maryland school medicin baltimor md 7depart radiat oncolog univers maryland school medicin madison wi',\n 'purposeobject reirradi rert recurr head neck cancer hnc prior hnc radiat therapi rt clinic challeng given prior radiat nearbi organ risk oar describ clinic outcom toxic pencil beam scan proton therapi pbspt recurr hnc materialsmethod perform retrospect analysi recurr hnc patient treat singl institut pbspt baselin demograph diseas treatment characterist record local control lc locoregion control lrc progress free surviv pf distant metastasi free surviv dmf overal surviv os estim use kaplanmei method uva complet use logist regress mva perform use backward elimin model also report acut late grade 3 toxic outcom grade per ctcae v50 result total 89 patient treat pbspt recurr hnc 2016 2022 includ primari site includ oropharynx 300 oral caviti 225 sinonas caviti 157 larynx 124 nasopharynx 67 common tumor histolog scc 730 median time rert 47 month median dose pbspt 60 gy rang 4072 506 receiv bid treatment median gtv volum 30cc rang 481083cc 24 patient receiv concurr system therapi 46 cytotox 45 immunotherapi median followup pbspt 8 month rang 071 median os 13 month 95 ci 93167 median pf dmf 7 month 95 ci 5090 9 month 95 ci 53127 respect 1 2year lc rate 808 95 ci 708908 662 95 ci 507817 1 2year dmf 410 95 ci 300520 263 95 ci 157369 uva mva smaller gtv volum associ improv os hr 1002 p 004 dmf hr 1002 p 0004 pf hr 1002 p 0014 addit shorter time rert associ wors lrc hr 1003 p 0002 higher kp associ improv pf hr 057 p 004 31 acut grade 3 toxic event 21 patient common odynophagia 90 follow mucos 56 dehydr dermat 45 one patient grade 4 toxic laryng edema requir intub 40 day complet rert one patient acut grade 5 toxic oropharyng bleed 74 day complet rert 35 late toxic event n 27 common dysphagia n 7 79 one patient suffer late grade 5 osteoradionecrosi result sepsi conclus pbspt recurr hnc result effect diseas control favor toxic patient smaller gtv volum appear improv os pf dmf may better candid shorter time rert also wors lrc howev distant failur df compris major failur pattern biomark identifi patient risk df may improv clinic decis make',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023061949 pmid 37785794',\n '29 int j radiat oncol biol phi 2023 oct 11172se593 doi 101016jijrobp2023061945',\n 'character antibodi repertoir patient hpvrelat hnscc undergo definit radiat immunotherapi',\n 'kim s1 sumner w1 miyauchi s1 jone rn2 mell lk3 sharabi a1',\n 'author inform 1uc san diego moor cancer center depart radiat medicin appli scienc la jolla ca 2uc san diego san diego ca 3univers california san diego la jolla ca',\n 'purposeobject integr immun checkpoint inhibitor ici immunotherapi agent definit treatment head neck squamou cell carcinoma hnscc challeng appar understand therapi affect specif compon immun respons critic improv outcom role b cell increasingli recogn especi hpv hnscc antibodi one chief downstream product b cell sought evalu antibodi repertoir patient hpv hnscc undergo definit radiat therapi rt ici rtici materialsmethod serum sampl patient p16 hnscc undergo rtici collect keychain clinic trial nct03383094 analyz 8 sampl 4 patient collect pretreat 3 month follow treatment use huprot human proteom microarray sampl 20000 human protein gene encod surfac protein gesp obtain cancer surfaceom atla mutat data obtain aacr project geni murin studi c3h mice inject 5x105 cell at84e7ova syngen scc right flank antipdl1 ici apdl1 given via intraperiton inject everi 3 day 3 dose rt 12 gy 1 fraction cell surfac marker lymph node ln analyz flow cytometri result total detect antibodi 10959 uniqu antigen pretreat serum 14 11 share 3 4 patient respect follow complet rtici detect antibodi 11019 uniqu antigen 20 18 share 3 4 patient respect 5824 53 antigen detect pretreat serum therefor repres antibodi newli detect antigen found 777 antigen newli detect share least 2 patient analysi antigen reveal enrich pathway respons oxygen level next found 114 147 repres gesp integr mutat analysi frequent mutat gene 1800 hnscc sampl found 2114 gesp share use murin model hpv hnscc found treatment rt apdl1 led greatest frequenc germin center gc b cell tumordrain nontumordrain ln conclus patient p16posit hnscc proteom analysi antibodi repertoir reveal mani antigen antibodi form rtici share patient intriguingli gc format nidu b cell respons locoregion ln greatest rtici find support investig bcell mediat respons hpv hnscc',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023061945 pmid 37785792',\n '30 int j radiat oncol biol phi 2023 oct 11172se587 doi 101016jijrobp2023061933',\n 'longterm outcom stereotact bodi radiat therapi without pd1 inhibitor metastat nasopharyng carcinoma',\n 'yang j1 j1 han j1 zeng n1 liao w2',\n 'author inform 1depart head neck oncolog cancer center west china hospit sichuan univers chengdu sichuan china 2sichuan cancer hospit institut sichuan cancer center cancer hospit affili univers electron scienc technolog china chengdu china',\n 'purposeobject data benefit stereotact bodi radiat therapi sbrt patient metastat nasopharyng carcinoma mnpc remain limit purpos studi assess outcom mnpc treat sbrt program deathligand 1 pd1 inhibitor materialsmethod review sbrt perform patient mnpc period 20132022 institut treatment carri abl intent stereotact condit dosefract 5 gy consid local control lc overal surviv os progressionfre surviv pf rate calcul use kaplanmei analys risk factor assess univari multivari analysi cox regress result total 55 patient 77 metastat lesion treat sbrt analyz patient receiv system treatment either chemotherapi alon n 34 chemotherapi pd1 inhibitor n 21 28 patient 509 five metastat lesion metastat site number irradi tumor rang 1 6 36 patient 655 47 lesion receiv physic dose 48 gy bed75gi 10 median followup 436 month rang 191153 month 20 patient 364 experienc local recurr complet sbrt metastat lesion 1 3year lc rate 769 619 respect 1 3year os rate 844 582 1 3year pf rate 500 299 respect patient 2 metastat lesion n 24 436 signific better lc hr 011 95 ci 00360313 p0001 os hr 024 95 ci 008074 p 0013 pf hr 016 95 ci 0063042 p0001 patient with2 metastat lesion total dose48 gy also found signific prognost factor better os hr 044 95 ci 018109 p 0044 pf hr 042 95 ci 017088 p 0005 lc hr 084 95 ci 036197 p 0678 addit ad pd1 inhibitor sbrt show signific benefit improv 2year lc 877 vs 506 sbrt hr 027 95 ci 018 041 p 0002 patient experienc grade 4 5 toxic conclus sbrt effect safe treatment option mnpc patient ad pd1 inhibitor sbrt offer benefit lc addit studi explor clinic benefit predict biomark combin sbrt pd1 direct immunotherapi warrant',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023061933 pmid 37785778',\n '31 int j radiat oncol biol phi 2023 oct 11172se582e583 doi 101016jijrobp2023062518',\n 'tempor incid pattern distant failur human papillomaviru hpv relat oropharyng cancer',\n 'gaffney j1 ramzan a2 dinizulu t3 onamusi do4 motamedighahfarokhi g4 mistri h4 price g5 garcez k3 hugh c3 thomson dd1 lee lw3 jain y2 price jm3 mcpartlin a6',\n 'author inform 1the christi nh foundat trust manchest unit kingdom 2depart radiolog christi nh foundat trust manchest unit kingdom 3depart clinic oncolog christi nh foundat trust manchest unit kingdom 4the univers manchest manchest unit kingdom 5the christi nh foundat trust manchest unit kingdom univers manchest manchest unit kingdom 6radiat medicin program princess margaret cancer centr univers health network toronto canada',\n 'purposeobject hpv relat oropharyng cancer hpvopc enjoy improv treatment outcom rel nonhpv relat diseas suffer similar rate distant metastas dm follow treatment emerg data support radic intent therapi oligometastat relaps hpvopc suggest earli diagnosi dm may benefici outcom assess tempor pattern distanc relaps investig ration post treatment imag materialsmethod retrospect singl center cohort studi carri consecut hpvopc treat radic intent chemoradiotherapi ctrt 2011 2020 electron record review identifi locat time develop dm oligometastat om state defin 5 metastasi one system result total 793 hpvopc patient identifi median followup 315 year rang 0289 median time recurr 151 month rang 2663 month 87 dm occur first two year treatment pattern failur stage shown tabl 1 indic scan perform identifi dm alon symptom 66 followup imag base previou radiolog find 15 diseas respons assess imag 15 incident find 4 site distant metastasi lung 64 thorac node 365 bone 27 viscer 23 brain 4 skin 2 site viscer metastasi involv includ liver 92 adren 18 kidney 18 spleen 9 treatment offer patient om alon best support care 46 palli chemotherapi 154 palli rt 23 immunotherapi 8 one patient lost follow 8 sbrt avail time period median surviv follow diagnosi 175 month rang 44854 month conclus despit routin imag beyond initi treatment respons assess identifi small minor hpv opc patient om recurr associ better outcom occasion longterm cure aggress therapi major 69 dm occur thoraxupp abdomen patient first two year post treatment find support potenti util regular imag thoraxupp abdomen earli follow',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023062518 pmid 37785768',\n '32 int j radiat oncol biol phi 2023 oct 11172se58e59 doi 101016jijrobp202306775',\n 'combin model ct radiom clinic paramet risk cachexia extensivestag small cell lung cancer patient treat firstlin immunotherapi',\n 'song r1 li b1 yao y1 wang l1',\n 'author inform 1depart radiat oncolog shandong cancer hospit institut shandong first medic univers shandong academi medic scienc jinan china',\n 'purposeobject cachexia occur 60 patient extensivestag small cell lung cancer essclc may contribut resist immunotherapi studi integr ct radiom clinic paramet aim identifi patient risk develop cachexia may associ prognosi extensivestag small cell lung cancer patient treat firstlin immunotherapi materialsmethod studi retrospect includ 200 essclc patient treat firstlin immunotherapi patient randomli divid train cohort valid cohort accord ratio 73 clinic characterist ct imag treatment collect univari multivari logist regress analys conduct evalu predict role clinic characterist 3d slicer use retriev radiom featur ct imag level third lumbar vertebra l3 radiom signatur conduct use least absolut shrinkag select oper lasso receiv oper characterist roc curv analysi delong test perform determin compar predict perform radiom clinic combin model result patient divid train n 140 valid n 60 cohort surviv analysi indic inferior pf 73 vs 87 month p 00053 os 79 vs 93 month p 000099 patient cachexia multivari analysi indic pretherapeut lactat dehydrogenas ldh posttreat advanc lung cancer inflamm index pretreat bmiserum albuminnl independ risk factor cachexia total 883 radiom featur obtain patient ct scan four ct featur select build radiom signatur radiom signatur achiev area curv auc 0706 95 ci 06240780 train cohort 0610 95 ci 04750733 valid cohort combin model achiev auc 0769 0674 train valid cohort respect perform better clinic model radiom model kaplanmei surviv analysi show train cohort pf p 00012 os p 00007 significantli longer among patient low rs compar patient high rs valid cohort similar result could also observ train cohort pf p 0029 os p 0091 estim respect conclus combin model base ct clinic paramet improv perform predict cachexia essclc patient receiv firstlin immunotherapi provid novel strategi clinician identifi essclc patient may suffer cachexia earli intervent would improv prognosi respons immunotherapi',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306775 pmid 37785762',\n '33 int j radiat oncol biol phi 2023 oct 11172se58 doi 101016jijrobp202306774',\n 'sabrseq random phase ib trial sabr sequenc pembrolizumab metastat nonsmal cell lung cancer nsclc',\n 'siva s1 mcmahon r2 bressel m2 dsouza c3 castl rg4 diiulio j3 jennen r3 thai a3 tan l3 morri t5 dawson sj2 shaw m3 plumridg n3 neeson p2 ball dl2 solomon b2',\n 'author inform 1peter maccallum cancer centr sir peter maccallum depart oncolog univers melbourn melbourn australia 2peter maccallum cancer centr sir peter maccallum depart oncolog univers melbourn melbourn vic australia 3peter maccallum cancer centr melbourn vic australia 4peter maccallum cancer centr melbourn australia 5southern blood cancer servic dunedin new zealand',\n 'purposeobject optim sequenc stereotact abl bodi radiotherapi sabr antipd1 checkpoint blockad unknown purpos sabrseq assess toxic combin sabr deliv either commenc pembrolizumab central hypothesi treatment combin safeti profil clinic accept demonstr antitumor efficaci furthermor hypothes differ system immun activ observ treatment arm materialsmethod singl institut phase ib random clinic trial trial id nct03307759 elig patient metastat nsclc ecog perform 01 receiv prior checkpoint immunotherapi highdos radiat 36 gy within 6 month either system radiat therapi within 4 week random elig patient either tps50 pdl1 express firstlin tps1 pdl1 express prior chemotherapi exposur patient random sabr commenc pembrolizumab arm1 sabr commenc pembrolizumab arm2 sabr deliv singl fraction 1820 gy 13 lesion primari endpoint treatmentrel advers event ae relat sabr andor pembrolizumab secondari endpoint includ best overal respons bor overal surviv os progressionfre surviv pf translat object includ evalu longitudin chang immunolog cellular subset within peripher blood explor chang system immun circul tumor dna ctdna dynam result decemb 2017 decemb 2019 13 patient random median followup 37 month studi close earli due poor accrual median age 66 year 11 patient 84 adenocarcinoma nine 69 enrol firstlin set median rang number lesion 6 311 median rang cycl pembrolizumab deliv arm 1 13 1232 arm 2 9 334 grade 3 treatmentrel ae experienc 0 5 patient arm1 1 8 patient arm 2 hyperglycemia grade 4 5 advers event report bor recist irecist criteria cr one patient pr seven patient sd five patient median 95 ci pf 124 month 63210 median 95 ci os 471 month 126not reach 2year point estim 62 3182 mass cytometri use serial peripher blood sampl examin chang frequenc immun cell chang cell activ differenti function polar state target sequenc perform assess ctdna translat outcom present conclus evid concern safeti signal either sabr start pembrolizumab combin demonstr activ promis pf os worthi evalu larger random trial',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306774 pmid 37785761',\n '34 int j radiat oncol biol phi 2023 oct 11172se572e573 doi 101016jijrobp2023061904',\n 'impact dosimetr paramet local control toxic head neck sbrt',\n 'chitti bs1 fraser m1 cooper dj2 wint a1 seetharamu n3 ghali m4',\n 'author inform 1northwel health cancer institut lake success ny 2zucker school medicin hofstranorthwel hempstead ny 3northwel health new hyde park ny 4depart radiat medicin northwel health cancer institut lake success ny',\n 'purposeobject sbrt potenti use local therapi head neck cancer patient requir reirradi well may candid surgic resect lengthi cours convent fraction radiat therapi object studi assess rate local control sbrt well impact mucos dosimetr paramet rate grade 3 higher toxic patient treat head neck sbrt materialsmethod retrospect review patient within institut underw sbrt cancer oral caviti oropharynx 2013 2022 primari endpoint local control lc grade 3 higher toxic potenti attribut sbrt base ctcae 50 analyz follow endpoint potenti predictor toxic 1 ratio total oral mucos volumeor mucos volum outsid ptv 2 mean dose oral mucosa 3 maximum dose oral mucosa conduct regress analysi determin predictor local failur sever toxic estim local control use kaplanmei analysi result treat 66 tumor 60 patient median age 71 year 41 patient 683 oral caviti cancer 19 316 oropharynx cancer 64 tumor 970 squamou cell carcinoma 32 tumor 485 previous irradi mean ptv volum 55 cc rang 394741 cc median prescrib radiat dose 40 gy given 5 biweekli fraction total 51 patient receiv system therapi platinumbas chemotherapi 52 cetuximab 38 10 patient 167 addit receiv immunotherapi constitut 56 18 patient treat 20192022 median pain score present 310 oral pain nonsignificantli increas 3 week 3 month start treatment subsequ return baselin sbrt p 0227 local control 685 median follow 98 month oral caviti tumor 1 2year local control rate 787 431 respect 1 2year rate lc 789 502 oropharynx tumor grade 3 higher toxic present 18 patient 300 includ osteonecrosi 6 100 ulcer extens tissu necrosi 12 200 signific relationship present mucos surfac radiat dose acut oral mucosa toxic regress analysi local control grade 3 higher toxic find signific associ prior radiat diseas site age ptv volum conclus sbrt provid compar local control tumor oropharynx oral caviti slightli higher 2year local control tumor oropharynx compar rate toxic appreci increas use immunotherapi studi popul 2019 onward find relationship dosimetr paramet rate grade 3 higher toxic local control though analysi limit small sampl size',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023061904 pmid 37785745',\n '35 int j radiat oncol biol phi 2023 oct 11172se57e58 doi 101016jijrobp202306773',\n 'molecular statu predict local control patient nonsmal cell lung cancer spinal metastas follow spine stereotact bodi radiotherapi',\n 'shor d1 zeng kl2 chen h2 louie av2 menjak i3 atenafu e4 tseng cl2 detski j2 larouch j5 zhang b2 soliman h2 maralani p6 myrehaug sd2 sahgal a2',\n 'author inform 1sunnybrook odett cancer centr toronto canada 2depart radiat oncolog odett cancer centr sunnybrook health scienc centr univers toronto toronto canada 3sunnybrook health scienc centr toronto canada 4princess margaret cancer centr univers health network toronto canada 5divis orthoped surgeri sunnybrook health scienc centr toronto canada 6depart neuroradiolog sunnybrook health scienc centr univers toronto toronto canada',\n 'purposeobject report outcom spine stereotact bodi radiotherapi sbrt patient metastat nonsmal cell lung cancer nsclc determin signific program deathligand 1 pdl1 statu epiderm growth factor egfr mutat local failur lf rate materialsmethod total 165 patient 389 spinal segment retrospect review 2009 2021 baselin patient characterist treatment outcom abstract primari endpoint lf secondari outcom includ overal surviv os vertebr compress fractur vcf rate os estim use kaplanmei method cumul lf vcf rate calcul use compet risk analysi method multivari analysi mva evalu factor predict lf vcf result median followup 13 month rang 0595 month median os 184 month 95 ci 114246 median age 67 year rang 282899 52 femal 76 adenocarcinoma histolog 61 smoke histori 49165 29 egfr mutat pdl1 statu analyz 109165 66 patient 16 pdl1 50 20 pdl1 149 35 pdl1 1 389 segment 79 de novo 21 previous radiat baselin 35 vcf 27 epidur diseas 27 paraspin extens 49 spinal instabl neoplasia score sin stabl 239389 61 treat either 24 28 gy 2 sbrt fraction within 1 month sbrt 39165 24 tyrosin kinas inhibitor 27165 16 immunotherapi io without chemotherapi 31165 19 chemotherapi alon lf cumul incid 1 2year 163 95 ci 128203 254 95 ci 20930 respect egfr posit p00001 pdl150 p 0013 treatment io within 1 month sbrt p 0004 predict improv local control mva 1 2year lf rate egfrposit vs neg patient 129 vs 166 177 vs 288 respect pdl1 50 vs pdl150 78 vs 196 78 vs 381 respect cumul incid vcf 1 2year 66 95 ci 4494 88 95 ci 61120 mva identifi prior sbrt treat segment p00001 baselin vcf p00001 signific predictor 18389 46 radiationinduc radiculopathi radiat myelopathi event detect conclus identifi predict util egfr mutat pdl1 50 statu local control nsclc patient spinal metastas treat spine sbrt therapeut benefit perisbrt io',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306773 pmid 37785740',\n '36 int j radiat oncol biol phi 2023 oct 11172se566 doi 101016jijrobp2023061890',\n 'toxic outcom definit local therapi elderli patient hpvassoci oropharyng cancer',\n 'barv r1 blakaj dm1 yildiz v2 jhawar sr1 mitchel dl1 konieczkowski dj1 gogineni e1 bhateja p3 bonomi m3 baliga s1',\n 'author inform 1depart radiat oncolog ohio state univers wexner medic center columbu oh 2the ohio state univers wexner medic center columbu oh 3depart medic oncolog ohio state univers wexner medic center columbu oh',\n 'purposeobject incid human papillomaviru hpv associ oropharyng squamou cell carcinoma hpvopscc increas elderli patient unclear surviv outcom elderli patient similar seen younger patient hpvopscc studi evalu diseas outcom toxic elderli hpvopscc popul treat curativeint treatment radiotherapi without chemotherapi materialsmethod perform retrospect studi elderli patient 70 year old hpvopscc treat 20112021 radiat therapi rt without chemotherapi time event analysi overal surviv os local control progress free surviv pf estim use kaplanmei method univari multivari cox regress model use estim hazard ratio associ covari result identifi 77 elderli hpvopscc patient 60 78 treat concurr chemotherapi twenti 26 receiv concurr carboplatin taxol 16 21 receiv cetuximab 14 18 receiv cisplatin7 9 receiv carboplatin alon 2 2 receiv immunotherapi pembrolizumab nivolumab major patient receiv radiat dose 6996 gy 70 gy 89 fortyseven patient 61 stage 11 14 stage ii 16 21 stage iii 3 4 stage iv diseas 50 patient 64 former smoker 27 35 nonsmok 1 1 current smoker 37 patient 48 10 pack year smoke histori 5year os lc pf entir cohort 61 94 58 respect univari analysi ecog perform statu hr 022 ci 006078 p 0019 charlson comorbid index cci hr 133 ci 106169 p 0014 signific predictor os multivari analysi cci hr 134 ci 102177 p 0035 signific predictor os rate longterm feed tube depend 9 late toxic includ osteoradionecrosi 4 patient 5 aspir 3 patient 4 esophag strictur 2 patient 3 conclus elderli hpvopscc patient treat definit intent radiotherapi without chemotherapi favor diseas outcom low rate late toxic charlsoncomorbid index identifi subset patient may prolong os therefor may benefit aggress treatment',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023061890 pmid 37785731',\n '37 int j radiat oncol biol phi 2023 oct 11172se556e557 doi 101016jijrobp2023061869',\n 'valu progressionfre surviv three year primari endpoint studi radiotherapi patient local advanc cervic cancer individu patient data valid 27 random trial',\n 'yang x1 j1 zhang y1 yang y2 jia s1 li w1 huang m1 wu l1',\n 'author inform 1nation cancer centern clinic research center cancercanc hospit chines academi medic scienc peke union medic colleg beij china 2fujian key laboratori intellig imag precis radiotherapi tumor fujian medic univers fuzhou china',\n 'purposeobject tradit endpoint local advanc cervic cancer lacc clinic trial overal surviv os five year followup present mani clinic trial evalu concurr chemoradiotherapi combin immunotherapi lacc underway worldwid use shorterterm endpoint could significantli speed translat research find practic primari hypothesi pf three year followup pfs36 appropri primari endpoint replac os five year followup 5year os materialsmethod primari hypothesi develop individu data investig use phase iii random control trial rct extern valid phase ii trial retrospect studi 2022 correl analysi treatmentarm level perform 2 3 4 5year pf rate 5year os use pearson correl coeffici r weight linear regress weight equal patient size medlin embas pubm databas togeth cochran central regist control trial search januari 1 1999 februari 2 2023 articl elig inclus contain complet surviv data result total 613 patient histolog confirm figo 2009 stage ibiva cervic cancer underw radiotherapi institut januari 2010 decemb 2013 elig individu patient data pool explor correl pf os trend recurr rate year 1 5 129 73 3 23 18 respect median recurr time 13 month median time recurr death 122 month within recurr 473 recurr occur first year 714 first two year 85 first three year patient achiev pfs36 5year os rate 303 contrast 5year os rate 982 observ patient achiev pfs36 data extract 27 rct local advanc cervic cancer trial includ 57 arm pool sampl size 7692 patient formal measur surrogaci satisfi qualiti control perform studi high risk bia exclud triallevel surrogaci pfs36 r2 0778 associ 5year os correl pfs36 os extern valid use independ phase ii trial retrospect data total 23 studi repres 5174 patient includ pfs36 r2 0719 found associ os conclus patient achiev pfs36 excel outcom wherea patient experienc earlier progress poor surviv signific correl found pfs36 5year os clinic trial patient local advanc cervic cancer result suggest pfs36 appropri endpoint lacc clinic trial radiotherapybas regimen',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023061869 pmid 37785708',\n '38 int j radiat oncol biol phi 2023 oct 11172se555 doi 101016jijrobp2023061865',\n 'role radiat therapi metastat cervic cancer',\n 'wu f1 tang x2 zhang y1 wei l1 wang t1 lu z1 wei j1 s1 jiang l1 gao t1 huang q1',\n 'author inform 1depart radiat oncolog first affili hospit guangxi medic univers nan guangxi china 2depart radiat oncolog first affili hospit guangxi medic univers nan guangxi china depart radiat oncolog liuzhou peopl hospit liuzhou guangxi china',\n 'purposeobject surviv rate women metastat cervic cancer cc low limit manag option radiat therapi rt metastat diseas led prolong surviv malign howev data scarc cc herein evalu effect rt metastat cc materialsmethod total 58 patient metastat cc septemb 2019 januari 2023 retrospect analyz patient treat platinumbas chemotherapi combin target therapi immunotherapi follow without rt nrt recent efficaci surviv statu prognost factor analyz statist result object respons rate orr 636 one complet twenti partial respons rt group n 33 400 two complet eight partial respons nrt group n 25 respect p 0074 diseas control rate dcr rt nrt group 794 vs 800 respect p 0861 median followup time 17 month 339month rt group 11333 patient experienc local region distant failur 9 273 patient dead nrt group 1560 patient progress 8 32 patient dead signific differ two group overal surviv os howev rt group display superior progressionfre surviv pf 1year os 727 vs 680 p 0460 1year pf 667 vs 400 p 0039 multivari analysi show rt immunotherapi lymph node metastasi relev predictor superior pf os subgroup analysi patient treat rt appear better pf specif cohort age45 year 720 vs 364 p 0015 squamou carcinoma histolog 710 vs 409 p 0017 metastat diagnosi 750 vs 476 p 0012 nontarget therapi 724 vs 438 p 0040 signific increas treatmentrel toxic observ rt group compar nrt group conclus rt provid superior pf metastat cc patient compar nrt well toler moreov rt immunotherapi lymph node metastasi independ signific prognost factor pf subgroup analysi show combin rt chemotherapi obtain favor pf metastat cc patient age45 year squamou carcinoma histolog metastat diagnosi nontarget therapi studi larger sampl size longer followup warrant',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023061865 pmid 37785704',\n '39 int j radiat oncol biol phi 2023 oct 11172se553 doi 101016jijrobp2023061861',\n 'poor surviv outcom patient stage iiic2 cervic cancer receiv concurr chemoradiotherapi',\n 'wang w1 zhang fq1 hu k2',\n 'author inform 1depart radiat oncolog peke union medic colleg hospit chines academi medic scienc peke union medic colleg beij china 2peke union medic colleg hospit chines academi medic scienc peke union medic colleg beij china',\n 'purposeobject patient cervic cancer paraaort lymph node metastasi stage iiic2 accord 2018 figo stage system studi evalu surviv toxic outcom patient stage iiic2 cervic cancer receiv concurr chemoradiotherapi materialsmethod includ patient stage iiic2 cervic cancer receiv definit concurr chemoradiotherapi institut 2007 2015 treatment consist intens modul radiat therapi imrt deliv dose 504 gy 28 fraction pelvic paraaort lymph node region escal dose 6070 gy posit lymph node dose 30 gy 5 fraction deliv intracavitari brachytherapi firstlin chemotherapi regimen weekli cisplatin result total 88 patient includ studi median followup period patient surviv patient 20 month rang 5114 month 62 month rang 5114 month respect median surviv 209 month 1year 3year 5year 8year overal surviv rate 734 413 345 253 respect progressionfre surviv rate 508 297 284 212 local control rate 586 522 522 428 respect multivari analysi show number posit paraaort lymph node histolog type independ factor affect progressionfre surviv 5year progressionfre surviv rate 402 0 patient one two posit paraaort lymph node respect 301 214 patient squamou cell carcinoma adenocarcinoma respect grade 3 higher toxic observ 8 patient 91 includ 4 patient 45 gastrointestin toxic 4 patient 45 genitourinari toxic conclus result studi suggest surviv outcom patient stage iiic2 cervic cancer receiv concurr chemoradiotherapi poor treatment option consolid chemotherapi immunotherapi consid patient',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023061861 pmid 37785699',\n '40 int j radiat oncol biol phi 2023 oct 11172se548e549 doi 101016jijrobp2023061851',\n 'predict valu circul exosom pdl1 cervic cancer immunotherapi',\n 'tang w1 guo q1 chen j1 wu q1 zhang t1 wang q1 zhang x1 xie p2',\n 'author inform 1shandong cancer hospit institut shandong first medic univers shandong academi medic scienc jinan china 2shandong cancer hospit institut jinan shandong china',\n 'purposeobject program death ligand 1 pdl1 express wildli use predictor immun checkpoint inhibitor ici effici howev emerg result show pdl1 great heterogen sampl time site recent studi found exosom pdl1exopdl1 relat ici respons studi aim explor predict valu exopdl1 ici treatment cervic cancer cc first time materialsmethod total 40 primarili diagnos cc patient accept radic radiotherapi rt march 2021 octob 2022 includ consecut tumor sampl collect rt anoth 37 advanc cc patient accept ici combin therapi june 2020 octob 2022 enrol studi blood sampl collect particip treatment exosom deriv differenti centrifug identifi western blot wb cd9tsg101calnexin transmiss electron microscop analysi nanoparticl track analysi exopdl1 detect conduct enzymelink immunosorb assay elisa knockout pdl1 conduct via crisprcas9 assay overexpress pdl1 conduct lentivir transfect cd8 cell extract murin spleen cd8 cell isol kit immun cell cytokin marker detect multicolor flow cytometri result consecut detect pdl1 show dynam chang rt compar level rt pdl1 express elev patient 875 3540 rt respond n 18 elev exopdl1 level first two circl ici combin therapi p0001 wherea level pretreat exopdl1 couldnt stratifi clinic respond nonrespond p 0181 median followup time 1413 month mpf increas group vs decreas group reach vs1102 month p 0025 hr 0218 00520913 continu blood sampl mice model also found effect therapeut intervent could increas exopdl1 earli stage combin exosom inhibitor gw4869 antipd1 inhibit tumor growth mice inject extern exopdl1o exopdl1ko result show exopdl1o suppress bodi immun promot tumor growth result flow cytometri show exopdl1o inhibit cd8 cell releas interferonand granzym b exopdl1o also suppress cd8 cell prolifer murin spleen cocultur cd8 cell exosom vitro also confirm conclus conclus compar unstabl impression tumor pdl1 exopdl1 seem better predictor efficaci immunotherapi cc easi access continu exosom pdl1 play immunosuppress role inhibit prolifer function factor releas cd8 cell',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023061851 pmid 37785688',\n '41 int j radiat oncol biol phi 2023 oct 11172se543 doi 101016jijrobp2023061839',\n 'favor toxic local control ultrahypofraction radiat therapi uhrt melanoma lower genit tract lgt',\n 'silver b1 white c2 zhang z3 shoushtari a4 leitao mm4 william vm5 alektiar km4 kollmeier ma6',\n 'author inform 1suni downstat medic center brooklyn ny 2depart epidemiolog biostatist memori sloan ketter cancer center new york ny 3depart epidemiolog biostatist memori sloan ketter cancer center new york ny 4memori sloan ketter cancer center new york ny 51959 ne pacif street box 356043 seattl wa 6depart radiat oncolog memori sloan ketter cancer center new york ny',\n 'purposeobject report experi use uhrt immunotherapi io women melanoma lgt materialsmethod retrospect identifi 23 patient receiv uhrt primari tumor vulvovagin melanoma 2012 2022 median age 69 year iqr 6276 stage includ local node posit metastat 18 78 tumor involv vaginacervix 5 22 vulvar tumor 6 patient ckit mutat 13 patient wildtyp 4 patient unknown 12 52 treat initi present cohort 11 48 local progressionrecurr follow prior therapi cohort b cohort n 11 receiv concurr io cohort b 3 recur surgeri alon 4 system therapi alon 4 surgeri system therapi rt consist 6 gy x 6 n 11 6 gy x 5 n 10 5 gy x 56 n 2 deliv primari tumor 05 cm margin patient initi io either 3 month prert n 8 concurr rt n 12 3 month follow rt n 2 1 patient cohort b receiv io toxic grade use ctcae v 5 overal surviv os measur end rt cumul incid local progress measur end rt kaplanmei method cox regress use surviv analys landmark method use time io median followup determin revers kaplanmei method 60 month 95 ci 37na result overal incid acutel grade 2 toxic entir cohort 34 grade 2 acut toxic includ dermat n 3 urinari n 2 vagin n 2 diarrhea n 1 3 patient experienc grade 3 acut dermat 1 patient experienc late grade 2 vagin grade 3 4 toxic note signific differ toxic note rt regimen local diseas control achiev 61 patient local local distant distantonli progress seen 17 22 30 patient respect 2year cumul incid local progress 33 whole cohort 28 cohort 36 cohort b p 04 uva factor associ local progress vulvar diseas p 002 ckit mutat p 0011 signific differ local control note base biolog effect dose bed10 48gi vs 48gi p 006 median os entir cohort cohort cohort b 46 72 30 month respect 2year surviv 95 ci 67 5091 73 51100 64 4199 respect uva nonloc diseas time rt p 0016 receipt io 3 month prior rt p 0030 wors os conclus uhrt io melanoma lgt welltoler local diseas control achiev 61 patient vulvar primari ckit mutat associ wors local control addit followup may necessari determin valu dose escal',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023061839 pmid 37785676',\n '42 int j radiat oncol biol phi 2023 oct 11172se54e55 doi 101016jijrobp202306767',\n 'comorbid impact treatment toler outcom elderli nsclc patient treat concurr chemoradi use proton photon follow immunotherapi',\n 'sasaki ym1 xu t1 koutroumpaki s1 sheshadri a1 deswal a1 nguyen qn1 gandhi s1 cascon t2 le x3 altan m4 chen ab1 liao z1',\n 'author inform 1depart radiat oncolog univers texa md anderson cancer center houston tx 2univers texa md anderson cancer center houston tx 3depart thorac head neck medic oncolog univers texa md anderson cancer center houston tx 4depart thoracichead neck medic oncolog univers texa md anderson cancer center houston tx',\n 'purposeobject investig comorbid impact treatment toler surviv elderli nsclc patient treat concurr chemoradi use proton beam therapi pbt intens modul radiat therapi imrt follow immunotherapi io materialsmethod retrospect studi senior patient 65 year inoper local advanc nsclc lansclc receiv concurr chemoradi crt therapi follow adjuv io comorbid list tabl 1 score accord hazard ratio hr death treatment toler comorbid compar modal use fisher exact test associ comorbid treatment toler analyz use logist regress associ comorbid surviv analyz cox proport hazard regress result total 218 patient includ median age 72 rang 6586 year fiftythre 243 pbt 165 757 imrt major patient white ethnic stage iii adenocarcinoma diseas good perform score receiv rt dose 6066 gy median followup time whole group 23 month 97 patient 1 62 4 comorbid combin comorbid score rang 0 25 signific differ comorbid modal except imrt patient copd 36 vs 51 p 0047 rate hospit er visit crtio 28 5 respect rate io discontinu interrupt 55 8 respect patient receiv 6 month io significantli lower risk death hr 025 p0001 signific differ treatment toler modal multivari analysi atrial fibril pulmonari diseas depress comorbid associ hospit crtio p005 dementia comorbid associ io interrupt p 0042 heart failur copd asthma osteoporosi hiv comorbid associ poor os p005 combin comorbid score associ os hr 113 p0001 adjust race gtv induct chemotherapi conclus comorbid associ hospit io interrupt whole cours crt io therapi increas io discontinu neg impact surviv evalu score comorbid diagnosi could use method predict risk death treatment start',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306767 pmid 37785668',\n '43 int j radiat oncol biol phi 2023 oct 11172se52 doi 101016jijrobp202306762',\n 'longterm surviv patient brainonli metastat lung cancer undergo upfront intracrani stereotact radiosurgeri definit treatment thorac primari site',\n 'salari k1 ye h1 seymour za1 jr kcl2 chinnaiyan p1 grill is1',\n 'author inform 1depart radiat oncolog corewel health william beaumont univers hospit royal oak mi 2depart radiat oncolog beaumont health royal oak mi',\n 'purposeobject evalu modern clinic outcom patient brainonli metastat lung cancer treat intracrani stereotact radiosurgeri sr without definit treatment primari site materialsmethod patient new diagnosi lung cancer synchron brainonli metastat diseas treat intracrani sr identifi prospect maintain singl institut databas patient stratifi base whether group receiv group b definit primari site treatment defin surgic resect radiat therapi rt dose 40 gy patient demograph treatment detail record intrathorac distant bodi intracrani progress well overal surviv os cancerspecif surviv css record 2 5y rate estim use kaplanmei method univari uva multivari analysi mva perform determin predictor os result 20082022 107 patient identifi 57 patient receiv definit primari site treatment forti receiv upfront seventeen receiv consolid treatment median 9 month diagnosi 45 patient underw fraction rt median dose 60 gy rang 4574 gy 9 underw sbrt median dose 50 gy 5 fraction rang 4060 gy 3 lobectomi median followup 27 12 b p001 median number brain metastas 1 rang 117 82 13 18 4 signific differ patient age sex race smoke statu histolog target mutat ajcc nstage receipt system therapi number volum brain metastas neurolog deficit resect brain metastas group 82 72 b patient t14n13 16 24 b t13n0 32 56 patient group receiv immunotherapi ici versu 19 38 group b p 0048 differ intracrani progressionfre surviv pf p 017 cnsrelat death p 030 group 2 5y estim os 614 385 versu 283 0 b p 0002 2 5y css 838 642 versu 486 0 b p 0002 2 5year intrathorac pf 90 75 versu 55 55 b p001 2 5y distant bodi pf 493 32 versu 173 0 b p 0001 uva definit primari site treatment receipt immunotherapi young age signific predictor os remain signific mva conclus definit treatment thorac primari site patient brainonli metastat lung cancer intracrani radiosurgeri associ reduc rate intrathorac progress also lower rate distant system progress improv overal cancerspecif surviv',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306762 pmid 37785620',\n '44 int j radiat oncol biol phi 2023 oct 11172se511 doi 101016jijrobp2023061768',\n 'program death ligand 1pdl1 express vulvar cancer prognost locoregion control',\n 'elgohari b1 patwardhan pp2 abdelhakiem mk1 bhargava r2 sukumvanich p3 courtneybrook m3 boisen mm3 berger jl3 taylor s3 olawaiy a3 lesnock j3 edward rp3 beriw s4 soong tr2 vargo jaa 4th1',\n 'author inform 1upmc hillman cancer center depart radiat oncolog univers pittsburgh school medicin pittsburgh pa 2upmc hillman cancer center depart patholog univers pittsburgh school medicin pittsburgh pa 3upmc hillman cancer center depart gynecolog oncolog univers pittsburgh school medicin pittsburgh pa 4allegheni health network cancer institut depart radiat oncolog pittsburgh pa',\n 'purposeobject vulvar cancer rare femal genit neoplasm surgeri radiotherapi play integr role treatment paradigm howev locoregion recurr remain predomin pattern failur littl known impact pdl1 statu vulvar cancer valu clinic outcom respons predict immunotherapi sought explor clinic outcom patient posit pdl1 express vulvar cancer materialsmethod singleinstitut retrospect analysi patient surgic resect invas vulvar carcinoma 20012021 perform patient local advanc diseas amend upfront surgeri de novo metastat diseas exclud immunohistochem pdl1 express assess use combin posit score cp posit express defin 1 tumor proport score tp posit express defin 1 surviv diseas control outcom calcul use kaplanmei method logrank ttest multivari analysi conduct use parsimoni cox regress analysi use forward condit select result total 85 patient identifi median age 69 year old iqr 5978 54 n 46 figo stage iii 97 n 82 squamou cell carcinoma histolog 41 n 35 p16 posit statu 74 n 63 without histori lichen sclerosi 40 n 34 without coexist vulvar intraepitheli neoplasm vin 49 n 42 treat surgeri alon 72 n 61 posit pdl1 tp 1 81 n 69 posit pdl1 cp 1 express median follow 49 month iqr 2175 month 5year os 79 95 ci 7089 df 55 95 ci 4367 local control lc 59 95 ci 4772 region control rc 86 95 ci 7894 distant metastasi dm 96 95 ci 92100 pdl1 express associ lower lc df tp 1 5year lc 82 95 ci 6598 pdl1 neg versu 50 95 ci 3465 posit diseas p 003 5year df 77 95 ci 5995 pdl1 neg versu 46 95 ci 3161 posit diseas p 003 signific df lc differ note cp level 1 signific differ observ rc dm os multivari analysi pdl1 tp remain signific predictor lc hr 301 95 ci 107895 p 004 signific differ df observ pdl1 tp multivari analysi conclus pdl1 express associ higher rate local recurr may repres potenti import action target independ p16 statu improv predomin pattern relaps uncommon malign',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023061768 pmid 37785600',\n '45 int j radiat oncol biol phi 2023 oct 11172se510 doi 101016jijrobp2023061766',\n 'effect concurr chemoradiotherapi regulatori cellscd8treg ratiopd1 ctla4 patient cervic cancer',\n 'du y1 fenghu l1 jiehui l2 hu l1 mei f3 tian x1 qin y1',\n 'author inform 1depart oncolog affili hospit guizhou medic univers guiyang guizhou china 2depart gynecolog oncolog affili cancer hospit guizhou medic univers guiyang guizhou china 3depart gynecolog oncolog affili cancer hospit guizhou medic univers guiyang guizhou provinc china',\n 'purposeobject investig signific chemoradiotherapi regulatori treg cell cd8 treg ratio squamou cell carcinoma antigen scc pd1 ctla4 peripher blood cervic cancer ccpatient materialsmethod retrospect studi perform 56 cervic cancer patient treat concurr chemoradiotherapi septemb 06 2019 april 19 2021 select patient underw surgeri flow cytometri use determin level regulatori cell cd8 treg ratio squamou cell carcinoma antigen pd1 ctla4 peripher blood patient concurr therapi differ rel level valu treatment calcul use statist protocol pair sampl ttest result proport cd4cd25cd127low treg cd4t cell 1596429 cervic cancer patient 976421 healthi control differ two group statist signific p 005 differ age group treg cd8 level cd4cd8 ratio cd8treg ratio radiotherapi chemotherapi signific relationship age patholog type p 005 cd8treg ratio higher patient adenocarcinoma patient squamou cell carcinoma radiotherapi chemotherapi differ statist signific z 2076 p 0038 postop patient cd8 level lower chemoradiotherapi chemoradiotherapi 2320 p 0020 term pd1 regardless age patholog type level pd1 radiotherapi chemotherapi higher chemotherapi differ statist signific level adenocarcinoma 53501016 significantli higher squamou carcinoma 43721189 2609 p 0011 pd1 level patient cervic cancer radic resect 41641329 lower patient without cervic cancer radic resect 46841061 differ statist signific 2187 p 0031 pd1 level patient without pelvic lymph node metastasi 48841004 significantli higher patient pelvic lymph node metastasi 42961085 differ statist signific 2019 p 0049 signific differ vascular posit invas depth stump posit pelvic lymph node posit treg level cd8 level ctla4 level scc cd4cd8 ratio cd8treg ratio p 005 conclus level treg cell patient cervic cancer significantli higher healthi peopl decreas immedi radiotherapi chemotherapi peripher blood treg pd1 cd8 cd8treg reflect immun function bodi may provid certain refer immunotherapi',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023061766 pmid 37785598',\n '46 int j radiat oncol biol phi 2023 oct 11172se475e476 doi 101016jijrobp2023061688',\n 'selfattentionbas neural network predict immun checkpoint inhibitor respons',\n 'liu j1 islam mt2 xing l2',\n 'author inform 1stanford univers palo alto ca 2depart radiat oncolog stanford univers school medicin stanford ca',\n 'purposeobject cancer cell evad immun system neg regul cell via immun checkpoint eg pd1 block checkpoint abil immun system recogn kill cancer cell restor individu respons rate checkpoint blockad vari among patient 5080 specif type cancer melanoma 1530 tumor yet still open question set biomark crucial respons immun checkpoint inhibitor ici overal goal studi develop valid biologicallyawar interpret deep learn model identifi biomark predict surviv outcom ici treatment materialsmethod selfattent mechan could yield interpret result import biomark may attent howev classic selfattent mechan prior biolog knowledg protein interact ppi gene pathway incorpor studi propos weight biologicallyawar attent score weight gene central pathway length gene close connect mutat gene receiv high attent gene far away mutat gene along pathway receiv lower attent train valid test model use 1660 patient nine type cancer valid predict 1 evalu accuraci via concord index 2 identifi gene receiv high attent verifi function exist literatur 3 perform saniti check remov gene data retrain predict compar predict accuraci result framework achiev averag accuraci measur via cindex 060 006 nsclc 058 007 melanoma superior gold standard coxph model 057 006 nsclc 053 003 melanoma deepsurv 054 005 nsclc 051 010 melanoma gene receiv high attent valid support literatur provid addit mean verifi predict comparison black box deep learn model way comprehend reason behind predict remov top 8 highattent gene 25 gene data use remain 92 make predict result drop accuraci 055 0073 nsclc 056 003 melanoma underscor signific gene patient stratif also perform divid patient respond nonrespond base predict score conclus studi propos valid biologicallyawar selfattent base deep learn model outperform commonlyus surviv model addit tool potenti identifi key biomark assist clinic decisionmak demonstr promis step immunotherapi respons predict',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023061688 pmid 37785508',\n '47 int j radiat oncol biol phi 2023 oct 11172se473 doi 101016jijrobp2023061683',\n 'valu equival dose calcul dosiom radiomicsbas predict pneumon thorac radiotherapi immun checkpoint inhibit',\n 'krau km1 oreshko m2 bernhardt d3 comb se4 peeken jc1',\n 'author inform 1depart radiat oncolog school medicin klinikum recht der isar technic univers munich tum munich germani institut radiat medicin irm helmholtz zentrum mnchen hmgu gmbh german research center environment health neuherberg germani 2depart radiat oncolog school medicin klinikum recht der isar technic univers munich tum munich germani medic faculti univers hospit lmu munich munich germani 3depart radiat oncolog school medicin klinikum recht der isar technic univers munich tum munich germani german cancer consortium dktk partner site munich germani munich germani 4institut radiat medicin irm helmholtz zentrum mnchen hmgu gmbh german research center environment health neuherberg germani depart radiat oncolog klinikum recht der isar technic univers munich munich germani',\n 'purposeobject posttherapi pneumon ptp relev side effect thorac radiotherapi rt immunotherapi checkpoint inhibitor ici impact combin unclear aim improv risk estim predict ptp without ici therapi analyz influenc differ fraction scheme valu voxelwis 2 gy equival dose eqd2 investig materialsmethod clinic data 100 patient receiv fraction rt singl dose 3gi rt collect 36 patient receiv addit ici therapi ptp grade monitor plan comput tomographi ct segment 3d dose data extract convert eqd2 dosiom radiom featur extract use 1000fold bootstrap use pearson intercorrel boruta algorithm 5 singl 4 combin predict model machin learn algorithm random forest rf logist elast net regress support vector machin logitboost train test use 5fold nest cross valid approach synthet minor oversampl techniqu resampl r analysi perform use area receiv oper characterist curv auc test set outer fold result investig model predict ptp better random auc5 tabl 1 dosiomicsradiom model base eqd2 use rf classifi result highest predict perform auc 83 95 confid interv 8384 perform wors physic dose data auc 72 7173 singl model radiom dosiom achiev best predict auc 73 7274 auc 8 7981 physic dose eqd2 respect clinic factor ici therapi auc 6 5962 minor impact ptp predict tabl 1 auc 95 confid interv ci investig machin learn model eqd2 physic dose conclus dosiomicsradiom machin learn model strong capabl ptp predict could contribut pretreat decis make fraction scheme consid dosebas predict strategi addit ici therapi limit impact ptp predict',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023061683 pmid 37785503',\n '48 int j radiat oncol biol phi 2023 oct 11172se424e425 doi 101016jijrobp2023061583',\n 'analysi patient treat stereotact bodi radiotherapi metastat urinari tract tumor identifi predictor respons',\n 'oh n1 nakashima j2 chadha js3 kish ja3 manley b3 powsang j3 yu a3 zhang j3 spiess p3 chatwal ms3 jain r3 zemp lw3 poch m3 sexton wj3 li r3 gilbert sm3 johnston pas2 torresroca jf2 yamoah k2 grass d2',\n 'author inform 1univers south florida morsani colleg medicin tampa fl 2h lee moffitt cancer center research institut depart radiat oncolog tampa fl 3h lee moffitt cancer center research institut depart genitourinari oncolog tampa fl',\n 'purposeobject identifi select criteria link outcom patient treat stereotact bodi radiotherapi sbrt metastat tumor urinari tract ut materialsmethod singl institut retrospect analysi sbrt treat patient oligometastaticprogress ut tumor 20062022 chart queri m1 statu diagnosi diseas cours treatment detail surgeri sbrt system therapi metabol statu diabet dm bmi outcom linear quadrat formula use calcul biolog effect dose bed use 10 tumor descript statist portray cohort analys done patient site level timetoev analys includ overal surviv os progressionfre surviv pf sbrt assess kaplanmei method cox regress use univari uva multivari analys mva identifi predictor outcom result total 35 patient treat 44 metastat site includ bone 25 node 364 lung 205 soft tissu 136 liver 45 male 743 median age 70 rang 5189 without dm 60 median bmi 298 ecog 2 971 time sbrt six 171 patient m1 diagnosi 29 nonm1 patient 862 receiv definit local therapi lt 586 least t3n diseas 758 receiv system therapi median 2 agent rang 16 prior sbrt sixteen 457 receiv immunotherapi io receiv 75 562 sbrt six patient posit pdl1 statu n 10 median rt dose fraction bed 40 gy rang 1446 5 fraction 72 rang 28132 respect median followup 348 median os 184 rang 93274 2year os 359 patient level 628 recur sbrt median pf sbrt 53 rang 1887 2yr pf 293 patientlevel pf improv lt 67 vs 14 p 0001 dm nr vs 29 p 0015 wherea improv os relat lt 189 vs 66 p 003 dm p 004 ecog p 0004 relaps sbrt nr vs 98 p 0001 exposur 3 system agent prior sbrt portend better pf 67 vs 26 p 004 without impact io site level 204 site local relaps 4 first event site relat pf p 0009 order increas relaps risk liver bone soft tissu node lung dosimetr featur relat recurr risk mva dm p 002 lt p 0002 predict pf recurr sbrt predict os mva hr 67 95 ci 1431 p 0014 io subset median pf 53 os 94 differ seen iosbrt sequenc pdl1 statu conclus optim select criteria metastasisdirect therapi patient ut tumor unclear notabl io futur studi may benefit assess circul tumor marker prior sbrt',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023061583 pmid 37785392',\n '49 int j radiat oncol biol phi 2023 oct 11172se412 doi 101016jijrobp2023061558',\n 'outcom target therapi plu immunotherapi highdos stereotact abl bodi radiotherapi sabr metastat renal cell cancer patient',\n 'mw1 gao xs1 li hz1 yang kw2 yu w2 zs2 bai y1 chen j1 wang zs3',\n 'author inform 1depart radiat oncolog peke univers first hospit beij china 2depart urolog peke univers first hospit beij china 3hebei yizhou proton center zhuozhou china',\n 'purposeobject stereotact abl bodi radiotherapi sabr one treatment option metastat renal cell carcinoma mrcc limit lack data evalu target therapi plu immunotherapi concurr highdos sabr multipl site evalu safeti diseas control mrcc patient concurr receiv trimod treatment materialsmethod patient treat sabr 4070 gy510 fraction small lesion partialsabr tumor center boost 68 gy35 fraction 5060 gy2025 fraction whole tumor volum bulki tumor tumor adjac critic organ sabrpartialsabr feasibl moder fraction radiotherapi plan usual 60gy20 fraction appli target therapi plu immunotherapi pd1 inhibitor interrupt radiotherapi rt advers event ae evalu diseas control rate dcr object respons rate orr progressionfre surviv pf overal surviv os calcul pfs1 defin first progress sinc start rt pfs2 defin second progress second rt cours new metastas occur first rt reirradi system therapi chang kaplanmei method use timetoev endpoint result total 51 patient median age 57 yr enrol median followup 12 month 75 patient intermediaterisk 18 favorablerisk diseas 61 patient oligometastat 71 clear cell renal cancer 241 metastas 161 67 irradi 80 lesion receiv sabrpparti sabr 1 patient 14 lesion irradi receiv proton therapi surviv patient continu use target therapi 81 patient complet least 1year pd1 therapi 10 patient 20 grade 3 drugrel ae pneumon n 2 elev alanin transaminas n 4 myositi n 1 handfoot syndrom myositi n 1 enter n 1 fatigu n 1 1 grade 4 ae upper gastrointestin bleed grade 35 rtrelat ae found orr dcr irradi lesion 51 98 median os pfs2 reach median pfs1 14622 month estim 1 2yr os pfs1 pfs2 90 90 56 38 74 51 respect univari analysi show pfs1 benefit found patient receiv radiat system therapi failur p 0038 conclus investig highdos rt combin concurr target immunotherapi patient metastat rcc found treatment regimen well toler good cancer control earli use highdos rt multiles may improv pf partialsabr bulki lesion close critic organ could safe effect appli certain circumst encourag find warrant investig',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023061558 pmid 37785365',\n '50 int j radiat oncol biol phi 2023 oct 11172se41e42 doi 101016jijrobp202306739',\n 'daili adapt vs nonadapt extern beam radiat therapi concurr chemotherapi local advanc nonsmal cell lung cancer nsclc prospect random trial individu approach toxic reduct artialung',\n 'stanley dn1 harm j1 kole aj1 dobelbow mc1 mccann c2 levin l2 russel k3 mcdonald am1',\n 'author inform 1univers alabama birmingham birmingham al 2varian medic system siemen healthin compani palo alto ca 3varian medic system palo alto',\n 'purposeobject radiotherapi rt concurr chemotherapi standard treatment stage iii nsclc howev radiat pneumon incid increas rapidli volum lung irradi esophag increas dose esophagu condit advers impact patient qualiti life daili onlin adapt rt art may allow reduc normal tissu dose due smaller margin around target well target size reduct tumor respons prospect random control trial test hypothesi proport studi particip experi score 3 proctca cough dyspnea dysphagia least 20 lower daili art nonadapt rt materialsmethod enrol goal 244 subject 10 cancer center worldwid elig criteria includ stage iiiaiiic ajcc v8 nsclc baselin grade 02 dyspnea cough dysphagia contralater hilar supraclavicularcerv lymph node involv subject random 11 cbctbase daili art nonadapt rt use imrt vmat deliv 6066 gy 3033 fraction concurr platinum doublet chemotherapi adjuv immunotherapi durvalumab permit followup studi particip 1year postcomplet chemort studi endpoint includ frequenc proctca score 3 cough dyspnea dysphagia random 30 day postchemort patientreport qualiti life factl eq5d5l questionnair percentag lung receiv 20 gy mean dose lung heart esophagu primari tumor respons ct petct recist v11 local diseas progress incid grade 2 pneumon within 1 year stratif factor treat institut presenc contralater mediastin lymph node metastas associ increas volum irradi lung interim analys futil superior perform primari endpoint data collect 50 evalu particip result studi open enrol 20 octob 2022 expect complet approxim 3 year conclus prospect random clinic trial rigor evalu impact daili onlin art radiat pneumon esophag qualiti life patient advanc nsclc collect standard tumor respons diseas progress metric assur reduc margin advers impact outcom onlin art emerg innov approach enabl increas spare normal tissu result clinic studi support evidencebas clinic decis around art technolog',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306739 pmid 37785360',\n '51 int j radiat oncol biol phi 2023 oct 11172se403 doi 101016jijrobp2023061539',\n 'squamou cell carcinoma bladder analysi treatment outcom',\n 'bhatt a1 larkin mc1 pasli m1 burk a2',\n 'author inform 1brodi school medicin east carolina univers greenvil nc 2depart radiat oncolog brodi school medicin east carolina univers greenvil nc',\n 'purposeobject squamou cell carcinoma scc bladder rare diseas compos 25 bladder cancer current consensu exist regard treatment recommend rare malign although establish regimen includ variou permut chemotherapi radiat laser treatment immunotherapi surgeri rang pelvic exenter local excis present studi aim analyz outcom aforement treatment guid clinic decisionmak patient diseas materialsmethod patient bladder scc diagnos 2000 2018 review util data surveil epidemiolog end result registri seer program data analyz use spss python examin variabl includ presenc metastas diagnosi surgeri radiotherapi chemotherapi recept fiveyear overal surviv os curv analyz use kaplanmei probabl stratifi treatment modal result total 5635 patient bladder scc identifi abundantli report demograph white race 86 patient age 70 year 61 male sex 63 median surviv 13 month significantli decreas patient treat chemotherapi radiat median surviv nine month 12 month respect patient treat radiat surgeri saw decreas 10year surviv rate 10 chemotherapi administ differ narrow 4 decreas patient treat chemotherapi radic surgic procedur includ partial total cystectomi total posterior exenter result statist signific increas surviv except patient underw radic cystectomi includ anterior exenter p 0101 patient underw surgeri saw increas median surviv 15 month heatmap analysi demonstr signific correl tumor size distant metastas r 0898 preliminari unsupervis cluster analysi identifi two distinct patient subgroup character strongli race treatment modal use conclus bladder scc carri high mortal burden median surviv time 13 month diagnosi base studi analysi radic surgeri may effect treatment diseas studi also set preced futur research advanc machin learn method includ cluster binari tree analysi done analysi use identifi explanatori variabl relat improv patient outcom',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023061539 pmid 37785346',\n '52 int j radiat oncol biol phi 2023 oct 11172se38 doi 101016jijrobp202306732',\n 'combin dosimetr radiom featur predict radiat pneumon local advanc nonsmal cell lung cancer machin learn',\n 'chen n1 zhou r1 luo q1 liu y1 li c1 zhang j1 guo j1 zhou y2 jiang h2 qiu b1 liu h1',\n 'author inform 1state key laboratori oncolog south china collabor innov center cancer medicin sun yatsen univers cancer center guangzhou china 2homolog medic technolog inc ningbo china',\n 'purposeobject studi aim analyz dosimetr factor radiom featur tumor lung local advanc nonsmal cell lung cancer lansclc establish machin learn model improv predict grade g 2 radiat pneumon rp materialsmethod studi retrospect collect data 284 lansclc patient underw concurr chemoradiotherapi ccrt median dose 64 gy 2033 fraction 2013 2021 cohort 211 patient g2 rp 4 region interest roi identifi plan comput tomographi imag gross tumor volum gtv ipsilesion lung il contralesion lung cl total lung tl calcul dosevolum histogram dvh lowest dose maximum dose increas degre 1 gy extract total 172 radiom featur 4 roi select best predictor classifi 2 group patient use sequenti backward elimin support vector machin model result best predictor g2 rp combin 8 radiom featur 7 dosimetr factor train group valid group achiev area curv auc 0847 accuraci 8038 sensit 7895 specif 8182 eight radiom featur includ 2 gtv 1 2 3 il cl tl respect dosimetr factor v65 gtv v20 v50 v55 il v10 cl v20 v55 tl appear significantli relat symptomat rp dosimetr factor constrain less 992 500 175 130 395 320 66 respect conclus combin dosimetr factor radiom featur within gtv il cl tl improv predict symptomat rp lansclc patient treat ccrt result suggest import v65 gtv v20 v50 v55 il v10 cl v20 v55 tl predictor symptomat rp provid use inform optim treatment plan era combin radiotherapi immunotherapi',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306732 pmid 37785286',\n '53 int j radiat oncol biol phi 2023 oct 11172se38 doi 101016jijrobp202306731',\n 'pilot trial consolid bevacizumab hypofraction concurr chemoradiotherapi patient unresect local advanc nonsquam nonsmallcel lung cancer',\n 'huo l1 chu c2 jiang x3 zheng s3 zhang p3 zhou r2 chen n2 guo j2 qiu b2 liu h2',\n 'author inform 1sun yatsen univers cancer center guangzhou guangdong china 2state key laboratori oncolog south china collabor innov center cancer medicin sun yatsen univers cancer center guangzhou china 3sun yatsen univers cancer center guangzhou china',\n 'purposeobject assess feasibl ad bevacizumab consolid hypofraction concurr chemoradiotherapi hypoccrt patient unresect local advanc nonsquam nonsmal cell lung cancer lansnsclc materialsmethod elig patient treat hyport 40 gy 10 fraction follow hypoboost 2428 gy 67 fraction combin concurr weekli chemotherapi patient complet hypoccrt withoutg2 toxic receiv consolid bevacizumab everi 3 week 1 year diseas progress unaccept treatment relat toxic primari endpoint risk g4 higher hemorrhag secondari endpoint progressionfre surviv pf overal surviv os locoregion failurefre surviv lrf distant metastasisfre surviv dmf object respons rate orr timetoev endpoint os pf lrf dmf measur start radiotherapi result decemb 2017 juli 2020 total 27 patient analyz median followup durat 280 month one patient 37 develop g5 hemorrhag bevacizumab consolid besid 7 patient 259 g3 cough 3 patient 111 g3 pneumon orr 926 whole cohort median os 370 month 95 confid interv 89651 month median pf 160 month 95 confid interv 140180 month median lrf reach median dmf 180 month conclus pilot studi met goal demonstr toler consolid bevacizumab hypoccrt investig antiangiogen immunotherapi combin lansclc warrant g3 respiratori toxic worth consid',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306731 pmid 37785285',\n '54 int j radiat oncol biol phi 2023 oct 11172se37e38 doi 101016jijrobp202306730',\n 'outcom consolid thorac radiat within firstlin chemoimmunotherapi extensivestag smallcel lung cancer result singl cancer center',\n 'li y1 jing w2 jing x1 sun y3 tang x3 guo j3 zhang y3 zhu h1',\n 'author inform 1depart radiat oncolog shandong cancer hospit institut shandong first medic univers shandong academi medic scienc jinan 250117 shandong provinc china jinan china 2shandong first medic univers shandong academi medic scienc jinan 250021 shandong provinc china jinan china depart radiat oncolog shandong provinci hospit shandong first medic univers jinan 250021 shandong provinc china jinan china 3depart medic oncolog shandong cancer hospit institut shandong first medic univers shandong academi medic scienc jinan 250117 shandong provinc china jinan china',\n 'purposeobject thorac radiat trt benefit local control undoubtedli surviv minor controversi extensivestag smallcel lung cancer essclc patient undergo radiotherapi chemoradiotherapi era howev whether trt could enhanc benefit immun checkpoint inhibitor ici mainten outcom immunotherapi era still unclear studi aim investig role consolid trt essclc patient receiv firstlin chemoimmunotherapi follow immunotherapi mainten materialsmethod outcom patient treat firstlin chemoimmunotherapi follow ici mainten essclc review base trt patient alloc trt group nontrt group progressionfre surviv pf overal surviv os localrecurr free surviv lrf calcul kaplanmei method compar logrank test result total 100 patient progress diseas 4 cycl chemotherapi retrospect analyz januari 2020 decemb 2021 alloc trt group n 47 nontrt group n 53 median followup time 203 month median pf os trt 91 month 218 month versu 88 month p 093 243 month p 063 respect nontrt ici agent consist durvalumab 590 atezolizumab 410 median dose trt 50 gy iqr 45 54 median interv time chemotherapi complet trt 31 day iqr 12 445 10 213 patient termin ici period trt rate intrathorac progress firstlin therapi trt significantli decreas compar nontrt 200 versu 559 p 0003 median lrf time trt reach significantli longer 108 month nontrt hr 027 p 001 secondlin chemotherapi significantli prolong surviv compar chemofre patient mo 245 vs 214 month p 0026 subgroup analysi show trend patient brain metastas benefit trt 218 versu 137 month hr 061 p 038 liver metastas 133 versu 150 month hr 180 p 021 47 patient trt 106 patient experienc grade 3 radiationinduc pneumon grade 4 5 advers event occur none patient experienc grade 3 treatmentrel cardiac event conclus consolid trt period immunotherapi mainten follow firstlin chemoimmunotherapi prolong os pf increas lrf essclc',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306730 pmid 37785262',\n '55 int j radiat oncol biol phi 2023 oct 11172se359 doi 101016jijrobp2023062444',\n 'sarcopenia predictor neoadjuv therapyrel toxic esophag squamou cell carcinoma patient',\n 'zheng s1 qi wx1 li s1 xu ff1 li h1 chen jy1 zhao s2',\n 'author inform 1depart radiat oncolog ruijin hospit shanghai jiaotong univers school medicin shanghai china 2ruijin hospit shanghai jiao tong univers school medicin shanghai china',\n 'purposeobject sarcopenia character loss muscl mass play critic role patient esophag squamou cell cancer escc preoper chemoradiotherapi immunotherapi escc patient report improv surviv therefor sought evalu predict valu preoper sarcopenia toxic patholog tumor respons neoadjuv therapi nat escc patient materialsmethod retrospect analysi perform use prospect collect patient cohort academ cancer center diagnos ct24n03m0 escc 20192022 treat neoadjuv chemoradiotherapi pembrolizumab sarcopenia assess skelet muscl index third lumbar vertebra comput tomographi scan nat men 43cmm bodi mass index bmi 25kgm 53cmm bmi25 kgm women 41cmm logist regress perform assess associ sarcopenia preoper therapyrel toxic tumor respons result studi includ 59 local advanc escc patient 53 male 6 femal 48 814 nonsarcopenia group 11 186 sarcopenia group mean age diagnosi 628 year mean bmi diagnosi 2213285 kgm 19 patient 322 stage 25 patient 424 b 15 patient 254 signific differ found group regard sex age bmi clinic stage acut grade 3 toxic occur significantli frequent sarcopenia group 545 vs 229 p 0045 mainli includ leukopenia neutropenia anemia thrombocytopenia discontinu nat owe toxic occur 8 patient 135 significantli associ sarcopenia p 0003 patient proceed surgeri 33 patient 559 patholog complet respons pcr univari analysi reveal signific associ sarcopenia pcr p 0071 conclus among patient local advanc ec sarcopenia predictor poor nat respons strongli associ discontinu nat due toxic',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023062444 pmid 37785234',\n '56 int j radiat oncol biol phi 2023 oct 11172se357e358 doi 101016jijrobp2023062440',\n 'perturb gut microbiota modul abscop effect immunoradiotherapi rectal cancer',\n 'zhang x1 xue z2 yue j3',\n 'author inform 1shandong cancer hospit institut jinan shandong china 2depart radiat oncolog shandong first medic univers shandong academi medic scienc jinan shandong china 3shandong first medic univers shandong academi medic scienc jinan shandong china',\n 'purposeobject abscop effectth regress malign outsid irradi zonecan increas combin radiotherapi rt immunotherapi studi aim investig whether gut microbiota affect abscop effect follow immunoradiotherapi irt rectal cancer materialsmethod bilater mc38 subcutan tumor primari abscop tumor establish c57b6 mice without oral antibiot treatment preadministr vancomycin streptomycin ampicillin 14 day therapi mice without antibiot therapi random eight group receiv one four treatment 1 rt primari tumor antipd1 therapi irt 2 rt primari tumor rt 3 antipd1 therapi antipd1 4 treatment flow cytometri use determin composit function immun cell primari abscop tumor well spleen 16 rrna sequenc use assess gut microbiom alter follow antibiot intervent multipl bioinformat explor investig impact specif flora relat abscop antitumor effect result found radiat primari tumor exhibit cytotox effect nonirradi abscop tumor p00057 rt vs untreat group p00037 irt vs antipd1 group contrast abscop tumor resist anticanc effect rt antibiot given p05374 rt antibiot vs untreat group antibiot p042 irt antibiot vs antipd1 antibiot group compar rtantibiot group rt group discov number cd8cd44 cell decreas significantli abscop tumor p0001 spleen p00061 antipd1tr group antibiot significantli reduc number cd8granzymeb cell primari tumor p00061 cd4cd25 cell spleen p0001 irttreat group antibiot reduc fraction cd4inf cell abscop tumor p00134 increas number cd4pd1 cell spleen p0001 moreov found divers decreas significantli gut microbiota antibiot treatment p00079 p0001 respect abund galistip glactobacillu glachnospiracea glactobacillu fell dramat presenc antibiot addit function analys picrust2 kegg reveal antibiot therapi profound impact dalanin metabol pathway p0001 conclus found alter gut microbiom antibiot significantli affect local system antitumor effect irt result may provid new insight gut modif convert local anticanc effect rt system respons target metastat tumor',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023062440 pmid 37785231',\n '57 int j radiat oncol biol phi 2023 oct 11172se355 doi 101016jijrobp2023062434',\n 'camrelizumab chemoradiotherapi local advanc biliari tract cancer preliminari result phase ii studi',\n 'guo q1 liu j2 dou x2 zhu k2 shi p2 zhang y2 li s2 feng r2 yue j1',\n 'author inform 1cheeloo colleg medicin shandong univers jinan shandong china shandong cancer hospit affili shandong first medic univers jinan shandong china 2shandong cancer hospit affili shandong first medic univers jinan shandong china',\n 'purposeobject local advanc biliari tract cancer btc capecitabinebas chemoradiotherapi crt commonli use limit benefit immunotherapi potenti effect btc may synerg crt follow gemcitabin cisplatin gp consolid chemotherapi ct evalu safeti efficaci combin camrelizumab capecitabinebas crt local advanc btc materialsmethod patient stage iiiii t4n0m0 t14nm0 btc per 7th 2010 edit american joint committe cancer stage system elig crt capecitabin plu 5060 gy radiotherapi follow gp ct camrelizumab given concurr crt safeti defin incid sever advers event ae efficaci defin overal surviv os progressionfre surviv pf object respons rate orr diseas control rate dcr result ten patient complet plan treatment none experienc grade 3 treatmentrel ae crt grade 3 immunerel ae occur 2 10 patient 20 gp ct mean os time 182 month 95 confid interv ci 129m235m median os time 141 month 95 ci 101m181m os rate 100 59 44 6 month 1 year 2 year respect orr 30 dcr 90 two patient 20 obtain os 2 year partial respons 259m 291m median pf time 141 month 95 ci 93m189m conclus camrelizumab combin concurr crt well toler impair deliveri crt patient local advanc btc',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023062434 pmid 37785226',\n '58 int j radiat oncol biol phi 2023 oct 11172se350e351 doi 101016jijrobp2023062424',\n 'role ctbase radiom nomogram differenti diagnosi immun checkpoint inhibitorrel pneumon radiat pneumon patient escc',\n 'wen q1 yang z2 qiu q3 xing l4 li r5',\n 'author inform 1shandong provinci hospit affili shandong first medic univers jinan shandong china depart radiotherapi stanford univers palo alto ca 2shandong provinci hospit affili shandong first medic univers jinan shandong china 3depart radiat oncolog shandong cancer hospit institut shandong first medic univers shandong academi medic scienc jinan china 4shandong cancer hospit affili shandong univers shandong academi medic scienc jinan shandong china 5depart radiat oncolog stanford univers stanford ca',\n 'purposeobject combin immunotherapi chemoradiotherapi wide use patient esophag squamou cell carcinoma escc induc treatmentrel advers effect particularli immun checkpoint inhibitorrel pneumon cip radiat pneumon rp aim studi differenti cip rp ct radiom clinic radiolog paramet materialsmethod total 76 escc patient pneumon enrol retrospect studi divid train dataset n 53 valid dataset n 23 total 837 radiom featur extract region interest roi base lung parenchyma window ct imag radiom signatur construct basi predict featur least absolut shrinkag select oper lasso logist regress appli develop radiom nomogram receiv oper characterist roc curv area curv auc appli evalu perform pneumon etiolog identif result signific differ detect train dataset valid dataset radiom signatur made four radiom featur shown favor perform differenti cip rp binormalbas empir auc 0831 0843 patient rp close relationship locat p 0003 shape lesion p 0002 nomogram combin radiom signatur clinic factor improv classifi perform discrimin train dataset aucbin 0963 aucemp 0964 result verifi valid dataset auc 0967 0964 conclus ctbase radiom featur potenti valu differenti patient cip rp addit bilater chang sharp border produc superior model perform classifi could use method improv relat clinic decisionmak',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023062424 pmid 37785215',\n '59 int j radiat oncol biol phi 2023 oct 11172se35 doi 101016jijrobp202306724',\n 'outcom supervis deep learn model patholog whole slide imag surviv predict immunotherapi nonsmal cell lung cancer patient multicent studi',\n 'li b1 yang l1 jiang c2 li h1 qin w1 dong t3 wang l1',\n 'author inform 1depart radiat oncolog shandong cancer hospit institut shandong first medic univers shandong academi medic scienc jinan china 2depart otorhinolaryngolog head neck surgeri shandong provinci hospit affili shandong first medic univers jinan china 3depart obstetr gynecolog qilu hospit shandong univers jinan china',\n 'purposeobject although pdl1 inhibitor mark durabl efficaci nonsmal cell lung cancer patient nsclc 60 patient still suffer recurr metastasi pdl1 inhibitor treatment robust biomark respons pdl1 inhibitor whole slide imag wsi hestain specimen found character tumor microenviron might potenti prognost predictor nsclc patient accur predict respons pdl1 inhibitor present deep learn model base wsi hestain specimen nsclc patient materialsmethod two independ cohort nsclc patient receiv pdl1 inhibitor two hospit enrol model train test respect wsi imag hestain histolog specimen obtain patient patch 10241024 pixel label patch imag determin due progress free surviv pf interv 4 month patchlevel model firstli train base vit identifi predict patch train cohort patchlevel probabl distribut perform train patientlevel surviv modelbas vitrnn framework test extern valid cohort result total 291 wsi imag hestain histolog specimen 198 nsclc patient primari cohort 62 wsi imag 30 nsclc patient test cohort includ model train extern valid patient divid 4 group due pf pdl1 inhibitor 246318 patch 291 imag primari cohort imag preprocess imag randomli divid train cohort valid cohort proport 73 patchlevel vit model highest accuraci save predict patch select 50 epoch train patch rank probabl correct predict first 50 toprank patch wsi imag sequenti pass patientlevel vitrnn model vitrnn surviv achiev accuraci 886 valid cohort accuraci 81 test cohort multivari cox analysi also indic vitrnn surviv model remain statist independ predictor surviv pdl1 inhibitor p 00085 conclus outcom supervis vitrnn surviv model base patholog wsi could use predict efficaci pdl1 inhibitor nsclc patient lay foundat deploy comput pathom clinic practic immunotherapi',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306724 pmid 37785211',\n '60 int j radiat oncol biol phi 2023 oct 11172se32e33 doi 101016jijrobp202306718',\n 'predict valu dynam tumor volum chang stage iii nonsmal cell lung cancer treat chemoradi consolid immunotherapi',\n 'kumar r1 almeldin ds2 kim j1 deek mp1 jabbour sk1',\n 'author inform 1depart radiat oncolog rutger cancer institut new jersey new brunswick nj 2depart clinic oncologycairo univers cairo egypt',\n 'purposeobject concurr chemoradi crt follow immunotherapi standard care unresect local advanc nonsmal cell lung cancer nsclc hypothes ontreat dynam chang tumor volum may predict oncolog outcom stage iii nsclc materialsmethod stage iii nsclc patient treat definit crt 60 gy 30 fraction 6 week concurr platinumbas concurr chemotherapi follow consolid immunotherapi retrospect review manual delin gross tumor volum gtv patient cone beam comput tomographi cbct acquir day 1 15 29 43 gtv reduct quantifi percent differ volum cbct compar cbct day 1 midtreat respons mtr end treatment respons etr defin day 29 40 gy day 43 60 gy respect locoregion control lrc overal surviv os evalu kaplanmei analysi logrank test group stratifi per treatment respons multivari cox regress analysi perform identifi addit prognost factor result evalu 24 consecut treat patient 012016 082019 median followup 305 month median age 69 year rang 5184 adenocarcinoma histolog present 58 squamou cell carcinoma 42 patient tumor stage iiia 38 stage iiib 62 patient patient receiv definit crt least 2 cycl immunotherapi median 8 cycl median etr cbct43 495 rang 1847 1year cumul incid locoregion failur lrf 27 versu 10 patient etr 495 compar patient greater etr p 031 median mtr cbct29 327 rang 181 1year cumul incid lrf 28 versu 9 patient mtr 327 compar patient higher respons p 003 3year actuari lrc patient 51 significantli better higher mtr 70 vs 30 p 002 logrank compar lower mtr 3year actuari os patient 45 54 patient higher mtr vers 37 low respond p 009 multivari analysi age tstage signific factor associ lrc histolog subtyp show impact find conclus stage iii nsclc patient approxim onethird 33 reduct gtv midtreat cbct crt significantli improv lrc trend toward improv os approach may justifi earli adapt intensif rt applic addit therapi patient nonoptim respons addit larg prospect studi cbct need determin whether treatment tailor base tumor respons improv outcom',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306718 pmid 3778514461 int j radiat oncol biol phi 2023 oct 11172se309e310 doi 101016jijrobp2023062335',\n 'radiotherapi patient local advanc esophag squamou cell carcinoma receiv neoadjuv immunotherapi combin chemotherapi',\n 'kong y1 ji y2 qiu g3 wang y2 fang j2 chen m2 chen q4 jiang y4 yang y3',\n 'author inform 1depart radiat oncolog zhejiang cancer hospit institut basic medic scienc cancer research chines academi scienc zhejiang provinci key laboratori radiat oncolog hangzhou china 2depart thorac radiotherapi zhejiang cancer hospit hangzhou china 3depart thorac radiotherapi zhejiang cancer hospit hangzhou china 4depart thorac surgeri zhejiang cancer hospit hangzhou china',\n 'purposeobject success immunotherapi advanc esophag cancer neoadjuv chemoimmunotherapi cit increasingli use local stage esophag cancer especi context clinic trial bring similar pcr neoadjuv chemoradiotherapi show promis result howev still part potenti oper patient cant undergo surgeri neoadjuv chemoimmunotherapi followup treatment prognosi popul remain unclear materialsmethod patient patholog diagnos escc clinic stage t13nm0 t34ananym0ajcc 8th ps 01 retrospect enrol 12020 62021 zhejiang cancer hospit patient firstli receiv pd1 inhibitor camrelizumab sintilimab tislelizumab plu chemotherapi albumin paclitaxel260 mgmon day 1 plu carboplatin auc 5 day 1 everi 3 week 24 cycl patient receiv surgeri definit radiotherapi 504gy28f 50gy25f adopt use vmat concurr chemotherapi alon concurr chemotherapi regimen includ weekli tc paclitaxel 50 mgm 2 d1 carboplatin auc 2 d1 s1 60mg bid d1142942 surviv outcom treatment toxic record analyz result total 56 elig patient final identifi 558 patient treat depart thorac surgeri 31 patient show respons neoadjuv cit 6 pd 25 sd 25 patient achiev pr receiv surgeri due poor perform statu refus oper median age 66iqr 5672 55982 male 12196 stage ii 44804 stage iii among patients25 446 receiv radiotherapi alon 31 554 receiv chemoradiotherapi neoadjuv cit median followup 118 month iqr 86201 median pf os 165 month 95ci 129214 186 month 95ci 112na respect subgroup analysi median pf patient pr cit 202 moth 95ci1723na 129 moth 95ci 068204 patient sd pd hr 045 95ci022 093 p 0027 signific differ observ patient receiv radiotherapi alon chemoradiotherapi hr 13695ci069271 p 037 common ae observ studi anemia 982 leukopenia 839 thrombocytopenia 536 advers event grade3 radiationinduc pneumon esophag 125 321 especi 6 patient 107 die esophag fistula 2 patient 36 die grade 5 pneumon conclus local advanc escc patient neoadjuv cit receiv surgeri definit radiotherapi option treatment strategi howev patient respons cit also show poor respons radiotherapi particular attent paid treatment relat toxic especi esophag fistula',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023062335 pmid 37785119',\n '62 int j radiat oncol biol phi 2023 oct 11172se308 doi 101016jijrobp2023062332',\n 'liverdirect combin radiotherapi downstag milan advanc hepatocellular carcinoma convert liver transplant',\n 'kim yt1 lee jg2 joo dj2 kim dy3 seong j1',\n 'author inform 1depart radiat oncolog yonsei cancer center yonsei univers colleg medicin seoul korea republ south korea 2depart surgeri yonsei cancer center yonsei univers colleg medicin seoul korea republ south korea 3depart intern medicin yonsei cancer center yonsei univers colleg medicin seoul korea republ south korea',\n 'purposeobject recent success combin immunotherapi shed light futur advanc hepatocellular carcinoma patient still remain palli set best oncolog outcom hcc obtain cur surgeri either resect liver transplant lt efficaci liverdirect combin radiotherapi ldcrt downstag subsequ surgic resect local advanc hcc report earlier team studi investig role ldcrt downstag strategi convert advanc hepatocellular carcinoma lt materialsmethod review 55 hepatocellular carcinoma patient undergon downstag ldcrt subsequ liver transplant januari 2009 februari 2022 patient within milan criteria time receiv radiotherapi exclud clinic characterist histopatholog explant liver evalu overal surviv diseasefre surviv assess use kaplanmei method result median followup period 486 month rang 69 1517 month 55 patient 24 436 treatment nave time rt 36 patient present larg tumor tumor diamet 5 cm multipl lesion 3 lesion 37 major vessel involv portal vein tumor thrombosi 7 extrahepat lesion ldcrt given local concurr chemoradi ccrt 41 patient 745 transarteri chemoembol tace plu rt 10 patent 182 substanti downstag achiev 38 69 patient initi milan within milan specif 29 37 patient initi major vessel invas tumor thrombosi success convert microscop vessel invas tumor thrombusfre statu explant liver 5year overal surviv 681 2year diseasefre surviv 51 respect recurr transplant observ 18 patient 4 intrahepat recurr 14 extrahepat metastasi major 1418 occur within 2 year conclus liverdirect combin radiotherapi downstag strategi liver transplant achiev favor oncolog outcom advanc hepatocellular carcinoma patient studi suggest activ adopt radiotherapi need full consider local advanc hcc patient open chanc cur lt',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023062332 pmid 37785116',\n '63 int j radiat oncol biol phi 2023 oct 11172se306e307 doi 101016jijrobp2023062329',\n 'molecular subtyp outcom multiinstitut review rectal cancer patient',\n 'hedg d1 nesbit ea2 mulcahi e3 mckean d1 reilley m4 ulahannan s5 boland pm6 jabbour sk7 cavnar m8 chan c9 felder s10 janowski em jr2',\n 'author inform 1m2gen tampa fl 2univers virginia depart radiat oncolog charlottesvil va 3univers virginia charlottesvil va 4depart hematologyoncolog charlottesvil va 5univers oklahoma depart medic oncologyhematolog norman ok 6rutger cancer institut new jersey depart medic oncolog new brunswick nj 7rutger cancer institut new jersey depart radiat oncolog new brunswick nj 8univers kentucki lexington ky 9univers iowa iowa citi ia 10gi oncolog moffitt cancer center tampa fl',\n 'purposeobject colorect cancer crc heterogen malign associ varieti genet mutat recent data indic crc broken uniqu biolog distinct consensu molecular subtyp cm base differ patholog genet signatur purpos studi evalu outcom rectal cancer patient multiinstitut network base tumor mutat assess cm group materialsmethod patient exom transcriptom sequenc data clinic outcom collect total cancer care protocol avatar project within oncolog research inform exchang network orien total 101 patient demograph outcom inform data microsatellit instabl msi tumor mutat burden tmb transcriptom whole exom sequenc we molecular subclass cms1 cms2 cms3 cms4 cmsmix assign base transcript signatur r packag cm caller surviv analysi perform r packag surviv survmin result total 101 rectal cancer patient median age 568 median follow 35 year rang 026235 78 patient treat cur intent clinic local diseas 35 patient develop metastat diseas remain 23 patient synchron metastat diseas present 5 5 cms1 29 29 cms2 13 13 cm 3 49 49 cm 4 5 5 cmsmix patient cohort respect cohort includ 5 5 braf 51 50 kra 63 62 tp53 mutat patient 5 5 msi high patient median surviv 188 1172 1257 119 month cms1 cms2 cms3 cms4 patient respect insuffici event cmsmix calcul p 015 cms1 patient significantli shorter surviv compar cohort p 002 2 5 patient receiv immunotherapi 40 20 cms1 52 78 cms2 15 11 cms3 59 1315 cms4 40 11 cmsmix present develop metastat diseas respect divid mutat group median surviv 43 versu 119 119 versu 117 126 versu 119 month braf kra tp53 mutat wild type patient respect p 018 p 048 p 093 evalu tmb msi statu reveal signific differ outcom p 054 p 07 median surviv 126 month versu 117 tmb high versu low patient unreach versu 119 month msi versu mss patient respect note 3 5 msi patient also cms1 two come cms4 cmsmix cohort conclus cm classif tumor mutat statu associ differenti outcom rectal cancer patient group larg likelihood develop metastat diseas work optim person treatment highrisk popul necessari',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023062329 pmid 37785113',\n '64 int j radiat oncol biol phi 2023 oct 11172se303 doi 101016jijrobp2023062321',\n 'salvag radiotherapi improv surviv patient metastat liver cancer immunotherapi oligoprogress',\n 'hsu sj1 chao yc2 zeng zc1 du s3',\n 'author inform 1depart radiat oncolog zhongshan hospit fudan univers shanghai china 2depart pulmonari medicin zhongshan hospit fudan univers shanghai 200032 china shanghai 200000 china 3zhongshan hospit fudan univers shanghai china',\n 'purposeobject immun checkpoint inhibitor ici amelior surviv outcom liver cancer major patient receiv ici eventu develop progress local therapi especi radiotherapi rt increasingli consid set oligoprogress delay need chang system therapi aim studi evalu efficaci safeti rt salvag treatment patient oligoprogress ici materialsmethod retrospect studi perform evalu use salvag radiotherapi oligoprogress metastat liver cancer patient patient metastat liver cancer previou stabil respons 6 mo ici elig develop progress five fewer metastas result overal 178 patient treat august 2018 march 2022 includ patient follow median 172 month overal respons rate orr diseas control rate dcr 382 578 respect median progressionfre surviv pf overal surviv os 65 95 ci51167884 173 95 ci1116623434 month multivari analysi factor associ os includ tumor size tumor number radiat tumor site intrahepat vs extrahepat frequent ae fatigu decreas appetit rash fever nausea abovement ae revers manag conclus salvag radiotherapi potenti activ toler oligoprogress ici appropri radiat tumor site patient select prospect random trial ongo valid find chictr2200060664',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023062321 pmid 37785106',\n '65 int j radiat oncol biol phi 2023 oct 11172se283 doi 101016jijrobp2023061268',\n 'hpv infect immunohistochem analysi p16 p53 pdl1 express prognost biomark squamou cell anal cancer patient receiv definit radiotherapychemoradiotherapi',\n 'topuz bb1 sert f1 sezak m2 soylu m3 yalman d1 ozkok s1',\n 'author inform 1depart radiat oncolog ege univers faculti medicin izmir turkey 2depart patholog ege univers faculti medicin izmir turkey 3depart microbiolog ege univers faculti medicin izmir turkey',\n 'purposeobject treatment anal squamou cell carcinoma scc definit radiotherapi rtchemoradiotherapi crt high likelihood success nevertheless treatment resist recurr rate ignor therefor aim identifi relationship immunohistochem ihc evalu treatment respons prognosi materialsmethod retrospect studi includ 42 patient anal scc treat definit rtcrt singl institut 2006 2020 detect highrisk hpvdna ihc analysi p16 p53 pdl1 express perform diagnost formalinfix paraffinembed ffpe biopsi posit stain accept 5 tumor cell p16 p53 express addit 1 combin posit score cp pdl1 posit tumor lymphocyt macrophag counttot viabl cell count x100 pdl1 express result thirti patient 714 complet respons definit rtcrt recurr observ 16 381 patient 3 71 locoregion recurr lrr 6 143 distant metastas dm 7 167 lrr dm twentyfour 571 patient aliv thirti 714 patient hpv 12 286 hpv signific correl hpv p16 statu p0001 hpv statu associ male gender p 0001 hpv p16 statu significantli associ lack complet respons definit rtcrt p0001 p0001 respect furthermor signific relationship lack complet respons increas recurr p 0016 distant metastas p 0015 ten 16 patient recurr p53 signific correl found recurr p53 statu p 0006 similarli p53 statu associ increas lrr p 0014 pdl1 cp 1 found 31 738 patient pdl1 posit significantli correl hpv p 0026 p16 p 0013 statu 10 238 patient lrr pdl1 pdl1 cp 1 associ poor local control p 0031 univari analysi age 65 p 0049 complet respons p 0015 hpv statu p 0010 relat increas 5year overal surviv os complet respons p 0001 hpv statu p 0025 p53 statu p 0010 associ increas 5y diseasefre surviv df multivari analysi age 65 p 0010 hpv statu p 0002 signific prognost factor 5y os wherea complet respons p 0007 p53 statu p 0038 signific prognost factor 5y df conclus patient hpv statu andor poor prognost biomark identifi diagnosi thu better outcom achiev differ treatment option combin immunotherapi standard crt',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023061268 pmid 37785055',\n '66 int j radiat oncol biol phi 2023 oct 11172se278 doi 101016jijrobp2023061256',\n 'impact combin puls low dose rate radiotherapi pldr antipd1 antibodi tumor growth mechan lung cancer mice',\n 'zhang p1 yin s2',\n 'author inform 1depart radiat oncolog sichuan cancer hospit institut sichuan cancer center school medicin univers electron scienc technolog china radiat oncolog key laboratori sichuan provinc chengdu china 2graduat school chengdu medic colleg chengdu china',\n 'purposeobject emerg antitumor strategi immunotherapi approv treatment varieti tumor recent data suggest efficaci radiotherapi variou cancer augment combin immun checkpoint blockad puls low dose rate radiotherapi pldr new radiotherapi segment method therefor studi investig inhibitori effect pldr combin antipd1 antibodi lung cancer mice impact tumor immun microenviron materialsmethod transplant murin llc cell right leg c57bl6 mice immun activ transplant subcutan tumor model establish mice randomli divid five group control convent radiotherapi rtantipd1 antibodi mabpldrantipd1 antibodi mab rt deliv dose 5 2 gy wherea pldr involv deliv dose 2 gy 10 puls 02 gy 3 minut apart last 5 day antipd1 antibodi isotyp control administ intraperiton everi three day dose 5mgkg three time total tumor blood tumordrain lymph node tdln harvest treatment singl cell suspens prepar flow cytometri analyz chang immun microenviron tumor tissu express pdl1 pd1 activ system immun respons final studi explor mechan abl explain observ synergi combin therapi result pldr combin antipd1 antibodi better inhibit growth tumor rtpldr rt combin group surviv analysi demonstr statist signific advantag pldrantipd1 group median surviv pldrantipd1mab 63d compar 54d rtantipd1mab41d rt 40d pldr 33 control meanwhil rt pldr induc upregul pdl1 express tumor surfac pd1 express lymphocyt frequenc cd4cd8t cell higher pldr combin treatment group tumor blood drain lymph node synergist reduc local accumul tumorinfiltr myeloidderiv suppressor cell mdsc other final main reason better tumor inhibit effect pldr combin group upgrad number activ cd8t cell tumor conclus pldr combin antipd1 antibodi result better tumor growth inhibit significantli delay surviv time mice mainli cytotox celldepend mechan meanwhil increas infiltr cd4 cd8 tcell tissu',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023061256 pmid 37785044',\n '67 int j radiat oncol biol phi 2023 oct 11172se278 doi 101016jijrobp2023061257',\n 'hypofraction radiotherapi prolong interfract interv hyposlow rt facilit immun prime tumor',\n 'shao s1 xiao j1 yang m2 zhao y2 liao w3 zhang j1 zhang s2',\n 'author inform 1sichuan cancer hospit institut sichuan cancer center cancer hospit affili univers electron scienc technolog china chengdu sichuan china 2sichuan cancer hospit institut sichuan cancer center cancer hospit affili univers electron scienc technolog china chengdu china 3sichuan cancer hospit institut sichuan cancer center school medicin univers electron scienc technolog china chengdu china',\n 'purposeobject daili fraction radiotherapi may pose constant stress immun activ mous model built explor whether hypofraction radiotherapi prolong interfract interv hyposlow radiotherapi hsrt may enabl better immuneprim tumor daili radiotherapi materialsmethod subcutan mc38 murin colon cancer mous model irradi differ radiat regimen impact interfract interv dose per fraction tumor control immun mobil synergist effect antipd1 immunotherapi explor immun activ assess analyz cd4 cd8 cell peripher blood intratumor cd4 cd8 cell flow cytometri sampl three day complet schedul irradi result fix dose per fraction experi 65gi qod 65gi qd irradi scheme result ident tumor control 65gi biw scheme led tumor progress moreov qod biw regimen show abil activ immun respons wherea qd regimen fix biolog equival dose bed experi comparison differ regimen increas dose per fraction prolong interfract interv show 123gi qd regimen hsrt regimen includ 65gi qod 47gi biw 211gi qw led ident tumor control importantli hsrt regimen show signific mobil host immun wherea 123gi qd peripher intratumor cd4 cd8 cell increas increas interfract interv dose per fraction final hsrt regimen combin antipd1 immunotherapi show enhanc tumor growth delay singl treatment 123gi qd regimen conclus preclin model demonstr convent daili fraction radiotherapi benefici host immun activ tumor preliminari result suggest prolong interfract interv increas dose per fraction may option strategi balanc tumor control immun activ',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023061257 pmid 37785043',\n '68 int j radiat oncol biol phi 2023 oct 11172se274e275 doi 101016jijrobp2023061247',\n 'dynam exosom analysi predict respons combin sabr immunotherapi oligoprogress diseas',\n 'martin jz1 onieva jl2 roman a3 garrido m2 oliv j2 martinezgalvez b2 dubbelman j2 mesa a4 villatoro r5 ramo i2 ruedadominguez a2 perezruiz e2 benitez jc2 medina ja3 alba e2 sett rc6 barragan i7',\n 'author inform 1group translat research cancer immunotherapi health medic research centr cime univers malaga uma institut biomed research malaga ibima malaga spain depart radiat oncolog virgen de la victoria univers hospit malaga spain 2group translat research cancer immunotherapi health medic research centr cime univers malaga uma institut biomed research malaga ibima malaga spain medic oncolog intercent unit region virgen de la victoria univers hospit malaga spain 3depart radiat oncolog virgen de la victoria univers hospit malaga spain 4medic oncolog intercent unit region virgen de la victoria univers hospit malaga spain 5depart medic oncolog costa del sol hospit marbella spain 6depart radiat oncolog la fe univers hospit valencia spain depart radiat oncolog ascir grupo biomedico valencia spain 7group translat research cancer immunotherapi health medic research centr cime univers malaga uma institut biomed research malaga ibima malaga spain group pharmacoepigenet depart physiolog pharmacolog karolinska institutet stockholm sweden',\n 'purposeobject 80 metastat patient face resist immun checkpoint inhibitor ici combin sabr ici isabr unleash antitumor immun cascad overcom resist improv respons minim toxic synergi particularli interest oligoprogress set extend clinic benefit cb ici howev current biomark patient select hypothes differenti express exosom rna liquid biopsi may predict respons isabr materialsmethod ongo prospect multicent studi two cohort cohort consist metastat patient oligoprogress ici 15 extracrani site maintain ici due cb receiv concomit sabr 35 gy 5 fraction fx oligoprogress site cohort b compar group oligometastat patient receiv sabr abl dose blood sampl extract sabr t1 first t2 last t3 fx two month postsabr t4 progress tp respons evalu irecist defin object respons rate orr lesion outoffield complet partial respons exosom analysi perform rna isol small rna sequenc plasma use cutadapt bowti featurecount quantifi number read mirna small nuclear rna snrna small nucleolar rna snorna pairwis differ express respond nonrespond examin deseq2 differenti express analysi differenti express transcript consult ingenu pathway analysi ipa result 22 patient recruit present preliminari result first 10 8 cohort 2 b undergon reevalu sabr frequent cancer type lung 60 renal cell 20 seventi percent polymetastat 5 lesion 90 singl progress site pembrolizumab 40 nivolumab 30 frequent ici lesion sabr lung 45 median followup 71 month 95 ci 37106 orr two month 60 6 partial respons 1 stabl diseas 3 progress median progressionfre surviv 103 month 95 ci 37not reach median overal surviv reach seven patient cohort avail small rna analysi identifi 3 mirna 24 snrna 9 snorna significantli differenti express t1 hsamir493 marker tumor progress upregul nonrespond rn7sk inhibit las1l known inductor metastasi lung cancer upregul respond snord71 inhibit ilf3 promotor progress also upregul respond conclus isabr effect approach extend cb ici oligoprogress patient exosom rna express analysi liquid biopsi novel noninvas techniqu may predict respons combin aid patient select',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023061247 pmid 37785033',\n '69 int j radiat oncol biol phi 2023 oct 11172se264 doi 101016jijrobp2023061221',\n 'compar analysi tumor microbiom molecular profil immun cell abund hpv statu head neck cancer impact surviv',\n 'upadhyay r1 dhakal a2 karivedu v3 wheeler c3 hoyd r3 bhateja p3 bonomi m4 valentin s3 gamez me5 konieczkowski dj6 baliga s7 grecula jc8 blakaj dm9 gogineni e8 mitchel dl8 denko n8 jhawar sr8 spakowicz d3',\n 'author inform 1the jame ohio state new delhi india 2the ohio state univers colleg medicin columbu oh 3the ohio state univers wexner medic center columbu oh 4depart medic oncolog ohio state univers wexner medic center columbu oh 5depart radiat oncolog mayo clinic rochest mn 6jame cancer hospit ohio state univers columbu oh 7ohio state univers columbu oh 8depart radiat oncolog ohio state univers wexner medic center columbu oh 9jame cancer hospit solov research institut ohio state univers columbu oh',\n 'purposeobject tradit clinic molecular prognost factor offer valuabl insight heterogen natur histori treatment respons head neck squamou cell carcinoma hnscc yet fail explain full spectrum observ variabl tumor microenviron tme compris microbiom immun cell impact treatment respons prognosi analyz cancer genom atla tcga evalu associ specif microb gene tme surviv differenti express hpv posit hpv neg hnscc materialsmethod hnscc rna sequenc rnaseq sampl tcga process exogen sequenc tumor immun cell exot pipelin identifi gene express microbi presenc hpv statu assess detect papillomavirida famili microb clinic data tcga extract compar overal surviv os control compet variabl use cox proport hazard regress differ immun cell abund evalu kruskalw test statist analysi perform use r result total 498 rnaseq sampl tcga analyz oral caviti oropharynx hypopharynx larynx tumor compris 216 15 18 222 specimen respect hpv detect 111 patient 22 commonli alpha papillomaviru 9 901 5838 enrich microb 330 significantli associ os control tumor stage smoke age specif presenc alpha papillomaviru 9 associ significantli improv os adjust hr 060 95 ci 040 089 p 001 microbi speci found abund hpv tumor includ citrobact farmeri thermoanaerobact kivui yersinia pesti gram neg anaerob gene relat cellular transport dna repair enrich gene relat prolifer eg sage1 deplet hpv sampl hpv tumor significantli higher number m0 p 0001 m2 macrophag p 0035 hpv tumor regulatori cell p 0001 cd8 tcell p 0001 conclus tumor microenviron significantli associ surviv hnscc patient particular microb alpha papillomaviru 9 correl improv os greater abund certain anaerob microb seen hpv tumor find suggest tme use predict patient outcom potenti guid person treatment approach found abund m0 m2 macrophag hpv tumor consid protumorigen antitumor m1 macrophag similar two group may help identifi mechan resist immunotherapi tailor novel immunotherapi combin specif patient subgroup prospect research extern valid find potenti significantli impact way treat hnscc futur',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023061221 pmid 37785006',\n '70 int j radiat oncol biol phi 2023 oct 11172se262e263 doi 101016jijrobp2023061218',\n 'analyz predict effect pdl1 express earli chang btmb circul cd8t cell treatment respons rt combin ici nsclc',\n 'teng f1 wang p2 yin t3 xing l4 yu j5',\n 'author inform 1depart radiat oncolog shandong cancer hospit institut shandong first medic univers shandong academi medic scienc jinan shandong china 2shandong cancer hospit institut cheeloo colleg medicin shandong univers jinan china 3cancer center union hospit tongji medic colleg huazhong univers scienc technolog wuhan hubei china 4shandong cancer hospit affili shandong univers shandong academi medic scienc jinan shandong china 5shandong cancer hospit shandong univers jinan shandong china',\n 'purposeobject benefici role immunotherapi clinic relev current biomark remain inconclus thu appropri strategi reliabl predictor need definit ration combin biomark need estim potenti predict factor respons radiotherapi rt combin immun checkpoint inhibitor ici phase ii trial determin efficaci safeti combin moder hypofraction rt ici patient oligometastat nsclc nct03557411 materialsmethod pretreat tumor tissu sampl longitudin blood collect immun tumor biomark analysi examin pretreat preici pdl1 express tumor cell circul tumor cell ctc pdl1ctc blood tumor mutat burden btmb cd8t cell cd4t cell nk cell b cell circul acquir preici 1 month ici start 1mth addit earli chang ctc ctc pdl1ctc pdl1ctc btmb btmb cd8t cell cd8t cell cd4t cell cd4t cell nk cell nk cell b cell b cell also analyz estim predict effect treatment result high preici btmb increas cd8t cell 1 month associ better pf p 0016 p 0006 interact analys reveal combin two marker 5 marker includ pdl1 preici btmb 1mth btmb 1mth cd8t cell cd8t cell significantli associ pf except ctc pdl1ctc cd4t cell nk cell b cell circul due low power unsupervis cluster analysi base marker reveal three subcohort cohort1 overrepres patient progress diseas 81 neg 34 5 biomark cohort3 overrepres patient partial respons 70 posit 34 5 biomark surviv analys 3 cohort indic signific associ pf p 0017 conclus studi suggest combin pdl1 express earli chang btmb circul cd8t cell better predict biomark respons rt combin ici consequ refin set biomark valid larger set patient warrant',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023061218 pmid 37785003',\n '71 int j radiat oncol biol phi 2023 oct 11172se253e254 doi 101016jijrobp2023061198',\n 'macrophag mediat abscop effect radiat therapi',\n 'nishiga y1 sage j2 grave ee3',\n 'author inform 1depart radiat oncolog stanford univers stanford ca depart pediatr genet stanford univers stanford ca 2depart pediatr genet stanford univers stanford ca 3depart radiat oncolog stanford univers school medicin stanford ca',\n 'purposeobject radiat therapi rt activ innat adapt immun respons combin rt immunotherapi thought promis strategi found donteatm molecul cd47 highli express surfac small cell lung cancer sclc cell highli metastat form lung cancer blockad cd47 enhanc phagocytosi sclc cell macrophag studi investig whether combin cd47 blockad rt could synerg inhibit tumor growth sclc well cancer preclin model materialsmethod evalu efficaci immun respons rt cd47 blockad sclc preclin model well colon cancer lymphoma preclin model engraft cancer cell flank recipi mice irradi one side tumor without cd47 antibodi investig local system effect rt cd47 blockad also use liver metastas model endogen lung tumor model investig antitumor effect immun respons tumor microenviron human patient investig immun respons rt use cibersortx result found cd47 blockad potent enhanc local antitumor effect rt preclin model sclc test strikingli cd47 blockad also stimul system abscop effect inhibit nonirradi sclc tumor mice receiv rt effect observ liver metastas model endogen lung tumor model well subcutan tumor model surprisingli abscop effect independ cell requir macrophag migrat nonirradi tumor site respons inflammatori signal produc rt local activ cd47 blockad phagocytos cancer cell similar abscop antitumor effect observ cancer model treat rt cd47 blockad also found rt increas tumor infiltr macrophag human cancer patient interestingli abscop antitumor effect enhanc pd1 blockad model conclus data clearli demonstr macrophagemedi abscop respons rt combin cd47 blockad rang cancer model system activ antitumor macrophag follow radiat cd47 blockad may particularli import cancer patient suffer metastat diseas rt part standardofcar cd47block strategi clinic trial therefor observ may rapidli translat cancer patient',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023061198 pmid 37784981',\n '72 int j radiat oncol biol phi 2023 oct 11172se247 doi 101016jijrobp2023061184',\n 'evalu antitumor immun combin treatment radiat antipd1 antiangiogen therapi esophag squamou cell carcinoma',\n 'liu y1 li t2',\n 'author inform 1school medicin univers electron scienc technolog china chengdu china affili cancer hospit school medicin univers electron scienc technolog china sichuan cancer hospit research institut chengdu china 2depart radiat oncolog sichuan cancer hospit institut sichuan cancer center school medicin univers electron scienc technolog china radiat oncolog key laboratori sichuan provinc chengdu china',\n 'purposeobject radiotherapi one main therapeut method esophag cancer immunotherapi improv antitumor immun radiotherapi special immun microenviron esophag cancer limit effect therefor explor combin therapi approach base tumor microenviron materialsmethod proof concept construct 4nqoinduc esophag carcinoma mous model human pbmc tumor cell cocultur system tumor suppress activ immunophenotyp radiotherapi alon combin program death1 pd1 antiangiogenesi therapi evalu vivo vitro result radiotherapi combin immunotherapi antiangiogen therapi increas express cd4 b lymphocyt nkt cell peripher blood spleen mice decreas express treg cell antiangiogen therapi significantli reduc rtinduc treg cell express suggest weak revers immunosuppress environ rt combin antipd1 antiangiogenesi therapi inhibit tumor growth similar signific effect observ antivegf ad rt combin antipd1 therapi observ improv surviv mice esophag cancer cocultur system observ combin therapi reduc express tgf1 tgf2 il6 gene tumor cell impli antitumor immun addit rather synergist result provid evid oper immunosuppress tumor environ provid insight design new combin therapi conclus radiotherapi combin pd1 monoclon antibodi antiangiogenesi therapi significantli improv efficaci singl radiotherapi target therapi esophag cancer cell also improv immun microenviron state tumor suppress esophag cancer',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023061184 pmid 37784966',\n '73 int j radiat oncol biol phi 2023 oct 11172se246 doi 101016jijrobp2023061182',\n 'dissect system cell respons stereotact abl radiotherapi nsclc singlecel rna cell receptor sequenc',\n 'liu c1 zou w1 huang r1 yu j1 sun b2',\n 'author inform 1depart radiat oncolog shandong cancer hospit institut shandong first medic univers shandong academi medic scienc jinan china 2depart radiat oncolog fifth medic center chines pla gener hospit beij china',\n 'purposeobject accumul evid stereotact abl radiotherapi sabr modul immun respons cancer combin sabr immunotherapi could promot abscop effect precis effect sabr patient system cell unclear investig sabrinduc system cell respons earlystag nonsmal cell lung cancer nsclc singlecel rna cell receptor sequenc materialsmethod perform singlecel rna cell receptor sequenc 29439 cell four pair peripher blood sabr earlystag nsclc patient cell cluster dimension reduct singler featur gene score tcr profil analys use investig heterogen cell chang follow sabr result identifi fourteen cell subtyp use unsupervis graphbas cluster uniform manifold approxim project compar gene set score cd8te cd8em pre postsabr found cytotox inhibitori score significantli elev cd8te p 0001 cytotox score significantli increas cd8em p 0001 sabr also found cd4te show increas cytotox score decreas treg score p 0001 005 respect treg cell show decreas inhibitori treg score p 0001 001 respect sabr proport larg tcr clone higher sabr accompani decreas proport singl clone compar transcriptom cd8te cell singl small larg clone postsabr found high express gzmb klrc3 cell larg clone gzmk il7r sell small singl clone suggest cell sabr larg clone may higher cytotox small singl clone conclus studi identifi system cell activ sabr singlecel resolut provid unpreced insight immunemodulatori role sabr earlystag nsclc',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023061182 pmid 37784964',\n '74 int j radiat oncol biol phi 2023 oct 11172se241 doi 101016jijrobp2023061169',\n 'combin immunotherapi partial versu whole tumor radiotherapi preclin melanoma tumor model',\n 'koerner sa1 rajkumar h2 eding r2 lalond rj3 patel rb3',\n 'author inform 1depart radiat oncolog upmc hillman cancer center pittsburgh pa 2univers pittsburgh pittsburgh pa 3upmc hillman cancer center pittsburgh pa',\n 'purposeobject partial tumor radiotherapi ptrt immun checkpoint inhibit ici current subject clinic trial may use clinic larg volum tumor full gross tumor volum gtv safe treat full dose ptrt deliv rt portion gtv underdos treat remaind gtv hypothes icimedi tumor infiltr lymphocyt til infiltr produc adequ diseas control un underirradi gtv standard treatment whole tumor radiotherapi wtrt potenti differ diseas control ptrt wtrt ici robustli assess hypothes ptrt ici wtrt ici demonstr similar tumor regress rt regimen demonstr superior tumor regress compar ici alon materialsmethod b78 melanoma flank tumor gener c57bl6 mice random tumor size 1 cm experiment cohort ptrt ici wtrt ici control group rt ici custom lead shield fabric deliv 16 gy singl fraction ptrt 50 tumor treatment wtrt dosimetri confirm via radiochrom film ici deliv ip inject murin antictla4 antipdl1 day 0 3 6 postrt tumor regress assess via differ tumor volum ten day post complet ici mean cohort tumor volum compar anova 005 varianc individu cohort assess via ttest 005 result treatment cohort demonstr signific varianc tumor volum ten day follow treatment complet p 0007 tabl 1 wtrt ici demonstr superior tumor regress compar ptrt ici p 0006 ici alon p 0002 control cohort p 0013 differ tumor regress ptrt ici ici alon p 0709 ptrt ici achiev signific regress compar control p 0083 tumor regress differ cohort receiv rt ici p 0103 conclus result ici resist melanoma model demonstr superior tumor regress wtrt ici compar ptrt ici ici alon suggest even concurr ici ptrt may suffici treatment melanoma ptrt ici tumor regress similar ici alon suggest ptrt may overcom immun resist unirradi tumor volum investig optim rt regimen potenti ici respons warrant correl studi examin spatial immunomodul unirradi irradi portion tumor underway',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023061169 pmid 37784952',\n '75 int j radiat oncol biol phi 2023 oct 11172se224 doi 101016jijrobp2023061130',\n 'tumor cellintrins pdl1 effect radiationinduc locoregion antitumor immun',\n 'clark ca1 zhang z2 zhang y3 xing c3 larim b3 yang es3',\n 'author inform 1uab hazelrig salter radiat oncolog center birmingham al 2uab birmingham al 3univers alabama birmingham birmingham al',\n 'purposeobject target pdl1 benefici strategi reinvigor antitumor immun howev variabl respons resist challeng suggest need multimod approach tumor cellintrins pdl1 signal also regul noncanon pathogen pathway may impact treatment resist ioniz radiat ir induc antitumor immun demonstr therapeut synergi immunotherapi case howev tumordriven immunolog mechan affect clinic outcom remain incomplet understood studi investig impact tumor cellintrins pdl1 signal irinduc locoregion immun respons tumor control materialsmethod use orthotop b16f10 melanoma wtb16 4t1 tripl neg breast cancer wt4t1 murin tumor model well pdl1 disabl variant ko gener crisprcas9 implant bilater ir 10 gy target one tumor alon evalu direct indirect ir effect base tumor pdl1 statu evalu respons tumor volum tv measur flow cytometri tumorinfiltr lymphocyt til tumor drain lymph node tdln irradi unirradi compart granzym b gzb pet imag assess function vivo chang chemokinebas multiplex assay use assess cell line receiv ir 4gi ex vivo tumor lysat serum result irinduc local tumor control significantli affect base tumor pdl1 statu howev deactiv tumor cell pdl1 enhanc irinduc region tumor control unirradi wt tumor mice harbor irradi ko irradi wt tumor demonstr signific mean reduct tv instanc complet distant tumor regress pet imag demonstr nearli 2fold higher concentr gzb ko versu wt tumor line known local immunosuppress effect tumor pdl1 remark gzb level 15fold higher unirradi wt tumor mice harbor irradi ko versu wt tumor correl 50 increas pd1cd8 cell higher level cd62cd44 nave cd4 4fold cd8 2fold memori cell seen tdln irradi ko versu wt tumor cytokin level posit correl immun recruit activ statu cxcl10 ccl2 ccl5 significantli upregul pdl1 ko versu wt tumor cell conclus result studi demonstr cellintrins pdl1 inhibit irinduc locoregion immun activ frequenc region tumor control clinic implic includ therapeut target tumor cellintrins pdl1 signal enhanc irinduc immunogen util ir base tumor pdl1 statu particularli metastat set immunotherapi combin futur studi investig mechan resist irinduc immun activ enhanc respons warrant',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023061130 pmid 37784910',\n '76 int j radiat oncol biol phi 2023 oct 11172se221 doi 101016jijrobp2023061123',\n 'carm1 inhibit potenti irradiationinduc antitumor immun via tumor intrins sting pathway activ',\n 'wang j1 wu m1 yu j1 chen d2',\n 'author inform 1shandong cancer hospit institut shandong first medic univers shandong academi medic scienc jinan shandong china 2shandong univers cancer center depart radiat oncolog shandong provinci key laboratori radiat oncolog shandong first medic univers shandong academi medic scienc jinan shandong china',\n 'purposeobject radiotherapi commonli appli multipl cancer type besid irradi induc direct cell death radiotherapi stimul signific immun respons tumor control intact function cgasst pathway tumor cell host cell indispens effici irradiationinduc antitumor effect coactivatorassoci arginin methyltransferas 1 carm1 emerg attract therapeut target biomark prognosi variou type cancer report carm1 inhibit could improv immunotherapi induc antitumor effect howev remain unclear tumor cell intrins carm1 affect irradiationinduc antitumor immun materialsmethod carm1 defici cell line establish mc38 b16f10 murin cancer cell use crisprcas9 technolog verifi effect tumor subcutan tumor mous model establish one fraction 15gi administr tumor volum reach 200mm3 follow flow cytometri assay transcriptom sequenc protein mass spectrometri singlecel sequenc digit spatial profil dsp realtim qpcr western blot immunofluoresc coimmunoprecipit carri explor verifi possibl molecular mechan result found carm1 defici tumor cell dramat enhanc irradiationinduc antitumor immun respons transcriptom sequenc irradi tumor cell experi valid cgasst pathway significantli activ irradi absenc carm1 tumor cell contribut enhanc antitumor immun irradi mechanist carm1 defici tumor cell attenu autophagi result increas cytoplasm mtdna enrich enhanc cgasst pathway activ hand also found carm1 caus asymmetr arginin methyl adma modif tbk1 reduc phosphoryl level carm1 defici could activ cgasst pathway reduc amda modif enhanc phosphoryl tbk1 final carm1 inhibitor ezm2302 appli combin radiotherapi vitro indic combin therapi result intens antitumor immun promin abscop effect conclus studi identifi carm1 ablat tumor cell could promot irradiationinduc antitumor immun tumor cell intrins sting pathway activ mechan carm1 defici directli activ cgasst pathway interact tbk1 increas mtdna accumul cytoplasm inhibit autophagi find provid new strategi target carm1 boost efficaci radiotherapi',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp2023061123 pmid 37784903',\n '77 int j radiat oncol biol phi 2023 oct 11172se22 doi 101016jijrobp202306695',\n 'role modal combin radiotherapi immunotherapi stage iiiiv unresect small cell lung cancer',\n 'guo yx1 q1 chen ll1 li ty1 chen d2 liang j3 wang l4 jiang w3',\n 'author inform 1depart radiat oncolog nation cancer centern clinic research center cancercanc hospit shenzhen hospit chines academi medic scienc peke union medic colleg shenzhen china 2nation cancer centern clinic research center cancercanc hospit shenzhen hospit shenzhen china 3depart radiat oncolog nation cancer centern clinic research center cancercanc hospit shenzhen hospit chines academi medic scienc peke union medic colleg shenzhen china shenzhen china 4depart radiat oncolog nation cancer centern clinic research center cancercanc hospit chines academi medic scienc peke union medic colleg beij china beij china',\n 'purposeobject combin radiotherapi immunotherapi rare report manag small cell lung cancer sclc retrospect assess role modal combin stage iiiiv unresect sclc materialsmethod patient stage iii iv sclc enrol accord ajcc 8th edit efficaci safeti immunotherapi combin radiotherapi evalu thereinto patient receiv firstlin chemoimmunotherapi sequenti thorac consolid radiotherapi tcrt evalu surviv descript analys perform result januari 1 2019 decemb 31 2021 51 patient includ analysi median followup 280 month 95 ci 228332 patient receiv radiotherapi treatment cours prolong 2year overal surviv os firstlin immunotherapi cohort 27 patient addit tcrt significantli improv 2yo 7222 vs 1389 p 00048 2ylocoregion recurr free surviv lrrf 9000 vs 4800 p 0011 2ydist progress free surviv dpf 6667 vs 1667 p 0039 subgroup analys show tcrt render superior outcom regardless brain metastas doseescal 45 gy15f earlier radiotherapi seem improv benefit 7037 1927 patient experienc diseas progress tcrt evalu cohort 6316 1219 patient fail brain tendenc toward better os superior brain metastas free surviv bmf observ receiv prophylact cranial irradi pci final common grade 2 higher toxic effect pneumon patient 1176 immunerel vs 784 radiat relat conclus earlier addit tcrt immunotherapi could significantli improv surviv extracrani control stage iiiaivb unresect sclc patient increas risk advers event era immunotherapi pci may still recommend strategi investig warrant',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306695 pmid 37784898',\n '78 int j radiat oncol biol phi 2023 oct 11172se21 doi 101016jijrobp202306694',\n 'induct immunotherapi vs consolid immunotherapi unresect stage iii nsclc',\n 'guan s1 ren k1 yan m1 zhang w1 liu n1 wang j1 zhao l1',\n 'author inform 1tianjin medic univers cancer institut hospit nation clinic research center cancer tianjin clinic research center cancer key laboratori cancer prevent therapi tianjin tianjin china',\n 'purposeobject consolid immunotherapi chemoradiotherapi crt standard care unresect stage iii nonsmal cell lung cancer nsclc howev whether upfront immunotherapi crt similar benefit address studi aim explor efficaci safeti induct immunotherapi unresect stage iii nsclc realworld data materialsmethod patient diagnos stage iii nsclc receiv immunotherapi combin sequenti scrt concurr crt ccrt novemb 2018 decemb 2021 retrospect identifi patient divid induct ind consolid con induct plu consolid indcon immunotherapi group progressionfre surviv pf overal surviv os assess initi treatment estim kaplanmei method potenti factor affect pf os analyz univari multivari cox regress model result one hundr two patient includ 52 510 patient ind group 35 343 con group 15 147 indcon group median pf 240 month vs 360 month vs 190 month three group 2year pf 430 vs 511 vs 444 p 0940 median os reach nr vs 440 month vs nr 2year os rate 805 vs 844 vs 862 p 0861 ccrt set 2year pf rate 567 vs 716 vs 1000 p 0439 2year os rate 923 vs 893 vs 1000 three group p 0827 multivari analysi elder hr 0487 p 0037 ccrt hr 0282 p 0001 independ factor favor pf elder hr 0088 p 0021 independ factor favor os advers event similar three arm analysi found object respons rate orr diseas control rate dcr ind indcon group induct immunotherapi 597 985 respect 1 15 patient develop progress subgroup analysi show signific differ pf p 0520 os p 0116 patient respond induct immunotherapi prcr sdpd patient 4 cycl induct immunotherapi exhibit numer better pf 4 cycl induct immunotherapi p 0113 improv os p 0021 conclus induct immunotherapi may achiev similar surviv benefit consolid immunotherapi combin induct consolid immunotherapi ccrt appear achiev better outcom seem feasibl safe upfront immunotherapi crt investig combin induct immunotherapi crt warrant',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306694 pmid 37784874',\n '79 int j radiat oncol biol phi 2023 oct 11172se19 doi 101016jijrobp202306689',\n 'outcom hypofraction radiotherapi induct sequenti chemotherapi unresect stage iii nonsmal cell lung cancer singl institut experi',\n 'gerard ij1 rastogi n2 paraga j1 connel t3 abdulkarim bs1 duclo m1 faria s1 kopek n1',\n 'author inform 1mcgill univers health centr divis radiat oncolog montreal qc canada 2mcgill univers montreal qc canada 3medic physic unit mcgill univers montreal qc canada',\n 'purposeobject standard care unresect stage iii nonsmal cell lung cancer nsclc patient candid concurr chemotherapi ct radiotherapi rt well establish hypofraction rt hrt use ct induct bridg sequenti ct offer cur intent treatment regimen tumor nodal proxim mediastin structur play import role regard degre safe hypofraction limit publish evid relat benefit hrt combin induct sequenti ct among group patient analyz outcom stage iii nsclc receiv hrt regimen 525 gy 15 fraction alon either induct sequenti ct materialsmethod retrospect review patient stage iii nsclc receiv hrt 525 gy 15 fraction 2008 2020 includ analysi patient separ three cohort hrt alon ii induct ct follow hrt iii hrt follow sequenti ct overal surviv os radiat toxic ctcae v50 analyz 3 cohort patient sequenti chemotherapi plan deliv includ cohort ii intentiontotreat analysi os 2 year statist evalu use logrank test alpha set 005 result eightythre patient met criteria analysi 35 30 18 patient respect cohort ii iii median age treatment 75 4391 53 patient men 43 women tumor histolog vari adenocarcinoma 43 squamou cell carcinoma 44 other 13 median2year os cohort ii iii 8 mo19 25 mo50 17 mo72 respect os chemotherapi chemotherapi statist signific p 61x107 time chemotherapi reach statist signific p 015 rt overal well toler grade 12 fatigu common side effect 81 1 patient grade 3 pneumon 1 patient rib fractur conclus among patient stage iii nsclc moder hrt 525 gy 15 fraction either induct sequenti ct appear provid surviv advantag compar hrt alon accept sideeffect profil 2year os report similar publish hrt regimen soccar trial convent fraction rtog0617 conclus limit retrospect natur studi introduct immunotherapi io stage iii nsclc 2019 canada futur work focu evalu dosimetri impact io patient includ analysi also receiv regimen oligometastasi locoregion failur stage',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306689 pmid 37784823',\n '80 int j radiat oncol biol phi 2023 oct 11172se17 doi 101016jijrobp202306683',\n 'symptomat pneumon rate among patient stage iii nonsmal cell lung cancer receiv adjuv durvalumab',\n 'edward dm1 bryant ak2 sankar k3 dess k4 alseri a4 ramnath n3 green m1',\n 'author inform 1depart radiat oncolog univers michigan ann arbor mi 2depart radiat oncolog veteran affair ann arbor health system ann arbor mi 3depart hematolog oncolog univers michigan ann arbor mi 4veteran affair ann arbor health system ann arbor mi',\n 'purposeobject adjuv durvalumab definit chemoradi stage iii nonsmal cell lung cancer nsclc improv overal surviv low report pneumon rate clinic trial howev realworld rate treatmentassoci pneumon remain poorli defin sought describ pneumon rate among largesttod realworld cohort stage iii nsclc patient receiv adjuv durvalumab materialsmethod perform retrospect cohort studi patient stage iii nsclc nation veteran health administr receiv concurr chemoradi alon 20152016 concurr chemoradi follow least one dose adjuv durvalumab 20172021 incid pneumon defin new worsen symptom radiograph chang ct chest least one steroid prescript like diagnosi pneumon treat physician within 2 year final radiat treatment sever grade ctcae v403 criteria pneumon event ascertain manual chart review assist keyword search steroid prescript data cox regress use identifi baselin clinic factor associ grade 2 pneumon result cohort includ 1994 patient stage iiii nsclc 989 receiv concurr chemoradi alon 1005 receiv adjuv durvalumab overal incid symptomat pneumon among patient receiv concurr chemoradi alon vs receiv adjuv immunotherapi 68 vs 11 grade 2 p 00005 6 vs 84 grade 3 p 0007 11 vs 16 grade 5 p 0292 respect cumul incid grade 25 pneumon 2 year 138 among patient treat chemoradi alon versu 221 patient treat chemoradi follow durvalumab p 00001 grade 2 pneumon pneumon occur 85 patient within one year receiv radiat 84 grade 35 pneumon develop pneumon within one year patient prescrib outpati steroid pneumon activ prescript last mean 153 day among hospit pneumon need supplement oxygen support multivari analysi use durvalumab associ higher risk grade 25 pneumon hr 14 p 0004 current smoker 50 risk reduct grade 2 pneumon rel never smoker p0001 conclus largesttod cohort found adjuv immunotherapi associ higher risk grade 2 pneumon increas symptomat pneumon associ durvalumab spur futur work refin patient select balanc riskbenefit adjuv immunotherapi potenti modifi radiat dosimetr constraint decreas pneumon rate',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306683 pmid 37784776',\n '81 int j radiat oncol biol phi 2023 oct 11172se16 doi 101016jijrobp202306681',\n 'stage iiia nonsmal cell lung cancer treatment outcom singl institut retrospect analysi',\n 'duan r1 kwan m1 kordon a1 hu c1 vanjani n1 thoma to1 patel jd2 yadav p1 abaze m1 gharzai la1',\n 'author inform 1depart radiat oncolog northwestern univers feinberg school medicin chicago il 2luri cancer center northwestern universityfeinberg school medicin chicago il',\n 'purposeobject treatment local advanc nonsmal cell lung cancer nsclc remain challeng multitud treatment option avail stage iii patient hypothes stage iiia outcom differ treatment receiv materialsmethod perform retrospect review nsclc patient 18 year old stage iiia diseas treat 11201003012022 demograph treatment receiv treatment outcom failur pattern collect progressionfre surviv pf overal surviv os assess use kaplanmei analysi kruskalw anova use compar group result 352 patient identifi 160 stage iiia nsclc median followup 291 month patient median age 63 year 79 494 male 137 856 currentform smoker 30 median packyear patient treat follow 17 11 surgeri alon 91 57 definit radiat chemotherapi crt 52 33 neoadjuv therapi follow surgeri neo 6 12 neo group receiv chemoimmunotherapi 21 51 41 crt patient receiv adjuv immunotherapi three group signific differ tumor size measur tstage p 083 baselin fev1fvc p 092 median pf 335mo 95 ci 132na group 184mo 95 ci 127422 crt 197mo 95 ci 139na neo signific intergroup differ p 072 median os 335mo 95 ci 132na 487mo 95 ci 360889 crt 509mo 95 ci 419na neo signific intergroup differ p 094 among 17 primari surgic patient 11 65 experienc failur 6 35 local 5 29 region 7 41 distant among 91 crt patient 57 63 experienc failur 40 44 local 35 38 region 28 31 distant among 52 neo patient 26 50 experienc failur 14 27 local 15 29 region 17 33 distant signific differ rate local failur p 026 region failur p 059 distant failur p 079 failur p 041 among three treatment group common locat distant failur pleural effus n 15 29 cn n 14 27 bone n 11 21 conclus singl institut retrospect studi find signific differ pf os failur pattern patient stage iiia nsclc treat definit chemoradi neoadjuv therapi numer improv pf surgeryonli patient consist expect patient select group work immunotherapi era need',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306681 pmid 37784754',\n '82 int j radiat oncol biol phi 2023 oct 11172se158 doi 101016jijrobp202306985',\n 'innov regimen base hfrtsbrt rc48adc coactiv salvag therapi patient her2express advanc solid tumor',\n 'xu m1 chen r2 xing p3 kong y4 zhang j5 zhao x4 zhang l6',\n 'author inform 1institut radiotherapi oncolog soochow univers suzhou china suzhou china laboratori combin radiotherapi immunotherapi cancer second affili hospit soochow univers suzhou china 2the second affili hospit soochow univers suzhou china institut radiat oncolog soochow univers suzhou china 3depart radiotherapi oncolog second affili hospit soochow univers institut radiotherapi oncolog soochow univers suzhou key laboratori radiat oncolog suzhou china 4depart radiotherapi oncolog second affili hospit soochow univers suzhou china 5depart radiotherapi oncolog second affili hospit soochow univers institut radiotherapi oncolog soochow univers suzhou key laboratori radiat oncolog suzhou china suzhou radiotherapi clinic medic center suzhou china 6institut radiotherapi oncolog soochow univers suzhou china',\n 'purposeobject wide accept radiotherapi especi hypofraction radiat therapi hfrt stereotact radiotherapi sbrt modul tumor phenotyp enhanc antigen present provok system immun respons give strong rational combin rt immunotherapi irt prag therapi innov irt combin hfrtsbrt pd1l1 inhibitor gmcsf activ immun respons modul tumor microenviron exert desir abscop effect previou studi demonstr encourag efficaci prag regimen treatment advanc refractori tumor rc48adc promis antiher2 antibodydrug conjug induc immunogen cell death widespread releas cancer cell antigen synerg immunotherapi promot effector tcell activ aim studi explor efficaci safeti rc48adc combin radiotherapi pd1l1 inhibitor sequenti gmcsf il2prag30 regimen treatment her2express advanc solid tumor materialsmethod particip advanc confirm her2express ihc3 2 1 solid tumor progress standard treatment intoler enrol prag30 regimen cycl receiv rc48adc 20 mgkg d1 everi 3 week hfrt 23 dose 58 gy deliv one metastat lesion everi day follow gmcsf 200 g d37 sequenti il22million iu d812 pd1l1 inhibitor dose within one week complet hfrt rc48adc combin pd1l1 inhibitor sequenti gmcsf il2 least 6 cycl mainten pd1l1 inhibitor administ diseas progress unaccept toxic primari endpoint object respons rate orr trial regist clinicaltrialsgov number nct05115500 result cutoff date 31 decemb 2022 total 30 patient n 6 gynecolog cancer n 5 pancreat cancer n 19 cancer enrol 21 patient complet least 1 tumor assess object respons rate orr 429 diseas control rate 714 recist11 orr 667 gynecolog cancer 253 pancreat cancer 364 cancer median progressionfre surviv pf patient 70 month 95 ci 34 107 common treatmentrel advers event trae includ fatigu fever alopecia anorexia grade 3 trae occur two patient 67 conclus preliminari result show prag30 regimen manag safeti profil encourag antitumor activ heavili pretreat patient her2 express cancer ultim regimen achiev accur integr rt immunotherapi target therapi',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306985 pmid 37784749',\n '83 int j radiat oncol biol phi 2023 oct 11172se157 doi 101016jijrobp202306983',\n 'priorit radiat target system therapi patient resect brain metastas lung cancer primari target mutat report multisit singl institut',\n 'wuu yr1 gui b1 kokabe m2 stone j3 karten jl4 harshan m2 damico r5 vojnic m6 wernick g7',\n 'author inform 1depart radiat medicin northwel health cancer institut lake success ny donald barbara zucker school medicin hofstranorthwel hempstead ny 2donald barbara zucker school medicin hofstranorthwel depart patholog laboratori medicin lenox hill hospit new york ny 3donald barbara zucker school medicin hofstranorthwel hempstead ny 4nyit colleg osteopath medicin old westburi ny 5donald barbara zucker school medicin hofstranorthwel depart neurosurgeri lenox hill hospit new york ny 6donald barbara zucker school medicin hofstranorthwel depart medic oncolog northwel health cancer institut meeth new york ny 7depart radiat medicin northwel health cancer institut lake success ny donald barbara zucker school medicin hofstranorthwel depart radiat medicin lenox hill hospit new york ny',\n 'purposeobject brain metastas brm common complic nonsmal cell lung cancer nsclc present 50 patient treatment brm requir multidisciplinari approach surgeri radiotherapi rt system therapi advanc sequenc improv outcom target alter pdl1 egfr alk kra mutat push toward molecular character cancer sought examin outcom treatment modal institut respect priorit rt target therapi materialsmethod irb approv identifi patient treat surgic resect brm nscl primari 2011 2022 5 site institut tumor molecular profil review patient pdl1 egfr alk kra mutat evalu treatment modal surgeri alon combin rt sr wbrt andor system therapi tki 1st3rd gener immunotherapi primari endpoint inbrain freedom progress ffp overal surviv os sa studio version 44 use perform statist analys result identifi 272 patient 162272 60 patient adequ followup includ analysi median followup 278 month rang 043 13445 month 592 femal 407 male median age diagnosi 67 year femal 66 male respect entir cohort 102162 63 patient receiv adjuv combin rt system therapi 60162 37 receiv adjuv monotherapi p 00001 use system therapi associ 989 month median time progress vs 487 month without p 0077 respect similarli patient treat combin rt system therapi median ffp time 977 month vs 528 month p 0064 signific differ os found without system therapi conclus resect brm nsclc pdl1 egfr alk kra mutat found system therapi includ tki immunotherapi may increas role delay time progress institut continu identifi action mutat statist signific number patient continu treat combin rt system therapi trend toward superior ffp',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306983 pmid 37784747',\n '84 int j radiat oncol biol phi 2023 oct 11172se151e152 doi 101016jijrobp202306972',\n 'adren stereotact bodi radiat therapi dosimetr factor predict grade 2 lymphopenia',\n 'singh p1 figura nb2 sawyer c3 latifi k2 oliv de2 grass d2 johnston pas2 yamoah k2 frake jm2 hoff s2 palm rf2',\n 'author inform 1usf health morsani colleg medicin tampa fl 2h lee moffitt cancer center research institut depart radiat oncolog tampa fl 3h lee moffitt cancer center research institut depart radiat oncolog tampa fl univers south florida physic depart tampa fl',\n 'purposeobject recent studi suggest improv outcom multipl oligometastat tumor site immunotherapi io radiat therapi rt howev rt may induc lymphopenia immunosuppress dosimetr consensu lack paramet predict grade 2 lymphopenia studi evalu lymphopenia post receipt stereotact bodi rt sbrt adren metastas see could identifi modifi treatment plan factor materialsmethod patient adren oligometastas treat convent sbrt mriguid mrgsbrt absolut lymphocyt count alc white blood cell count wbc data avail within 6 week radiat treatment contour data avail review includ irb approv retrospect studi lymphopenia grade alc grade 1 1008 noul grade 2 08 05 noul grade 3 0502 noul grade 4 02 noul vertebr bodi vb level plan treatment volum ptv one spleen contour dosimetr variabl interest includ spleen vb mean dose gy well v2520 gy 25 gy increment regress analys use identifi dosimetr variabl associ absolut rel differ alc postsbrt result total 30 patient identifi slight male predomin n 17 57 commonli left adren n 17 versu right adren n 10 33 bilater metastas n 3 10 grade 2 lymphopenia observ n 7 patient presbrt 23 n 17 patient postsbrt 57 n 26 87 patient previou chemotherapi n 17 57 previou immunotherapi multipl primari tumor type repres common nonsmal cell lung cancer n 14 47 follow melanoma n 4 13 small cell lung cancer n 3 10 patient treat nonmrgsbrt n 19 63 vs mrgrt n 11 37 receiv sbrt 5 fraction median dose 50 gy rang 25 60 gy median presbrt alc 113 rang 039 296 median postsbrt alc 072 rang 011 415 linear regress analysi signific associ post sbrt alc lymphopenia grade splenic vertebr bodi dose treatment later sbrt dose conclus retrospect seri predomin metastat lung cancer patient treat adren sbrt observ high rate post sbrt grade 2 lymphopenia yet dosimetr paramet predict even leftsid lesion futur work includ clinic valid find larger popul like multiinstitut collabor studi investig iort sequenc issu heavili pretreat patient',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306972 pmid 37784736',\n '85 int j radiat oncol biol phi 2023 oct 11172se150e151 doi 101016jijrobp202306971',\n 'selectedles sr novel strategi treatment patient multipl brain metastas',\n 'singh c1 theriault bc2 y3 yu jb4 knise jps5 shepard m6 wegner re7 warnick re8 peker s9 samanc y9 trifiletti dm10 lee cc11 yang hc11 bernstein k12 kondziolka d13 tripathi m14 mathieu d15 mantziari g16 piki s16 sheehan jp17 chiang vl18',\n 'author inform 1yal univers school medicin new ct 2yal school medicin new ct 3depart therapeut radiolog yale school medicin new ct 4depart radiat oncolog columbia univers new york ny 5weill cornel medic collegenew yorkpresbyterian hospit new york ny 6allegheni health network pittsburg pa 7allegheni health network cancer institut depart radiat oncolog pittsburgh pa 8jewish hospit mayfield clinic cincinnati oh 9koc univers school medicin istanbul turkey 10depart radiat oncolog mayo clinic jacksonvil fl 11depart neurosurgeri taipei veteran gener hospit taipei taiwan 12depart radiat oncolog nyu langon health new york ny 13depart neurosurgeri nyu langon health new york ny 14postgradu institut medic educ research chandigarh india 15centr hospitali universitair de sherbrook sherbrook qc canada 16univ virginia health system charlottesvil va 17depart neurosurgeri univers virginia charlottesvil va 18depart neurosurgeri yale school medicin new ct',\n 'purposeobject increas use intracrani sr sr treatment patient 1015 brain metastas treatment debat remain literatur patient treat mani advoc treatment lesion either sr whole brain radiat therapi wbrt sever group consid selectedles sr slsr subset intracrani lesion treat howev current practic pattern slsr known materialsmethod survey 19 question creat use openend multiplechoic style question slsr practic indic survey distribut provid us intern perform sr frequent ten 50 institut provid respons reflect practic 16 provid descript statist use compar answer question applic includ percentag rang result slsr perform 810 institut 5 6 us institut 3 4 intern institut 2 institut establish clinic indic slsr one us one intern one addit us institut report clinic trial requir slsr studi efficaci cn penetr target therapi one program report research protocol untreat brain metastas would take prioriti slsr program outsid us size lesion cite import factor 90 decid treat singl lesion next lesion locat focal signssymptom consid moder import 80 rank distanc prior sr least import factor perilesion edema also less import program 90 lesion locat presenc symptom also consid import sever factor would encourag provid consid slsr patient prior wbrt progress system diseas cnspenetr drug option avail progress system diseas immunotherapi option avail common respons respond cite specif request medic oncolog well cooper studi topic factor might push toward slsr sever institut specifi factor beyond list option one institut report patient 20 lesion treat largest lesion sr follow wbrt term prewbrt boost progress untreat lesion common reason provid would bring back patient addit treatment conclus respons survey demonstr patient 1520 intracrani lesion prior wbrt worsen system diseas cn penetr system therapi avail consid slsr',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306971 pmid 37784735',\n '86 int j radiat oncol biol phi 2023 oct 11172se138 doi 101016jijrobp202306945',\n 'pneumon palli thorac radiotherapi immunotherapi retrospect propensitymatch cohort studi',\n 'miller dg1 yegyaraman n1 fried c2 cengel ka1 plastara jp2 simon ii cb3 cohen r4 langer c4 feigenberg sj1 butala aa1',\n 'author inform 1depart radiat oncolog perelman school medicin univers pennsylvania philadelphia pa 2depart radiat oncolog univers pennsylvania philadelphia pa 3new york proton center new york ny 4depart hematolog oncolog univers pennsylvania philadelphia pa',\n 'purposeobject patient pt advanc lung cancer often receiv combin palli thorac radiotherapi rt immun checkpoint inhibitor ici limit data assess toxic combin icirt set sought compar rate clinic signific pneumon among pt lung cancer receiv palli thorac rt without recent concomit ici hypothes would higher rate grade 2 pneumon among rt pt receiv recent concomit ici compar materialsmethod retrospect identifi consecut pt advancedrecurr lung cancer tertiari academ center receiv palli thorac rt recent defin within 95 day rt start concomit ici icirt group januari 2014 februari 2020 pt propens match 11 manner age sex ecog rt modal rt dose lung cancer pt receiv palli thorac rt without histori ici receipt rtonli group presenc grade ctcae v50 pneumon independ assess two investig primari endpoint grade 2 pneumon estim use cumul incid function compar icirt rtonli group use gray test secondari endpoint overal surviv estim use kaplanmei method compar group use logrank test result total 146 pt includ studi 73 group statist signific differ icirt rtonli group respect age median 677 vs 676 p 097 sex 52 vs 52 femal p 100 pretreat ecog 01 74 vs 75 p 085 biolog effect dose greater 45 48 vs 48 p 100 common rt regimen 30 gy 10 fraction 33 pt 23 20 gy 5 fraction 18 patient 12 plural case util 3dcrt 67 pt 46 icirt group median time last dose ici start palli rt 16 day three pt groupiniti ici receiv rt treatment common ici pembrolizumab 36 pt 49 total eleven grade 2 pneumon event nine grade 2 two grade 3 event observ icirt group higher cumul incid grade 2 pneumon compar rtonli group 1year rate 123 vs 27 p 0029 grade 3 pneumon occur 173 14 group differ overal surviv group median 239 vs 218 day p 076 conclus pt advanc lung cancer treat palli thorac rt recent concomit ici use associ higher cumul incid grade 2 pneumon howev incid grade 3 pneumon low 14 regardless ici receipt',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306945 pmid 37784706',\n '87 int j radiat oncol biol phi 2023 oct 11172se128 doi 101016jijrobp202306924',\n 'clinic outcom follow initi stereotact radiosurgeri cours brain metastas melanoma',\n 'leng jx1 huang cc1 qazi jj1 carpent dj2 natarajan bd3 arshad m4 ferreira m5 schultz o6 moravan mj jr7 mullikin tc1 reitman zj8 kirkpatrick jp1 floyd sr1 salama aks5 fecci p9 chmura sj3 hong jc10 salama jk11',\n 'author inform 1depart radiat oncolog duke univers medic center durham nc 2depart radiat oncolog duke univers cancer center durham nc 3depart medicin univers north carolina chapel hill nc 4depart radiat cellular oncolog univers chicago chicago il 5duke univers medic center durham nc 6univers chicago pritzker school medicin chicago il 7depart radiat oncolog washington univers st loui st loui mo 8duke univers durham nc 9duke univers medic center depart neurosurgeri durham nc 10depart radiat oncolog univers california san francisco san francisco ca univers california san francisco bakar comput health scienc institut san francisco ca 11depart radiat oncolog duke univers medic center durham nc durham va health care system durham nc',\n 'purposeobject brain metastas bm common melanoma patient effect gene mutat well character sinc firstlin metastat therapi shift chemotherapi cht molecularli target therapi tt immunotherapi io report outcom melanoma bm patient stratifi molecular subtyp prestereotact radiosurgeri sr system therapi materialsmethod identifi patient complet initi sr cours bm two institut 12015 122020 patient prior wbrt andor resect elig demograph clinic paramet collect along melanoma tumor molecular characterist intracrani progress icp defin radiograph distant andor infield progress per multidisciplinari consensu overal surviv os freedom icp fficp estim via kaplan meier method result total 1383 sr bm patient identifi 118 85 melanoma median follow 87 month median age 64 year iqr 5172 81 cutan origin 55 kp 90100 molecular subtyp includ braf 45 nra 93 ckit 34 overal 61 receiv io prior sr 25 93 receiv tt cht prior sr respect 60 patient harbor mutat receiv io first line therapi 10 receiv tt 30 receiv tt io prior sr brafmut patient like receiv tt prior sr 43 vs 92 p0001 compar brafwt patient median os 97 month 95 ci 7813 significantli differ nonmelanoma patient p 06 median fficp wors melanoma patient 59 mo 95 ci 3585 nonmelanoma patient 896 mo 95 ci 8297 p 0009 total 72 icp event occur 56 778 distant icp case 3 42 infield icp 13 18 icp event radionecrosi rn rn associ presenc target mutat 18 vs 2 p 0006 receipt tt presr 36 vs 98 p 0001 brafmut patient significantli wors fficp 38 mo 95 ci 3068 compar brafwt patient 85 mo 95 ci 58302 p 0006 although median os significantli differ 96 mo 95 ci 6916 vs 107 mo 95 ci 67155 p 08 nrasmut associ better fficp 29 mo 95 ci 294na p 002 conclus modern multiinstitut cohort sr patient melanoma bm patient wors fficp compar nonmelanoma bm patient brafmut patient wors fficp brafwt patient rn associ mutat statu receipt tt presr os vari significantli across group analysi may help inform system therapi decis futur genom studi patient bm melanoma',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306924 pmid 37784684',\n '88 int j radiat oncol biol phi 2023 oct 11172se122 doi 101016jijrobp202306912',\n 'outcom stereotact bodi radiat therapi sbrt femur oligometastas',\n 'kwan c1 chen yh2 killoran jh3 ferron ml4 marcu kj1 tanguturi s1 balboni ta1 spektor a1 huynh ma1',\n 'author inform 1depart radiat oncolog brigham women hospitaldanafarb cancer institut boston harvard medic school boston 2harvard medic school boston depart data scienc danafarb cancer institut boston 3depart radiat oncolog brigham women hospitaldanafarb cancer institut boston 4harvard medic school boston depart orthoped surgeri brigham women hospit boston',\n 'purposeobject stereotact bodi radiat therapi sbrt increasingli use oligometastat bone diseas limit data regard clinic outcom util sbrt treatment femur metastas exclud sabrcomet aim identifi patient treatment factor associ clinic outcom among patient treat sbrt femur metastas oligometastat diseas control reirradi materialsmethod identifi 50 patient 56 femur lesion consecut treat sbrt singl institut may 2017june 2022 kaplanmei method use character timetoev endpoint cox proport hazard model perform evalu associ baselin factor clinic outcom local control defin absenc region tumor progress treat area need surgic fixat post radiat result patient ecog 01 90 prostat 50 breastlung 16 cancer 13 lesion 100 includ 30 proxim 5 distal 55 lesion receiv concurr system therapi includ adt n 18 immunotherapi n 6 median ptv volum 547cc rang 66 387cc ptv v100 99 rang 715100 fraction includ 1820 gy1f 2730 gy3f 2540 gy5f 50 gy10f 43 lesion mirel score 7 91 lesion extraoss bone extens diagnost ct andor mri acut toxic includ grade 1 fatigu 143 pain flare 71 decreas blood count 18 late toxic includ fractur 18 15 year 2 patient radiationinduc osteonecrosi 36 dose 40 gy 5f 30 gy 5f prior 30 gy10f one patient n 2 requir fixat postradi due progress diseas symptom median follow 194 month 1 2year rate local control 84 69 progressionfre surviv 55 27 overal surviv 91 74 conclus signific associ patient treatment characterist local control outcom femur sbrt oligometastat diseas control wellselect patient associ good outcom minim rate acut late toxic prospect studi warrant',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306912 pmid 37784673',\n '89 int j radiat oncol biol phi 2023 oct 11172se11 doi 101016jijrobp202306670',\n 'baselin serum lipid level outcom nsclc patient receiv immunotherapi combin noncombin radiotherapi singl center retrospect studi',\n 'zhang j1 shang s1 wang f2 wang r2 shangguan j2 zhang y2 wu m3 j4 yu j3 chen d2',\n 'author inform 1shandong univers cancer center jinan shandong china depart radiat oncolog shandong provinci key laboratori radiat oncolog shandong cancer hospit institut shandong first medic univers shandong academi medic scienc jinan shandong china 2depart radiat oncolog shandong provinci key laboratori radiat oncolog shandong cancer hospit institut shandong first medic univers shandong academi medic scienc jinan shandong china 3shandong cancer hospit institut shandong first medic univers shandong academi medic scienc jinan shandong china 4depart radiat oncolog shandong provinci key laboratori radiat oncolog shandong cancer hospit institut shandong first medic univers shandong academi medic scienc jinan shandong china lung cancer center west china hospit sichuan univers chengdu sichuan china',\n 'purposeobject recent year mani studi shown lipid lipidlik substanc key regulatori factor tumor develop play import role immun regul howev remain unclear whether serum lipid influenc outcom immunotherapi therefor determin serum lipid level immun treatmentbeneficiari popul may valuabl aim studi evalu prognost valu baselin serum lipid level nonsmal cell lung cancer nsclc patient receiv immunotherapi materialsmethod retrospect includ 294 patient stage iiiiv nsclc receiv immunotherapi continu decemb 2018 novemb 2021 hospit collect pretreat lipid level total cholesterol tc triglycerid tg highdens lipoprotein cholesterol hdlc lowdens lipoprotein cholesterol ldlc 160 receiv immunotherapi without combin radiotherapi icisnrt 134 combin radiotherapi irt endpoint correl pretreat serum lipid level overal surviv os well progressionfre surviv pf xtile tool use determin optim cutoff valu indic kaplanmei surviv curv use calcul os pf log rank test use comparison cox proport hazard model use univari multivari analysi result 294 patient low tg low tc low hdlc predict poor os p0001 poor pf p005 low ldlc associ poor os p 00001 among 160 patient receiv icisnrt 134 irt patient low level tg p 00134 00024 tc p 00003 00023 hdlc p 00004 00043 ldlc p 00003 00419 associ wors os compar high level icisnrt patient low hdlc predict poor pf p 00011 134 irt patient low level tg p 00017 tc p 00028 ldlc p 00330 poor prognost factor pf univari multivari analysi os patient tg hdlc independ risk factor tg independ risk factor analysi pf icisnrt patient hdlc independ prognost factor patient os pf irt patient tg hdlc prognost risk factor os conclus data confirm higher serum lipid level associ better outcom patient nsclc undergo immunotherapi serum lipid may identifi tumor like respond immunotherapi radiat therapi may affect lipid metabol within bodi enhanc efficaci immunotherapi',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306670 pmid 37784645',\n '90 int j radiat oncol biol phi 2023 oct 11172se109e110 doi 101016jijrobp202306887',\n 'pretreat clinic paramet associ intracrani progress burden follow initi stereotact radiosurgeri cours multiinstitut brain metastas cohort',\n 'huang cc1 qazi jj1 leng jx1 carpent dj2 natarajan bd3 arshad m4 schultz o5 moravan mj jr6 mullikin tc1 reitman zj7 kirkpatrick jp8 floyd sr1 chmura sj9 hong jc10 salama jk11',\n 'author inform 1depart radiat oncolog duke univers medic center durham nc 2depart radiat oncolog duke univers cancer center durham nc 3depart medicin univers north carolina chapel hill nc 4depart radiat cellular oncolog univers chicago chicago il 5depart radiat oncolog univers chicago chicago il 6depart radiat oncolog washington univers st loui st loui mo 7duke univers durham nc 8depart radiat oncolog duke univers medic center durham nc depart neurosurgeri duke univers medic center durham nc 9depart radiat cellular oncolog univers chicago medic center chicago il 10univers california san francisco bakar comput health scienc institut san francisco ca depart radiat oncolog univers california san francisco san francisco ca 11depart radiat oncolog duke univers medic center durham nc durham va health care system durham nc',\n 'purposeobject brain metastasi bm veloc valuabl prognost metric time intracrani progress icp presr risk factor postsr highburden intracrani progress icp remain poorli character hypothes presr clinic paramet associ subsequ highburden icp defin either 5 icp5 newprogress 11 bm icp11 materialsmethod patient complet initi sr cours bm two institut 12015122020 retrospect identifi patient prior whole brain radiat therapi wbrt andor bm resect elig demograph clinic paramet collect icp defin radiograph concern distant andor infield progress per multidisciplinari consensu overal surviv os freedom icp estim via kaplan meier method cox model assess associ paramet freedom icp5 icp11 result identifi 1383 patient complet sr median follow 87 month patient 548 femal 456 kp 90 median 634 year old primari tumor type includ nonsmal cell lung 487 breast 147 melanoma 85 469 oligometastat diseas 5 metastat foci includ bm sr 534 underw sr 1 bm 103 patient undergon prior wbrt 261 surgic resect 555 patient 401 experienc icp follow sr 726 14 115 510 159 11 newprogress bm among patient icp 6month freedom icp 355 95 ci 311405 14 bm time icp 297 95 ci 204433 510 bm 205 95 ci 135301 11 bm p 0016 respect 12month os rate 568 95 ci 521619 460 95 ci 351601 387 95 ci 294509 p0001 neurolog symptom time icp observ 211 patient 14 bm 281 510 bm 500 newprogress 11 bm p0001 multivari analysi superior freedom highburden icp associ follow presr paramet oligometastat burden icp5 hr 068 95 ci 047099 icp11 059 95 ci 036097 prior immunotherapi icp11 hr 057 95 ci 034057 singl bm time initi sr 1 vs 2 bm icp 5 hr 051 95 ci 031082 icp11 hr 045 95 ci 024084 primari tumor type associ icp5 icp11 conclus presr paramet includ polymetastat burden prior receipt immunotherapi 1 bm associ postsr highburden icp high burden icp develop earlier follow sr complet associ higher rate neurolog declin inferior os',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306887 pmid 37784644',\n '91 int j radiat oncol biol phi 2023 oct 11172se108e109 doi 101016jijrobp202306885',\n 'stereotact radiosurgeri sr brain metastasi era evolv system treatment immunotherapi target therapi patient nonsmal cell lung cancer nsclc',\n 'hou y1 markley p2 katelyn k1 guida k1 soultan d1 jiang h1 wang f1',\n 'author inform 1depart radiat oncolog univers kansa medic center kansa citi ks 2univers kansa school medicin kansa citi ks',\n 'purposeobject evolv role target immunomodulatori agent surviv rate nsclc improv even brain metastasi studi analyz outcom brain metastasi treat sr conjunct immunotherapi target therapi well chemotherapi materialsmethod obtain institut review board irb approv 229 patient nsclc brain metastasi treat sr institut retrospect review 20082021 demograph inform eg age sex race perform statu ps extracrani metastasi ecm sequenc system therapi sst surgeri bm sbm review collect overal surviv os intracrani recurr free surviv icrf analyz use kaplanmei methodcox regress time event measur date first sr treatment statist analys perform use sa version 94 carey nc result 229 pt median age pt first sr 641 rang 348 830 year 386 biomark egfralkrospdl1 posit 30 pdl1 posit 288 surgeri sr median number sr 1 rang 1 6 10 patient receiv salvag whole brain radiat therapi wbrt sr median followup 96 month mo median os icrf 140 mo 81 mo respect univari outcom analysi ps ecm sbm pdl1 associ os biomark sbm sst close relat icrf pt poor ps wors median os 83 mo compar 291 mo good ps p 0001 median os ecm vs ecm 207 mo vs 96 mo respect p 0002 patient underw sbm initi better median os 287 mo compar 99 mo without sbm p0001 trend signific impact posit pdl1 median os 211 mo vs 117 mo p 006 similarli sbm found close relat icrf median icrf 81 mo vs 49 mo without sbm respect posit biomark 131 mo vs 64 mo p 017 sr first sst 81 mo vs 49 mo p 011 demonstr trend increas median icrf multivari analys sbm link wors os hr 185 95 ci115 297 p 001 decreas icrf hr 165 95 ci 109 251 p 002 31 pt inform caus death 32 die brain metastasi relat caus conclus studi demonstr effect treatment brain metastasi nsclc multipl srss especi patient favor prognosi notic small number patient receiv salvag wbrt patient didnt die brain metastasi relat progress',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306885 pmid 37784642',\n '92 int j radiat oncol biol phi 2023 oct 11172se10e11 doi 101016jijrobp202306669',\n 'aideriv ct bodi composit advanc nonsmal cell lung cancer multicohort studi',\n 'chaunzwa tl1 qian jm2 li q3 ricciuti b4 zhang z4 weiss j5 mackay j3 kagiampaki i3 bikiel d3 federico ad4 alessi j4 mak rh1 jacob e6 awad mm7 aert h1',\n 'author inform 1depart radiat oncolog brigham women hospitaldanafarb cancer institut boston 2brigham women hospit danafarb cancer institut harvard boston boston 3astrazeneca waltham 4danafarb cancer institut boston 5artifici intellig medicin aim program brigham women hospit harvard medic school boston 6astrazeneca boston 7brigham women hospit danafarberharvard cancer center boston',\n 'purposeobject relationship bodi composit bc cancer outcom complex incomplet understood previou research nonsmal cell lung cancer nsclc limit small singleinstitut studi yield inconsist result materialsmethod conduct comprehens multicohort analysi evalu impact bc overal surviv os advanc nsclc treat system therapi analysi includ data phase iii cp1108 studi nsclc durvalumab cohort chemotherapi arm phase iii mystic trial also analyz data danafarb cancer institut dfci cohort receiv immunotherapi alon combin chemotherapi baselin followup fu ct scan collect analyz use deep neural network automat l3 slice select bodi compart segment skelet muscl sm subcutan adipos tissu sat viscer adipos tissu vat compar os base baselin bc measur chang first fu scan impact sarcopenia baselin evalu associ delta metric result total 1865 nsclc patient analyz 222 treat cp1108 257 treat mystic 870 receiv io monotherapi dfci dfciio 516 receiv chemoimmunotherapi dfci dfcicio median age 65 63 66 65 respect loss sm mass 5 indic chang l3 sm area significantli associ poorer os across patient group median month 5 vs 19 p0001 cp1108 11 vs 14 p 003 mystic 11 vs 17 p0001 dfciio 12 vs 22 p0001 dfcicio effect driven male patient nonsignific associ p05 among femal patient mystic dfcicio cohort increas sat densiti 5 quantifi averag ct attenu hu sat compart significantli link poorer os three patient group median month 4 vs 19 p0001 cp1108 10 vs 17 p0001 dfciio 12 vs 20 p 0003 dfcicio primarili observ among femal patient nonsignific associ p05 among male patient dfcicio cohort subgroup analysi loss sm mass impact os patient baselin sarcopenia median month 5 vs 22 p0001 cp1108 5 vs 12 p 003 mystic 11 vs 17 p0001 dfci io 9 vs 17 p 0003 dfcicio convers associ observ chang sm mass os patient without sarcopenia baselin mystic dfciio cohort conclus sarcopenia loss sm mass system therapi nsclc marker poor outcom especi male patient sat densiti chang also strongli associ prognosi particularli femal patient autom ctderiv bc measur consid along risk factor determin lung cancer prognosi abil toler oncolog treatment',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306669 pmid 37784624',\n '93 int j radiat oncol biol phi 2023 oct 11172ss92s93 doi 101016jijrobp202306422',\n 'unplan hospit subsequ mortal lung cancer patient undergo concomit chemoimmunotherapi radiotherapi analysi 10000 patient nationwid databas',\n 'kim j1 harri a2 pitt h3 saraiya b4 jabbour sk1 deek mp1 moor df5 kim s1 enni rd1',\n 'author inform 1depart radiat oncolog rutger cancer institut new jersey new brunswick nj rutger robert wood johnson medic school rutger univers new brunswick nj 2vizient chicago il 3rutger robert wood johnson medic school rutger univers new brunswick nj divis surgic oncolog rutger cancer institut new jersey new brunswick nj 4rutger robert wood johnson medic school rutger univers new brunswick nj divis medic oncolog rutger cancer institut new jersey new brunswick nj 5depart biostatist epidemiolog rutger school public health rutger cancer institut new jersey piscataway nj',\n 'purposeobject radiotherapi rt concomit chemotherapi cht major modal treat mani malign includ lung cancer associ toxicityrel unplan hospit uph previou investig factor associ uph singl institut retrospect studi none assess role concurr immunotherapi io aim identifi factor associ uph inhospit mortal leverag multiinstitut nationwid databas materialsmethod vizient clinic data base includ data 98 aamc hospit 110 cancer hospit queri lung cancer patient histolog treat 20192021 rtchtio endpoint uph mortal within 30 day complet rt variabl includ age sex race ethnic incom level quartil educ level quartil concomit cht io drug rt techniqu 3d vs imrt vs sbrt obes prior hospit within 3 month prior oncolog surgeri within 3 month prior cht andor io within 3 month insur type hospit type rural vs urban aamc vs nonaamc nccn vs nonnccn bed size tertil logist regress perform identifi variabl associ uph inhospit mortal data vizient clinic data base use permiss vizient inc right reserv result total 10337 patient includ rate uph mortal among uph 245 32 respect factor associ uph includ race vs white 144 95 ci 111188 p0001 live low incom zip code 17 95 ci 139209 p 00006 live zip code lower educ attain 071 95 ci 058086 p 00007 chtio type cisetoposid vs carbotaxol 133 95 ci 113157 p00001 obes 171 95 ci 153192 p00001 prior hospit 20 95 ci 180222 p00001 prior oncolog surgeri 034 95 ci 022052 p00001 primari payer vs commerci 175 95 ci 137223 p00001 rural hospit 13 95 ci 107162 p001 small bed size 059 95 ci 05071 p00001 factor associ inhospit mortal includ chtio type p00001 cisetoposid vs carbotaxol differ prior hospit 034 95 ci 02056 p00001 aamc 212 95 ci 123367 p 0007 bed size 058 95 ci 038088 p001 conclus largest studi date regard uph inhospit mortal relat lung rt identifi factor contribut endpoint futur prospect studi warrant develop strategi prevent complic highrisk popul',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306422 pmid 37784605',\n '94 int j radiat oncol biol phi 2023 oct 11172ss72 doi 101016jijrobp202306381',\n 'radiotherapi show synergist antitumor efficaci treg deplet reprogram immuneexclud tumor microenviron',\n 'zhang y1 vilalta m1 tang l1 sharma r1 pfister sx1',\n 'author inform 1varian siemen healthin compani palo alto ca',\n 'purposeobject tumorinfiltr treg cell titr neg regul antitumor immun respons promot tumor progress increas level titr cell associ poor prognosi multipl cancer indic led develop immunotherapi target tumor treg ccr8 antibodi one bestinclass therapi clinic develop deplet titr cell demonstr potent efficaci tumor respons checkpoint inhibitor fail cold tumor lack immun infiltr activ radiotherapi rt shown induc proinflammatori respons tumor still fail show consist synergi checkpoint inhibitor test hypothesi rt synerg treg deplet improv antitumor efficaci reprogram immuneexclud tumor microenviron materialsmethod ccr8 rt combin therapi test syngen mous tumor model 4t1 breast ll2 lung b16f10 melanoma present cold tumor phenotyp tumorbear mice n 10 per group receiv singl dose focal irradi sarrp 4 dose anticcr8 deplet antibodi combin two tumor size measur 3 time per week surviv monitor day 42 tumor metastasi evalu endpoint necropsi mous tumor spleen drain lymph node blood collect 1 day last dose ccr8 therapi analyz multicolor flow cytometri rnasequenc pharmacodynam mechan studi result syngen mous model ccr8rt combin therapi display significantli improv tumor growth inhibit metastasi control prolong surviv compar either treatment alon without increas toxic flow cytometri show reduc titr popul increas infiltr activ cd8 cytotox cell tumor ccr8 rt treat mice increas activ cd8 cell also observ blood drain lymph node mice treat combin therapi moreov transcriptom analysi identifi upregul pathway associ tnf ifn respons combinationtr tumor suggest creation proinflammatori tumor microenviron interestingli chang induc combin therapi either treatment alon conclus immunotherapi target tregtitr cell far fail show promis clinic trial data suggest titr deplet suffici treat tumor minim immun infiltr anim data demonstr combin rt ccr8 therapi significantli inhibit tumor growth prevent metastasi enrich tumor microenviron proinflammatori cytokin activ cytotox cell find clinic relev appli titr deplet therapi combin rt',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306381 pmid 37784563',\n '95 int j radiat oncol biol phi 2023 oct 11172ss72s73 doi 101016jijrobp202306382',\n 'overcom radioimmunotherapi treatment resist ilt4 blockad revers hfrt induc cxcl1cxcr2 axi activ tumorassoci macrophag immunosuppress',\n 'chen x1 wang m1 wu f1 lu j1 xiao c1 wu m1 yu j1 chen d1',\n 'author inform 1shandong cancer hospit institut shandong first medic univers shandong academi medic scienc jinan shandong china',\n 'purposeobject immunotherapi combin radiotherapi irt unlimit potenti 60 cancer patient benefit enhanc antitumor immun stimulatori effect trigger radiotherapi key overcom irt resist immunoglobulinlik transcript ilt 4 potenti immun checkpoint molecul highli express variou tumor cell role radiotherapi still unknown studi confirm role molecular mechan ilt4 suppress radiotherapi immunosuppress microenviron format promot tumor radiotherapi resist propos new therapeut strategi block ilt4 enhanc efficaci radiotherapi cooper radiotherapi revers immunotherapi resist materialsmethod use multiplex immunohistochemistri analyz ilt4 express tumorassoci macrophag tam cell phenotyp quantiti tumor patient treat sbrt use mice subcutan tumor model singlecel rna sequenc multiplex flowcytometri assess role ilt4 inhibit hyperfraction radiotherapi hfrt prevent tumor growth immun escap molecular signal cytokin regul ilt4 hfrt analyz transcriptom sequenc verifi molecular experi establish cancer celltam cocultur system vitro use cxcl1 protein cxcr2 inhibitor macrophagecd8 cell delet antibodi vivo identifi downstream pathway cytokin ilt4 enhanc hfrt induc tam immun respons result tumor specimen nsclc patient treat sbrt found high ilt4 express predict poor progressionfre surviv m2tam recruit among c57bl6 mice model ilt4 inhibit cancer cell reduc hfrt mediat m2tam accumul sustain activ prolifer cd8 cell eventu suppress tumor progress mechanist rt promot ilt4 express subsequ induc nfb pathway activ cxcl1 secret enhanc m2tam migrat vitro use cxcl1 protein cxcr2 inhibitor administr infer ilt4 promot tam migrat via nfbcxcl1cxcr2 axi consist deplet tam block cell function impair radiotherapi resist induc ilt4 vivo importantli target ilt4 potenti effect radiotherapi overcom radioimmunotherapi treatment resist conclus ilt4 mediat hfrtinduc m2like tam recruit subsequ cell respons impair regul nfbcxcl1cxcr2 axi ilt4 attract drug target enhanc radiotherapi overcom radioimmunotherapi treatment resist',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306382 pmid 37784562',\n '96 int j radiat oncol biol phi 2023 oct 11172ss71s72 doi 101016jijrobp202306380',\n 'effect parp inhibitor radiosensit mrna translat regul cell chemokin',\n 'ran x1 zhang x2 teng m1 alawi wb1 nahum s3 h4 lok bh5',\n 'author inform 1univers health network toronto canada 2depart biochemistri mcgill univers montreal qc canada 3depart biochemistri mcgill univers montreal canada 4univers toronto toronto canada 5radiat medicin program princess margaret cancer centr univers health network toronto canada',\n 'purposeobject immunotherapi modestli improv surviv small cell lung cancer sclc patient low respons rate rapid diseas progress remain intract challeng one factor contribut immunotherapi resist lack cytotox cell infiltr express chemoattract cytokin like ccl5 cxcl10 essenti cell infiltr control chemokin express fulli understood transcript translat control pathway could play major role previou studi shown correl dna damag chemokin express parp inhibitor parpi radiosensit sclc increas dna damag object studi defin potenti parpi immunogen radiosensit relationship materialsmethod identifi dose olaparib radiat treatment rt confer radiosensit sclc celllin cell viabil andor clonogen assay olaparibrt induc ccl5 cxcl10 mrna express measur qpcr across sclc celllin protein level chemokin assess immunoblot sbc5 cell treat olaparibrt submit rna sequenc analysi gene adjust p value005 consid signific protein level chang target gene knockout ko confirm immunoblot chemokin cxcl10 mrna protein level wildtyp wt ko cell measur qpcr western blot respect mrna decay assay dualluciferas report assay use identifi region cxcl10 mrna confer mrna stabil control vivo antitumor efficaci tumor cell infiltr studi done b6129f mice bear kp1 tumor cell infiltr measur immun profil result vitro olaparibrt significantli increas cxcl10 mrna four sclc subtyp celllin comparison vehicl control consist increas cxcl10 protein level 3fold observ sbc5 cell rnaseq toprank translat repressor eif4e2 4ehp mrna downregul eif4e2 protein olaparibrt valid four sclc subtyp western blot eif4e2 ko hek293 sbc5 cell increas cxcl10 mrna protein level mrna decay assay western blot absenc eif4e2 stabil cxcl10 mrna increas cxcl10 protein level dualluciferas assay demonstr eif4e2 destabil cxcl10 mrna via 3utr cxcl10 vivo immun profil show olaparibrt significantli increas total cell cd8 cell infiltr final antipdl1 inhibit potenti olaparib ir improv tumor control kp1 allograft conclus studi demonstr olaparib rt increas cxcl10 protein level downregul eif4e2 subsequ increas cell infiltr olaparib rt enhanc antipdl1 immunotherapi efficaci therapeut potenti immunogen radiosensit',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306380 pmid 37784561',\n '97 int j radiat oncol biol phi 2023 oct 11172ss71 doi 101016jijrobp202306378',\n 'neoantigen cancer vaccin immunolog cold microsatellitest colorect cancer',\n 'huang kcy1 lee cy2 wu ch3 sung cy4 chen wtl5 ke tw5 liang ja5 lai cy5 hong wz5 chuang ey3 chao ksc6',\n 'author inform 1china medic univers taichung taiwan china medic univers hospit taichung taiwan 2china medic univers taichung taiwan 3china medic univers taichung taiwan nation taiwan univers taipei taiwan 4nation taiwan univers taipei taiwan 5china medic univers hospit taichung taiwan 6depart radiat oncolog china medic univers hospit china medic univers taichung taiwan',\n 'purposeobject immunotherapi immun checkpoint inhibitor ici revolution manag cancer littl benefit microsatellitest colorect cancer patient msscrc part due low mutat neoantigen express immunogen cold msscrc therefor aim develop novel share neoantigenbas therapeut cancer vaccin reinvigor antitumor immun enhanc therapeut benefit radiotherapi msscrc materialsmethod identifi novel highli express share neoantigen collect 40 matchpair adjac normal tumor tissu msscrc patient wesseq rnaseq liquid chromatographymsm lcmsm incorpor databas establish neoantigen discoveri valid neodiva system identifi cluster highli express share neoantigen deriv noncod region evalu immunogen hlaa11 transgen mice develop neoantigenbas therapeut cancer vaccin engin adenovirusassoci viru aav evalu therapeut efficaci combin radiotherapi msscrc anim model result identifi cluster highli express share neoantigen hlaa11restrict deriv noncod region immunogen novel neoantigen demonstr hlaa11 transgen mice ex vivo stimul moreov engin aavbas neoantigen cancer vaccin significantli erad cancer cell prevent distant metastasi prolong surviv period combin radiotherapi flow cytometri elispot mhcitetram assay demonstr recruit tumorinfiltr lymphocyt remark increas neoantigenspecif cell respons enhanc moreov isol neoantigenspecif cell recogn cancer cell produc ifng kill cancer cell conclus neoantigen identifi neodiva platform via combin radiotherapi novel aav vaccin deliveri system boost antigenspecif tcell function improv tumor control limnolog cold mss colorect cancer vivo process obtain ind initi phase iii clinic trial valid safeti efficaci excit find',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306378 pmid 37784559',\n '98 int j radiat oncol biol phi 2023 oct 11172ss65 doi 101016jijrobp202306367',\n 'differenti respons quantit mri paramet detect head neck cancer patient treat concurr immunotherapi hypofraction mrgrt',\n 'bonat r1 paulson es2 frei a2 shukla me2 tarima s3 wong s4 himburg ha2 zenga j5 awan mj2',\n 'author inform 1depart biophys medic colleg wisconsin milwauke wi 2depart radiat oncolog medic colleg wisconsin milwauke wi 3medic colleg wisconsin milwauke wi 4depart medic oncolog medic colleg wisconsin milwauke wi 5depart surgeri medic colleg wisconsin milwauke wi',\n 'purposeobject recent multipl clinic trial demonstr success pd1pdl1target immun checkpoint inhibit ici recurr metastat head neck cancer hnc howev three larg clinic trial combin pd1pdl1target ici rt chemort crt definit manag hnc shown benefit combin therapi ici rt crt alon overarch hypothes hypofraction may ultim better synerg ici compar convent rt regimen ii immunolog chang tumor microenviron may detect use quantit mri qmri paramet collect rt materialsmethod seven patient treat hypofraction mrguid rt 50 gy 15 fraction dehart nct04477759 includ studi four patient group 1 treat concurr atezolizumab monoclon antibodi three patient group 2 treat rt alon daili dwi t1 map t2 map sequenc acquir 15t mrlinac idl time adapt plan gener median adc t1 t2 dslow deriv bvalu 150 550 smm2 valu extract physiciandefin gtv manual construct posterior paraspin muscl contour latter serv control wilcoxon sign rank test conduct use prepost treatment data qmri paramet result gtv adc dslow t2 t1 increas patient group cours treatment signific differ adc dslow t2 detect fraction 1 15 patient studi p 00156 p 00156 p 00469 respect signific differ detect control qmri paramet prepost treatment signific differ adc dslow t2 detect group fraction 1 15 small cohort howev interestingli observ differenti chang increas median gtv t2 dslow valu fraction 1012 group 1 compar group 2 suggest time interv may prime antitumor immun respons conclus combin hypofraction rt ici lead differenti respons quantit mri qmri paramet hnc patient result suggest qmri paramet chang ten day follow start rt may reflect critic junctur antitumor immun respons ici combin hypofraction rt',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306367 pmid 37784546',\n '99 int j radiat oncol biol phi 2023 oct 11172ss58s59 doi 101016jijrobp202306354',\n 'safeti efficaci analysi patient extensivestag small cell lung cancer essclc treat shr1316 plu chemotherapi sequenti chest radiotherapi firstlin therapi phase ii trial',\n 'wang l1 zou b2 huang w2 shao q3 meng x1 tang x4 zhang p1 hu x1 zhang y4 guo j4 fu l1 zhao w1 zhao c5 yuan j5 yu j6 chen d1',\n 'author inform 1shandong cancer hospit shandong univers jinan china 2depart radiat oncolog shandong cancer hospit institut shandong first medic univers shandong academi medic scienc jinan china 3shandong cancer hospit institut jinan china 4depart medic oncolog shandong cancer hospit institut shandong first medic univers shandong academi medic scienc jinan 250117 shandong provinc china 5jiangsu hengrui pharmaceut co ltd shanghai china 6shandong cancer hospit shandong univers jinan shandong china',\n 'purposeobject capstone1 phase 3 trial show shr1316 pdl1 antibodi combin standard firstlin chemotherapi could prolong overal surviv os patient pt essclc crest trial report consolid thorac radiotherapi trt 30 gy 10 fraction provid 10 2year os benefit intens trt investig essclc era immunotherapi role trt also need explor therefor design clinic trial investig efficaci safeti shr1316 plu firstlin chemotherapi follow trt combin shr1316 materialsmethod key inclus criteria pt age 1875 year previous untreat histolog cytolog confirm essclc ecog perform statu 01 elig pt would receiv 46 cycl shr1316 20mgkg d1 q3w combin epec etoposid 100mgm2 d15 q3w cisplatin 75mgm d13 q3w carboplatin auc 5 d1 q3w follow shr1316 combin trt 3 gy10 f 2 gy25 f involvedfield irradi mainten therapi shr1316 diseas progress intoler advers event ae main endpoint includ orr pf safeti result octob 2020 januari 2023 33 pt receiv shr1316 sequenti consolid trt among 19 pt receiv highdos trt 3 gy10 f 2 gy25 f 14 pt receiv lowdos trt 3 gy10 f or2 gy25 f median age 62 rang 3873 pt male 28 848 former smoker 22 667 ecog perform statu 1 32 97 ten 303 pt diagnos brain metastasi 10 303 pt liver metastasi baselin data cutoff date 9 pt remain treatment averag number treatment cycl 92 33 pt least one 1 posttreat tumor assess confirm orr dcr 909 3033 100 3333 pt 895 1719 100 1919 highdos trt group 929 1314 100 1414 lowdos trt group median pf 102ci 58147 month pt 7 ci 38102 month highdos trt group 104 ci 84123 month lowdos trt group ae occur 27 818 pt grade 3 4 ae occur 20 606 pt common grade 3 4 ae includ neutropenia 15 455 leukopenia 8 242 lymphocytopenia 5 152 pneumonia 3 91 anemia 3 91 thrombocytopenia 2 61 conclus shr1316 plu chemotherapi sequenti trt firstlin therapi essclc show promis efficaci accept safeti signific differ highdos lowdos trt group term safeti efficaci accord current data',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306354 pmid 37784531',\n '100 int j radiat oncol biol phi 2023 oct 11172ss57 doi 101016jijrobp202306351',\n 'thorac radiotherapi improv outcom extens stage smallcel lung cancer patient receiv firstlin immunotherapi multicent retrospect analysi',\n 'yao y1 li b2 song r2 yang l2 zou b2 wang l2',\n 'author inform 1shandong first medic univers shandong academi medic scienc jinan china depart radiat oncolog shandong cancer hospit institut shandong first medic univers shandong academi medic scienc jinan china 2depart radiat oncolog shandong cancer hospit institut shandong first medic univers shandong academi medic scienc jinan china',\n 'purposeobject platinumetoposid chemotherapi combin immun checkpoint inhibitor recommend first line standard treatment extensivestag smallcel lung cancer essclc howev role thorac radiotherapi trt still unknown patient aim studi evalu efficaci safeti trt essclc patient receiv firstlin immunotherapi chemotherapi materialsmethod essclc patient receiv 4 6 cycl chemotherapi immunotherapi firstlin therapi two hospit includ analysi juli 2018 januari 2023 patient divid two group base whether receiv trt firstlin set primari endpoint overal surviv os progressionfre surviv pf secondari endpoint toxic effect kaplanmei method use estim overal surviv progressionfre surviv advers event grade senior doctor accord common terminolog criteria advers event version 50 result total 253 patient two hospit enrol analysi median age 62 year patient men 83 36 patient stage t4 52 n3 common site metastasi brain 32 liver 32 bone 30 107 patient 42 receiv trt 146 58 without trt baselin characterist well balanc two group median followup time 167 month statist signific benefit observ patient receiv trt compar patient without trt median pf 104 vs 73 month p 0001 median os 222 vs 137 month p 0009 term safeti signific increas grade advers event ae p 0115 grade 3 4 ae p 0631 observ patient receiv trt common grade 3 4 ae neutrophil count decreas white blood cell count decreas nausea two group trt group common grade 1 2 ae relat trt esophag 40 pneumon 25 grade 3 4 esophag pneumon 4 8 respect one patient develop grade 4 toxic effect pneumon lead radiotherapi withdraw grade 5 advers event occur conclus addit trt show signific surviv benefit well toler essclc patient receiv platinumetoposid chemotherapi immun checkpoint inhibitor could feasibl firstlin treatment strategi essclc patient',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306351 pmid 37784528',\n '101 int j radiat oncol biol phi 2023 oct 11172ss54 doi 101016jijrobp202306344',\n 'multitask ai model joint predict overal surviv progressionfre surviv death without progress composit endpoint lansclc patient treat chemoradiotherapi',\n 'lee sh1 yegyaraman n1 duan l1 li b1 fried c1 iocolano m1 caruana r2 apt a3 deasi jo3 fan y4 kao gd1 feigenberg sj1 xiao y1',\n 'author inform 1depart radiat oncolog univers pennsylvania philadelphia pa 2microsoft research redmond wa 3depart medic physic memori sloan ketter cancer center new york ny 4depart radiolog univers pennsylvania philadelphia pa',\n 'purposeobject prior method model risk endpoint separ herein construct composit ai model consid multipl endpoint jointli includ overal surviv os progressionfre surviv pf death without progress dwp hypothesi composit model potenti improv predict perform patient local advanc nonsmal cell lung cancer lansclc treat chemoradiotherapi crt materialsmethod total 335 lansclc patient treat definit crt includ evalu patient accru oct 2017 dec 2021 randomli split trainingtest subset n 234101 cardiopulmonari substructur cpss autocontour manual review edit necessari total 1093 nonindepend dosimetr paramet extract includ gtvp gtvn gtv ptv esophagu lung minu igtv leftright lung 15 cpss overlap volum oar ptv distanc oar gtvpgtvn clinic paramet includ age consolid immunotherapi ci ecog score charlson comorbid index coronari heart diseas histolog pdl1 express clinic stage ajcc 8 within train censor timetoev data imput base condit event distribut deriv kaplanmei estim cast surviv analysi regress problem train neural addit model nam regressor featur select lasso regress singl endpoint os pf dwp multitask mt lasso regress four separ composit endpoint ospf osdwp pfsdwp ospfsdwp perform mt nam test set jointli predict composit endpoint evalu use cindex compar singl task st nam predict endpoint separ result best test perform predict os dwp attain mt nam jointli predict endpoint cindex 065 95 ci 058071 os cindex 078 95 ci 069087 dwp best model predict pf also mt pf dwp cindex 059 95 ci 052065 cindic st nam less 056 best mt nam significantli outperform st nam predict os p 0001 dwp p 001 except pf p 032 best mt nam predict os dwp includ ecog score atriaptv overlap volum d75 gy left atrium la pulmonari arteri volum histolog adenocarcinoma d65 gy descend aorta da v10 gy la ci order overal import ecog score consist rank import featur four mt nam increas ecog score 0 2 indic 6month earlier risk mortal dwp atriaptv overlap volum d65 gy da includ four mt nam conclus mt ai model improv outcom predict patient lansclc treat crt jointli learn common primari auxiliari endpoint',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306344 pmid 37784521',\n '102 int j radiat oncol biol phi 2023 oct 11172ss40 doi 101016jijrobp202306311',\n 'toripalimab combin chemoradiotherapi local advanc cervic squamou cell carcinoma patient earli result safeti feasibl',\n 'ou d1 cai r2 qi wx1 chen jy1 xu hp1',\n 'author inform 1depart radiat oncolog ruijin hospit shanghai jiaotong univers school medicin shanghai china 2ruijin hospit shanghai jiao tong univers school medicin shanghai china',\n 'purposeobject assess safeti efficaci toripalimab combin chemoradiotherapi local advanc cervic squamou cell carcinoma materialsmethod twentytwo local advanc cervic cancer patient regardless program death ligand1 pdl1 statu receiv toripalimab treatment combin concurr chemoradiotherapi ccrt includ cisplatin 40 mgm2 week 5 week radiotherapi 45504 gy2528fx 5 fraction week follow brachytherapi 2430 gy35fx toripalimab 240mg day 1 22 43 primari endpoint safeti 2year progressionfre surviv pf result median age 55 year old 42 72 2 patient figo stage 15 patient stage c 5 patient stage patient complet ccrt success grade higher advers event ae observ 11 patient 1122 50 patient grade ae frequent grade ae leukopenia 822 364 common immunotherapyrel advers event hypothyroid 222 91 object respons rate orr 100 data cutoff sep 30 2022 median followup 197 month 767 261 month lc pf rate 955 818 os rate 909 patient baselin absolut lymphocyt count alc 1255 109l signific higher rate metastasi alc 1255 109l 429 vs 0 p 0023 conclus toripalimab combin ccrt achiev good toler demonstr promis antitumor effect patient local advanc cervic cancer longer followup result phase studi expect chines clinic trial registri number chictr2000032879',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306311 pmid 37784493',\n '103 int j radiat oncol biol phi 2023 oct 11172ss30 doi 101016jijrobp202306292',\n 'residu ctdna detect predict benefit definit chemoradiotherapi immun checkpoint inhibitor local advanc nsclc',\n 'wang y1 yang y1 zhang t2 wang j2 wang l3 bi n1',\n 'author inform 1depart radiat oncolog nation cancer centern clinic research center cancercanc hospit chines academi medic scienc peke union medic colleg beij china 2depart radiat oncolog nation cancer centern clinic research center cancercanc hospit chines academi medic scienc cam peke union medic colleg pumc beij china 3depart radiat oncolog nation cancer centercanc hospit shenzhen hospit chines academi medic scienc peke union medic colleg shenzhen china',\n 'purposeobject therapeut efficaci differ across unresect local advanc nonsmal cell lung cancer lansclc patient receiv definit chemoradiotherapi crt dynam chang circul tumor dna ctdna close associ clinic outcom howev evid predict effect ctdna lansclc patient crt immunotherapi current standard care remain limit unclear whether residu ctdna definit crt guid clinic decis use immun checkpoint inhibitor ici consolid materialsmethod prospect includ 73 patient unresect stage iiiii nsclc patient receiv definit concurr sequenti crt prescrib dose 60 gy 2 cycl platinumbas chemotherapi thirtyseven 507 patient underw ici therapi 18 durvalumab 9 pembrolizumab 10 other peripher blood sampl collect patient treatment baselin 1 month crt postcrt time progress plasma specimen analyz nextgener sequenc panel 474 cancerrel gene plasma sampl 1 variant detect defin detect ctdna primari endpoint progressionfre surviv pf result median followup 254 month median overal surviv os reach nr median pf 167 month 95 ci 124266 patient compar baselin ctdna abund significantli decreas definit crt p0001 rel increas progress p 0051 patient treat crt plu ici exhibit significantli longer os median nr vs 221 month 95 ci 167nr p 0002 pf median 248 month 95 ci 161nr vs 114 month 95 ci 65nr p 0016 crt alon postcrt residu ctdna associ significantli poorer os median 183 month 95 ci 148nr vs nr p 0002 pf median 65 month 95 ci 56nr vs 248 month 95 ci 188nr p0001 wherea baselin ctdna predict neither os p 0310 pf p 0570 patient postcrt detect ctdna ici therapi brought signific benefit os median nr vs 148 month 95 ci 120nr p 0012 pf median 161 month 95 ci 58nr vs 62 month 95 ci 42nr p 0043 howev patient postcrt ctdna clearanc signific differ os p 0080 pf p 0151 patient without ici suggest less clinic benefit conclus postcrt residu ctdna predict wors surviv lansclc indic benefit ici therapi therebi could facilit person consolid immunotherapi prospect studi larg sampl size warrant valid find',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306292 pmid 37784472',\n '104 int j radiat oncol biol phi 2023 oct 11172ss27s28 doi 101016jijrobp202306287',\n 'prospect phase ii trial primari lung tumor stereotact bodi radiat therapi sbrt follow concurr mediastin chemoradi adjuv immunotherapi locallyadvanc nonsmal cell lung cancer la nsclc',\n 'heinzerl jh 2nd1 mileham k2 robinson m3 symanowski jt3 induru r3 corso cd4 brous g3 prabhu rs4 haggstrom d3 moeller bj4 bobo we4 fasola c4 thakkar vv4 gregori j3 burri sh4 simon cb 2nd5',\n 'author inform 1levin cancer institut atrium healthwak forest school medicin southeast radiat oncolog group charlott nc 2levin cancer institut atrium healthwak forest school medicin charlott nc 3levin cancer institut atrium health charlott nc 4levin cancer institut atrium health southeast radiat oncolog group charlott nc 5new york proton center new york ny',\n 'purposeobject report efficaci toxic outcom prospect phase ii trial primari tumor sbrt follow convent chemoradi lymph node adjuv immunotherapi patient pt unresect la nsclc materialsmethod elig pt includ stage iiiii la nsclc peripher primari tumor 7cm central base tumor least 2 cm separ involv nodal diseas pt receiv sbrt primari tumor 5054 gy 35 fraction follow standard radiat 60 gy 30 fraction involv lymph node concurr platinum doublet chemotherapi trial amend allow pt without diseas progress chemoradi receiv adjuv durvalumab per pacif trial primari endpoint 1 year progress free surviv pf evalu binari variabl frequenc proport use report primari endpoint addit advers event pattern failur median pf os estim use kaplan meier method result safeti efficaci report first 50 pt enrol trial median followup 24 month mo rang 154 mo pt primarili stage iiia 60 stage iiib 34 6 pt stage iib overal grade 3 higher toxic relat sbrt andor mediastin radiat 8 two pt 4 develop grade 3 pneumon one pt grade 5 lung infect possibl relat radiat overal grade 2 pneumon relat sbrt mediastin radiat 20 one pt 2 develop grade 3 esophag late cardiac event observ oneyear pf pt 62 median pf 263 mo median overal surviv 408 mo 50 pt enrol 37 receiv least one dose adjuv durvalumab oneyear pf pt receiv least one dose durvalumab 703 median pf yet reach group median followup 24 mo pattern failur mostli distant 26 pt experienc distant failur 6 region 2 distant region one local failur 2 sbrt 50 pt conclus sbrt primari tumor follow convent chemoradi involv lymph node adjuv immunotherapi well toler show improv 1year pf compar prior convent chemoradi trial local advanc nsclc result trial evalu random phase iii studi nrg lu008 pt receiv either convent chemoradi vs sbrt primari tumor follow chemoradi involv lymph node follow consolid immunotherapi evalu possibl util sbrt new standard care la nsclc',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306287 pmid 37784465',\n '105 int j radiat oncol biol phi 2023 oct 11172ss23 doi 101016jijrobp202306279',\n 'concurr radiat immunotherapi augment local immun improv surviv aneuploid nsclc',\n 'spurr lf1 martinez c1 kang w1 chen m1 zha y1 hseu r1 gutiontov s2 turchan wt1 lynch c3 pointer kb4 voke ee5 bestvina cm6 patel jd7 diehn m8 weichselbaum rr9 chmura sj10 pitroda sp2',\n 'author inform 1univers chicago chicago il 2depart radiat cellular oncolog univers chicago medic center chicago il 3northwestern univers feinberg school medicin chicago il 4univers wisconsinmadison madison wi 5depart medicin section hematologyoncolog univers chicago chicago il 6depart hematolog oncolog univers chicago medic center chicago il 7luri cancer center northwestern universityfeinberg school medicin chicago il 8depart radiat oncolog stanford univers school medicin stanford ca 9depart radiat cellular oncolog univers chicago medicin chicago il 10depart medicin univers north carolina chapel hill nc',\n 'purposeobject 500 clinic trial combin radiat rt immun checkpoint blockad icb initi base preclin evid rt augment local immun improv efficaci icb howev mani recent clinic trial found benefit combin rt icb rais question whether synergi exist examin whether rt icb interact benefici stimul immun respons patient identifi biomark respons rt icb materialsmethod perform molecular analysi 1740 patient 3 cohort cosinr dataset random clinic trial 22 nonsmal cell lung cancer nsclc patient treat concurr sequenti sbrt ipilimumabnivolumab pair pre ontreat biopsi irradi metastasi underw whole exom sequenc rnaseq ontreat biopsi obtain sbrt prior icb sequenti sbrt one cycl icb concurr uc cohort consist target dna sequenc 58 nsclc patient treat icb alon sequenti rticb concurr rticb mskcc dataset pancanc cohort target dna sequenc 1660 patient treat icb aneuploidi score defin fraction chromosom arm armlevel copi number alter surviv analys util kaplanmei method multivari cox proport hazard model result cosinr trial sbrticb increas wherea sbrt alon decreas express effector cell ifngamma adapt immun signatur p005 establish biomark icb respons includ ifngamma signatur tumor mutat burden tmb pdl1 express neoantigen burden associ surviv p005 howev patient whose tumor exhibit high median low improv surviv treat concurr vs sequenti sbrticb 1year overal surviv os 100 vs 17 p 0025 find corrobor uc cohort high tumor treat rt icb superior 1year os compar treat icb alon 59 vs 31 p 0021 among receiv rt icb concurr treatment improv os rel sequenti 1year os 76 vs 38 rt improv os patient low median mskcc cohort high associ poor os follow icb control tmb icb paradigm hazard ratio 95 ci 144 107194 p 0014 among tumor low tmb 80th percentil high tmb high median associ poor os p 0003 conclus find distinguish genom transcriptom effect rt versu rticb challeng prevail paradigm local abl rt posit stimul immun respons propos use tumor aneuploidi biomark person treatment approach patient variou cancer',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306279 pmid 37784457',\n '106 int j radiat oncol biol phi 2023 oct 11172ss22s23 doi 101016jijrobp202306278',\n 'prognost signific pretreat immun cell infiltr muscl invas bladder cancer treat definit chemoradi analysi nrg rtog 0524 0712',\n 'deek mp1 shetti a2 song y2 efstathi ja3 feng fy4 shipley wu5 simko j6 mouw kw7 miyamoto dt5 pollack a8 michaelson d9 zietman al5 coen jj10 dahl dm9 jani a11 souhami l12 chang bk13 lee rj14 rodger j15 tran pt16',\n 'author inform 1depart radiat oncolog rutger cancer institut new jersey new brunswick nj 2univers maryland baltimor md 3depart radiat oncolog harvard school medicin boston 4depart radiat oncolog univers california san francisco san francisco ca 5depart radiat oncolog massachusett gener hospit harvard medic school boston 6ucsf san francisco ca 7broad institut mit harvard cambridg 8depart radiat oncolog univers miamisylvest comprehens cancer center miami fl 9massachusett gener hospit harvard medic school boston 10massachusett gener hospit boston 11depart radiat oncolog emori univers atlanta ga 12depart radiat oncolog mcgill univers health centr montreal qc canada 13radiat medicin associ oklahoma citi ok 14intermountain medic center murray ut 15nrg oncolog statist data manag center philadelphia pa 16depart radiat oncolog univers maryland school medicin baltimor md',\n 'purposeobject chemoradi therapi crt organ conserv approach treatment local advanc bladder cancer chemoradi thought potenti result immunogen stimul bladder cancer often tumor high immun cell infiltr thu aim profil tumor immun microenviron bladder cancer identifi prognost immun biomark crt respons profil tumor sampl nrgrtog 0524 0712 two prospect trial crt muscl invas bladder cancer mibc materialsmethod pretreat tissu sampl trial profil use cofactor genom immunopr rna sequenc assay use gene express profil quantifi immun cell popul tumor microenviron tme differenti gene express estim differ immun cell type proport across sampl kaplanmei surviv analysi log rank test perform evalu differ overal surviv os stratifi gene influenc immun cell proport gene associ immun respons signatur result total 70 sampl 43 rtog 0524 27 rtog 0712 underw analysi use immunopr assay immun cell proport follow cd8 cell median 12 cd4 cell median 08 treg cell median 92 cd19 b cell median 51 m2 macrophag median 08 m1 macrophag median 0 unbias cluster base gene express profil driven immun cell proport demonstr two group cluster 1 low percentag immun cell shorter os median 31 month cluster 2 high percentag immun cell longer os median 101 month p 0036 higher express gene associ cell infiltr cd8a ico associ improv os 104 vs 35 month p 0028 hr 048 025 094 p 0031 higher express ido1 associ interferon gamma pathway 104 vs 35 month p 0042 hr 049 024 099 p 0046 conclus bladder tumor wide rang immun cell infiltr tme increas immun cell proport prognost os follow crt well higher express gene associ cell infiltr interferon gamma signal find implic integr immunotherapi definit manag mibc explor ongo nrgswog 1806 trial',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306278 pmid 37784456',\n '107 int j radiat oncol biol phi 2023 oct 11172ss172 doi 101016jijrobp202306638',\n 'radiosurgeri dose reduct brain metastas immunotherapi radremi oneyear safeti efficaci outcom multicent phase trial',\n 'iii sm1 lautenschlaeg t2 miller ac2 zang y3 lauer ki4 hanna n5 rhome rm2 agraw n2 anthoni pa5 jaboin jj6 shiue k2 watson g2',\n 'author inform 1depart radiat oncolog univers hospit seidman cancer center case western reserv univers cleveland oh 2depart radiat oncolog indiana univers school medicin indianapoli 3depart biostatist indiana univers school medicin indianapoli 4indiana univers depart radiat oncolog indianapoli 5indiana univers indianapoli 6oregon health scienc univers portland',\n 'purposeobject combin immunotherapi singlefract stereotact radiosurgeri sr treatment metastat brain diseas yield symptomat radiat necrosi rate high 20 pmid 29327059 consequ radiosurgeri dose reduct brain metastas immunotherapi radremi multicent phase trial regist clinicaltrialsgov nct04047602 creat address whether reduceddos sr improv morbid without compromis efficaci report present oneyear find materialsmethod elig radremi enrol requir brain metastas patient histologicallyconfirm primari malign b receipt immunotherapi within 30 day sr c 110 mrivis brain metastas estim median surviv least 6 month via diseasespecif grade prognost assess e histori whole brain radiat therapi reduceddos sr util 18 gy lesion 02 cm 14 gy lesion 213 cm 12 gy lesion 314 cm symptomat radiat necrosi defin imag find consist radiat necrosi combin clinic symptom requir steroid administr andor oper intervent local control defin respons assess neurooncolog rano criteria result decemb 18 2019 june 30 2022 54 lesion 17 patient treat radremi least oneyear followup oneyear local control occur 52 54 lesion 15 17 patient yield control rate 96 per lesion 88 per patient radiograph radiat necrosi occur 2 54 lesion 4 symptomat radiat necrosi occur conclus find concurr immunotherapi reduceddos sr oneyear posttreat reveal excel local control 96 symptomat radiat necrosi minim radiograph radiat necrosi result attest durabl safeti efficaci reduceddos sr immunotherapi metastat brain diseas',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306638 pmid 37784430',\n '108 int j radiat oncol biol phi 2023 oct 11172ss172s173 doi 101016jijrobp202306639',\n 'initi report boswellia serrata manag cerebr radiat necrosi stereotact radiosurgeri brain metastas',\n 'upadhyay r1 elguindi an2 sengupta s3 wang k4 beyer s5 thoma em5 raval r5 palmer jd5',\n 'author inform 1the jame ohio state new delhi india 2the jame cancer center ohio state univers wexner medic center columbu oh 3depart neurolog univers cincinnati cincinnati oh 4depart radiat oncolog univers cincinnati cincinnati oh 5depart radiat oncolog ohio state univers wexner medic center columbu oh',\n 'purposeobject radiat necrosi rn concern late toxic radiat therapi rt brain metastas oral corticosteroid mainstay manag howev optim longterm use given multipl side effect drug interact particularli emerg immunotherapi sever cancer boswellia serrata bs overthecount supplement use antiinflammatori properti recent shown reduc cerebr edema brain rt evalu respons rate bs seri patient brain metastas treat stereotact radiosurgeri sr develop rn materialsmethod includ patient develop rn sr brain metastas institut 20202022 treat bs patient prescrib counter bs 4245g daili divid dose followup mri imag obtain everi 23 month start bs respons assess use respons assess neurooncolog rano criteria primari endpoint 25 decreas edema volum t2flair mri baselin patient censor tumor progress repeat rt necrot area death kaplanmei curv use surviv estim result total 50 patient receiv bs grade 13 ctcae v50 rn g1 11 g2 36 g3 3 median age 628 year rang 369 50 median rt dose 24 gy 3 fraction median time rn sr 10 monthsm median followup start bs 6m 40 patient least 1 follow mri avail evalu respons best respons complet respons cr 15 patient partial respons pr 40 35 stabl diseas sd 10 progress diseas median time cr 9m 612m pr 6m 312m percentag patient respons cr pr 3 6 9 12 month 25 60 43 50 respect 56 patient symptomat rn 357 improv symptom bs alon 64 requir steroid use overal median durat respons patient cr pr sd 75mrang 231m salvag treatment rn steroid 33 surgeri 4 bevacizumab 5 hyperbar oxygen therapi 1 patient ctcae grade 3 higher toxic 3 patient 6 sideeffect grade 12 gastrointestin intoler diarrhea 2 patient stop treatment due enrol immunotherapi clinic trial overal 39 patient remain bs last followup death conclus observ 50 respons rate use bs cohort patient grade 13 rn sr 13rd patient symptomat rn abl avoid longterm steroid use bs easili avail overthecount drug appear safe promis treatment option rn potenti decreas steroid depend patient reduc risk sever sideeffect prospect studi compar boswellia placebo warrant',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306639 pmid 37784429',\n '109 int j radiat oncol biol phi 2023 oct 11172ss168s169 doi 101016jijrobp202306270',\n 'evalu pneumon phase ii studi consolid immunotherapi nivolumab ipilimumab nivolumab alon follow concurr chemoradiotherapi unresect stage iiiaiiib nonsmal cell lung cancer nsclc',\n 'weisman m1 shield m2 althous s3 durm g2 lautenschlaeg t1',\n 'author inform 1depart radiat oncolog indiana univers school medicin indianapoli 2depart medic oncolog indiana univers school medicin indianapoli 3depart biostatist simon cancer center indiana univers school medicin indianapoli',\n 'purposeobject unresect stage iii nonsmallcelllungcanc nsclc evolv landscap treatment option approv immunooncolog io therapi rel studi evalu risk pneumon patient receiv io concurr chemoradi treatment ccrt studi evalu relationship pneumon radiat dose patient receiv consolid io nivolumab nivolumab plu ipilimumab materialsmethod patient stage iii nsclc underw ccrt enrol btcrclun16081 random phase ii trial assess efficaci nivolumab nivolumab plu ipilimumab consolid therapi patient evalu radiat dose paramet correl pneumon examin result ccrt patient enrol receiv consolid io therapi btcrclun16081 104 patient dose volum histogram dvh inform avail analysi patient 58 558 stage iiia 46 442 stage iiib diseas accord 7th edit iaslc period 29 patient 279 least grade 2 pneumon util logist regress evalu differ cut off lung v20 patient receiv v20 greater 23 higher risk grade 2 greater pneumon pvalu 00246 38 vs 16 signific differ rate pneumon two differ io regimen tradit lung dvh cutoff v565 v2035 mean 20 gy associ pneumon studi conclus use nivolumab nivolumab plu ipilimumab definit ccrt safe effect lung v20 23 associ higher risk grade 2 higher pneumon radiat dose constraint lung patient receiv consolid io ccrt continu evalu optim feasibl',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306270 pmid 37784419',\n '110 int j radiat oncol biol phi 2023 oct 11172ss157s158 doi 101016jijrobp202306583',\n 'singlecel spatial transcriptom reveal role ido1 hpv cervic cancer tumor immun microenviron implic radiotherapi immunotherapi',\n 'danyang z1 xu z2 ye b3 zhang y4 zhao c5 xu w4 liang z4 yu h6 kong fm7',\n 'author inform 1the univers hong kong hong kong china depart clinic oncolog univers hong kong hong kong china 2univers virginia health system charlottesvil va 3shenzhen institut advanc technolog chines academi scienc shenzhen china 4the univers hong kongshenzhen hospit shenzhen china 5depart clinic oncolog univers hong kong hong kong china 6chines academi scienc shenzhen institut advanc technolog shenzhen china shenzhen china 7the univers hong kong hong kong china',\n 'purposeobject persist infect human papillomaviru hpv one major etiolog cervic cancer cc antipd1 immunotherapi approv advanc cc patient respons rate 1020 tumor immun microenviron time might one factor affect efficaci indoleamin 23dioxygenas ido metabol immun checkpoint recent shown correlationship hpv carcinogenesi cc unknown mechan studi use singl cell transcriptom singlecel sequenc spatial transcript sequenc analysisimmunolog technolog aim exam role ido1 express hpv cc time explor chang radiotherapi materialsmethod newli diagnos advanc hpv cc hpv cc patient test tumor tumor immun microenviron time heterogen chang fraction radiat therapi tumor tissu collect singl cell suspens made singlecel rna sequenc scrnaseq use 10 genom frozen tissu embed spatial transcriptom sequenc strnaseq seurat 40 use cluster annot cell cluster map scrnaseq data strnaseq data specif charact cell cluster comput gene set enrich analysi gsea spotlight cellchat use analyz cell locat interact respect result total 28631 cell cluster 31 cell subset hpv cc hpv cc tissu includ baselin pre hpv cc pre hpv cc 3week radiotherapi post 3w hpv cc post 3w hpvcc 10431 epitheli cell epi 4 tumor tissu heterogen ido1 express includ ido1high epi ido1low epi ido1neg epi interestingli 99 epi pre hpv cc tissu ido1neg cell 99 pre hpv cc tissu ido1high furthermor proport ido1high epi pre hpv cc patient drop 167 radiotherapi proport ido1low epi rase 633 use gsea charact ido1high epi group shown posit regul leukocyt chemotaxi neg regul cell adhes differenti ido1high epi cell also hallmark interferon gamma respons cell could mainli receiv regul inform interferon gamma pathway exhaust cd8 cell could affect apoptosi tumor cell conclus studi comprehens analyz immun suppress role ido1high epi cell hpv cc time singlecel transcript scale explor function charact cc radiotherapi would abl provid evid combin radiotherapi immunotherapi improv patient prognosi',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306583 pmid 37784395',\n '111 int j radiat oncol biol phi 2023 oct 11172ss157 doi 101016jijrobp202306582',\n 'influenc radiat fraction immun repertoir divers solid tumor patient',\n 'ellsworth sg1 ross a2 shiue k3 murthi p4 patel rb5 zellar rc6 miller ac7 russ ka8 lotz m4',\n 'author inform 1depart radiat oncolog upmc hillman cancer center pittsburgh pa 2univers pittsburgh pittsburgh pa 3depart radiat oncolog indiana univers school medicin indianapoli 4univers pittsburgh hillman cancer center pittsburgh pa 5upmc hillman cancer center pittsburgh pa 6indiana univers depart radiat oncolog indianapoli 7icon plc indianapoli 8indiana univers school medicin indianapoli',\n 'purposeobject radiat rtinduc lymphopenia ril occur 75 patient undergo rt associ wors tumor control surviv across spectrum solid tumor patient undergo hypofraction rt lower risk ril compar patient treat prolong rt cours howev unknown whether immun repertoir divers similarli affect fraction scheme patient undergo rt prospect studi analyz rtinduc chang immun repertoir divers patient treat convent cfrt vs hypofraction rt hfrt materialsmethod rnabas b cell receptor sequenc perform peripher lymphocyt collect prospect rt within 4 week last rt fraction 23 patient 18 men 5 women median age 67 primari solid tumor undergo cfrt 3 gyday x 10 day n 13 hfrt 5 gyday x 5 day n 10 absolut lymphocyt count alc cellsl obtain clinic laboratori data number uniqu cdr3 receptor ucdr3 shannon entropi use monitor chang tcr v b bcr igh receptor divers result alc decreas rt 90 2022 patient mean prert alc 1830 vs 1040 postrt p 0001 mean alc loss greater cfrt vs hfrt patient 443 vs 352 rt entropi igh v decreas 1823 78 1723 74 patient respect ucdr3 igh v decreas 1423 61 1523 65 among patient concord decreas alc ucdr3 moder correl magnitud alc loss ucdr3 level tcell receptor v observ r 064 p 002 receptor speci studi igh v hfrt patient like increas either entropi ucdr3 face decreas alc 36 vs 15 x2 p 003 furthermor decreas entropi observ among cfrt patient igh median entropi 104 vs 94 p 006 v 97 vs 81 p 002 entropi significantli chang follow rt hfrt patient igh 106 vs 104 p 074 v 109 vs 108 p 024 conclus rtinduc chang immun repertoir divers variabl reflect peripher alc hfrt cfrt deplet circul lymphocyt patient undergo hfrt like experi increas b cell divers metric despit lymphopenia therefor possibl rel spare repertoir divers among patient undergo hfrt could increas likelihood tumor antigen recognit peripher blood lymphocyt immun repertoir divers associ likelihood respons immunotherapi find also implic rtimmunotherapi combin studi requir understand relationship rt exposur circul lymphocyt popul immun repertoir divers',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306582 pmid 37784394',\n '112 int j radiat oncol biol phi 2023 oct 11172ss154s155 doi 101016jijrobp202306577',\n 'dosimetr studi indic spinal cord irradi contribut acut hematolog toxic nonsmal cell lung cancer patient receiv radiotherapi combin immunotherapi',\n 'j1 zhang j2 shang s3 wang f3 yu j4 chen d5',\n 'author inform 1depart radiat oncolog shandong provinci key laboratori radiat oncolog shandong cancer hospit institut shandong first medic univers shandong academi medic scienc jinan shandong china lung cancer center west china hospit sichuan univers chengdu sichuan china 2shandong univers cancer center jinan shandong china 3depart radiat oncolog shandong provinci key laboratori radiat oncolog shandong cancer hospit institut shandong first medic univers shandong academi medic scienc jinan shandong china 4shandong cancer hospit institut shandong first medic univers shandong academi medic scienc jinan shandong china 5shandong univers cancer center depart radiat oncolog shandong provinci key laboratori radiat oncolog shandong first medic univers shandong academi medic scienc jinan shandong china',\n 'purposeobject assess radiat therapi rt dose radiationassoci hematolog toxic ht patient nonsmal cell lung cancer nsclc rt combin immunotherapi materialsmethod case nsclc treat rt combin immunotherapi shandong cancer hospit china identifi mean dose volum spinal cord receiv least 5 40 gy v5v40 retrospect record logist regress use estim associ grade 3 ht ht3 dosimetricclin paramet receiv oper characterist analysi use determin dosimetr cutpoint result ninetynin patient analyz major male n 78 788 receiv chemotherapi n 83 839 patient receiv either antipd1 immun checkpoint n 89 899 antipdl1 immun checkpoint n 10 101 therapi rate ht3 242 n 24 spinal cord mean dose v5 v40 bmi paramet associ ht3 includ multivari analysi multivari analysi increas mean spinal cord dose per gy associ higher odd develop ht3 odd ratio 1053 95 confid interv 10021105 p 041 increas spinal cord v5 v20 show tabl optim cutpoint identifi v5 525 v10 475 v20 394 mean dose 233 gy patient valu cutpoint approxim 2fold increas risk ht3 conclus found mean spinal cord dose lowdos paramet v5v20 associ ht3 nsclc patient rt immunotherapi mean dose spinal cord kept lower 233 gy patient data suggest effort spare dose spinal cord might reduc rate sever ht',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306577 pmid 37784388',\n '113 int j radiat oncol biol phi 2023 oct 11172ss128 doi 101016jijrobp202306474',\n 'earli stereotact bodi radiotherapi primari lung lesion patient advanc nsclc treat firstlin system therapi',\n 'tao d1 sun l1 wang ll1 yang d1 jiang y1 zhou w1 wang y2 wu yz1',\n 'author inform 1depart radiat oncolog chongq univers cancer hospit chongq china 2radiat oncolog center chongq univers cancer hospit chongq china',\n 'purposeobject although ad consolid stereotact bodi radiotherapi sbrt system therapi improv surviv advanc nonsmal cell lung cancer nsclc optim time sbrt remain unclear studi aim explor clinic outcom earli delay sbrt primari lung lesion advanc nsclc patient treat firstlin system therapi materialsmethod identifi patient advanc nsclc suitabl receivesbrt primari lung tumor firstlin system therapi elig patient treat firstlin system therapi sbrt primari lung lesion earli sbrt group defin patient receiv sbrt primari lung tumor maxim respons system therapi delay sbrt group defin patient receiv sbrt occurr oligoprogress primari lung tumor primari endpoint progressionfre surviv 1 pfs1 time start firstlin system therapi diseas progress pfs2 time start firstlin system therapi diseas progress sbrt overal surviv os advers effect ae secondari endpoint twosid p valu 005 consid statist signific statist analys perform statist softwar result total of184 patient advanc nsclc treat sbrt primari tumor screen 49 patient elig enrol studi median age entir cohort 66 year rang 3780 year 34 694 patient male thirtyfour patient 694 treat target therapi 15 306 treat chemotherapi immunotherapi 49 elig patient 28571 receiv earli sbrt lung primari tumor 21429 receiv delay sbrt lung primari tumor earli sbrt group show significantli prolong pfs1 compar delay sbrt group mpfs1 30 month vs 8 month p0001 median pfs2 earli sbrt group longer delay sbrt group differ two group achiev statist signific mpfs2 42 month vs 23 month p 0303 median os group reach sever toxic grade 3 observ earli sbrt group one patient delay sbrt group experienc grade 3 radiat pneumon conclus earli sbrt primari lung lesion significantli improv pf new potenti effect toler treatment option patient advanc nsclc stabl diseas firstlin system therapi',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306474 pmid 37784330',\n '114 int j radiat oncol biol phi 2023 oct 11172ss128s129 doi 101016jijrobp202306475',\n 'treatment efficaci outcom combin dual checkpoint immunotherapi abl radiat site oligometastat nonsmal cell lung cancer surviv analysi phase ib trial',\n 'morri ba1 leal ta2 sethakorn n3 lang j4 schehr j5 zhao sg6 morri zs6 buehler d7 eickhoff j8 harari pm jr6 traynor am4 campbel t4 baschnagel am6 bassetti mf6',\n 'author inform 1depart human oncolog univers wisconsin carbon cancer center madison wi 2emori univers school medicin atlanta ga 3loyola school medicin chicago il 4depart medic oncolog univers wisconsin hospit clinic madison wi 5univers wisconsin school medicin public health madison wi 6depart human oncolog univers wisconsin hospit clinic madison wi 7depart patholog laboratori medicin univers wisconsin madison wi 8univers wisconsin madison madison wi',\n 'purposeobject aggressiveloc treatment limit number metastat site patient oligometastat nsclc increas progress free surviv pf overal surviv os prior studi shown safeti combin high dose stereotact bodi radiat therapi sbrt singl agent antipd1pdl1 therapi report secondari surviv endpoint outcom phase ib clinic trial investig safeti combin abl high dose radiat dual checkpoint antictla4 antipdl1 immunotherapi patient oligometastat nsclc materialsmethod patient 6 site extracrani metastat diseas elig trial enrol site diseas treat stereotact bodi radiat therapi dose 30 50 gy 5 fraction dual checkpoint immunotherapi start 7 day follow complet radiat util antictla4 tremelimumab antipdl1 durvalumab immunotherapi total four cycl follow durvalumab alon dose limit toxic progress observ primari toxic outcom previous report progress free overal surviv analyz use kaplan meier statist method result fifteen patient treat sbrt receiv least one dose dual agent immunotherapi per protocol median follow 43 month median number extracrani metastat site 2 seven patient 3 site extracrani diseas commonli treat site separ metastat pulmonari lesion osseou metastat lesion median progress free surviv pf 42 month median overal surviv os 48 month seven patient remain aliv without evid progress diseas prior histori brain metastas associ significantli wors pf median pf 4 month vs 42 month hr 61 95 ci 16 370 p 00248 differ os median os 24 vs 42 month hr 19 95 ci 03 104 conclus abl sbrt radiat 6 site diseas follow dual checkpoint immunotherapi oligometastat nsclc result favor progress free surviv 42 month overal surviv 48 month compar histor control find suggest potenti benefit patient outcom compar immunotherapi radiat alon patient popul warrant investig',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306475 pmid 37784329',\n '115 int j radiat oncol biol phi 2023 oct 11172ss127s128 doi 101016jijrobp202306472',\n 'pdl1 inhibitor combin thorac radiotherapi firstlin treatment extens stage small cell lung cancer propens scorematch realworld studi',\n 'peng j1 zhang l2 wang l3 feng h4 yao d5 meng r6 liu x7 li x8 liu n9 tan b10 huang z11 li s12 meng x13',\n 'author inform 1depart radiat oncolog shandong cancer hospit institut shandong first medic univers shandong academi medic scienc jinan china 2depart thorac depart hunan cancer hospit changsha china 3depart medic oncolog baotou cancer hospit baotou china 4depart clinic oncolog affili hospit qingdao univers qingdao china 5depart medic oncolog chaoyang second hospit chaoyang china 6depart cancer center union hospit tongji medic colleg huazhong univers scienc technolog wuhan china 7depart oncolog depart jinzhou medic univers jinzhou china jinzhou china 8depart respiratori critic care chifeng municip hospit chifeng china 9tianjin medic univers cancer institut hospit nation clinic research center cancer tianjin clinic research center cancer key laboratori cancer prevent therapi tianjin tianjin china 10qilu hospit shandong univers jinan china 11shandong provinci hospit affili shandong first medic univers jinan china 12depart oncolog zibo municip hospit zibo china 13depart radiat oncolog shandong cancer hospit institut shandong first medic univers shandong academi medic scienc jinan shandong china',\n 'purposeobject crest studi show addit thorac radiotherapi trt could improv surviv extens stage small cell lung cancer essclc whether trt bring surviv benefit era immunotherapi controversi studi aim explor efficaci safeti ad trt combin pdl1 inhibitor chemotherapi materialsmethod thepati receiv pdl1 inhibitor combin platinumbas chemotherapi firstlin treatment essclc januari 2019 decemb 2021 retrospect collect accord whether receiv trt divid two group followup analysi perform propens score match psm 11 ratio perform balanc baselin characterist two cohort endpoint progressionfre surviv pf os result total 211 patient essclc enrol 70 332 patient receiv standard therapi plu trt firstlin treatment 141 668 patient control group receiv pdl1 inhibitor plu chemotherapi psm total 65 pair patient enrol analysi signific differ baselin characterist two group patient receiv trt patient median pf mpf trt group nontrt groupwer 95 month 72 month respect hr 060 95 ci 041087 p 0007 median os mo trt group also significantli longer nontrt group 241 month vs 185 month hr 053 95 ci 032085 p 0009 multivari analysi show baselin liver metastasi bone metastasi independ prognost factor os term safeti immunotherapi combin thorac radiotherapi increas incid treatmentrel pneumonia p0001 grade 12 conclus realworld studi show ad trt durvalumab atezolizumab plu chemotherapi significantli improv surviv essclc lead treatmentrel pneumonia reliev symptomat treatment treatment model deserv explor prospect clinic trial',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306472 pmid 37784327',\n '116 int j radiat oncol biol phi 2023 oct 11172ss111s112 doi 101016jijrobp202306439',\n 'outcom mrguid stereotact bodi radiotherapi mrgsbrt adren metastas multiinstitut pool analysi',\n 'ugurlu g1 schneider fl2 corradini s3 boldrini l4 kotecha r5 kelli p6 portel l7 camilleri p8 bendavid ma9 poiset sj10 marschner s3 panza g4 kutuk t5 palacio m2 mustafayev tz11 atalar b1 senan s2 ozyar e1',\n 'author inform 1depart radiat oncolog acibadem maa univers school medicin istanbul turkey 2depart radiat oncolog amsterdam univers medic center cancer center amsterdam amsterdam netherland 3depart radiat oncolog univers hospit ludwigmaximiliansunivers munich germani 4depart radiolog radiat oncolog hematolog fondazion policlinico universitario gemelli ircc rome itali 5depart radiat oncolog miami cancer institut baptist health south florida miami fl 6depart radiat oncolog orlando health cancer institut orlando fl 7depart radiat oncolog univers miami miami fl 8radiat oncolog genesiscar oxford unit kingdom 9depart radiat oncolog assuta medic center tel aviv israel 10depart radiat oncolog sidney kimmel cancer center thoma jefferson univers philadelphia pa 11depart radiat oncolog acibadem maslak hospit istanbul turkey',\n 'purposeobject stereotact bodi radiotherapi sbrt effect treatment adren metastas technic challeng concern toxic due proxim organ risk hypothes mrguid sbrt mrgsbrt use 035 mrlinac adren metastas achiev durabl local control lc low probabl toxic materialsmethod ethicsapprov studi analyz clinic dosimetr data patient treat mrgsbrt 10 institut 20162022 lc local progressionfre surviv lpf distant progressionfre surviv dpf overal surviv os estim use kaplanmei method logrank test respons evalu use recist criteria toxic grade accord ctcae v40 os dpf calcul perpati basi lc lpf calcul perles basi result total 249 patient 260 adren lesion includ median age 65 year rang 2891 655 male 839 ecog ps 01 common primari tumor lung cancer 691 adren metastas synchron metachron oligoprogress oligopersist 20 415 358 27 patient respect metastat pattern solitari 269 oligometastat 573 polymetastat 158 patient rightsid metastas compris 40 leftsid 515 lesion bilater 85 chemotherapi immunotherapi administ 671 606 patient respect median gross tumor volum 218 cc rang 113832 median plan target volum 369 cc rang 365169 median total dose 45 gy rang 1660 median fraction number 5 rang 18 median fraction dose use 10 gy rang 524 median bed10 100 gy rang 375132 878 fraction use adapt plan median followup 177 month iqr 55217 local respons score complet respons cr partial respons pr stabl diseas sd progress diseas pd 369 282 257 91 respect median os 304 month 1 2 year os rate 753 571 respect multivari analysi significantli higher os rate seen patient achiev cr p 0007 hr 050 ecog score 01 p 0001 hr 043 one 2 year lpf rate 945 888 respect local recurr observ treatment bed10100 singl fraction rang 1624 gy 2 patient 08 grade 3 chronic toxic conclus multiinstitut studi mrgsbrt outcom adren metastas reveal 2year lpf 89 1 risk grade 3 toxic daili adapt perform 90 plan indic benefici role mr guidanc',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306439 pmid 37784293',\n '117 int j radiat oncol biol phi 2023 oct 11172ss105 doi 101016jijrobp202306064',\n 'relationship microbiom respons neoadjuv chemoradiotherapi rectal cancer',\n 'lee hi1 jang bs2 lee th2 park jh3 chang jh2 chie ek2',\n 'author inform 1depart radiat oncolog asan medic center univers ulsan colleg medicin seoul korea republ south korea 2depart radiat oncolog seoul nation univers hospit seoul nation univers colleg medicin seoul korea republ south korea 3depart patholog smgsnu borama medic center seoul korea republ south korea',\n 'purposeobject gut microbiom known involv antitumor immunotherapi chemotherapi respons howev research focus role gut microbiom set concurr chemoradiotherapi ccrt studi investig tumor microbiom dynam patient undergo neoadjuv ccrt local advanc rectal cancer sought determin whether divers composit microbiom affect treatment respons materialsmethod total 103 sampl 26 patient local advanc rectal cancer collect 16 ribosom rna amplicon sequenc perform patient underw neoadjuv ccrt follow surgic resect 2008 2016 sampl obtain tumor normal rectal tissu pre postccrt accord american joint committe cancer tumor regress grade trg system patient divid respond trg 0 1 nonrespond trg 2 3 perform divers taxonomi network analys compar respond nonrespond establish bayesian network model predict treatment respons patient rectal cancer result overal detect 1260 microbi genera 287 famili 132 order 56 class 32 phyla bacteria kingdom tumor normal rectal tissu differ microbi divers composit hand signific decreas divers composit alter compar pre postccrt sampl p0001 ten patient 385 classifi respond 16 patient 615 classifi nonrespond group ccrt significantli reduc microbi divers alter composit pronounc nonrespond taxonom analysi preccrt sampl butyrateproduc bacteria differenti enrich respond meanwhil postccrt sampl opportunist pathogen overrepres nonrespond network analysi reveal butyrateproduc bacteria strong interact respond wherea opportunist pathogen demonstr strong interact nonrespond pearson coefficient05 final five microb select optim set respons predict model yield area curv valu 8233 conclus ccrt significantli chang divers composit microbiom especi nonrespond sever microb might relat treatment respons find highlight potenti microbiom play import role biomark patient rectal cancer nct02533271',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306064 pmid 37784278',\n '118 int j radiat oncol biol phi 2023 oct 11172ss104 doi 101016jijrobp202306061',\n 'listeriolysin drive innat adapt immun respons cd47 immunotherapi',\n 'schrank br1 wang y2 antoni a2 jiang w3',\n 'author inform 1depart radiat oncolog univers texa md anderson cancer center houston tx depart experiment radiat oncolog univers texa md anderson cancer center houston tx 2depart experiment radiat oncolog univers texa md anderson cancer center houston tx 3depart radiat oncolog univers texa md anderson cancer center houston tx',\n 'purposeobject radioimmunotherapi combin radiat antibodi dont eat signal cd47 show increas promis one opportun synerg rt anticd47 via stimul interferon gene sting pathway facilit potent immun respons cytoplasm dna anticd47 activ sting increas macrophag consumpt tumor dna howev tumor content destroy phagolysosom listeria l monocytogen escap lysosom secret poreform protein listeriolysin llo recent engin proteinantibodi conjug link anticd47 llo demonstr llocd47 enhanc macrophag sting signal tumor cell phagocytosi tumor antigen present dose compat minim toxic mice llocd47 delay growth orthotop breast tumor contrast anticd47 fail activ sting macrophag inhibit tumor growth hypothes llocd47 requir innat adapt immun cell antitumor immun materialsmethod anticd47 conjug llo use watersolubl spdp crosslink purifi affin chromatographi transmiss electron microscopi tem use visual integr macrophag phagolysosom follow treatment c57b6 mous bone marrowderiv macrophag bmdm use studi impact llocd47 m2tom1 polar tumor cell phagocytosi sting activ antigen present cd8 cell tumorassoci macrophag tam deplet tumorbear mice use anticd8 antibodi anticsf1r antibodi prior llocd47 treatment result 1 llocd47 skew bmdm m2tom1 inflammatori phenotyp enhanc phagocytosi e0771 tumor cell 2 bmdm visual tem show breach phagosom membran follow llocd47 anticd47 treatment 3 llocd47 increas level phosphoryl sting ifn tnf rel cell treat anticd47 4 llocd47 significantli inhibit growth orthotop implant e0771 murin breast tumor rel anticd47 5 elimin cd8 cell tam abrog antitumor effect llocd47 conclus llocd47 de novo proteinantibodi conjug engin cgasst pathway activ innat immun cell cd8 cell tam requir antitumor activ llocd47 orthotop model breast cancer novel immunotherapi build clinic interest myeloid checkpoint inhibitor may studi supplement therapi patient metastat breast cancer',\n 'copyright 2023 publish elsevi inc',\n 'doi 101016jijrobp202306061 pmid 37784275',\n '119 hla 2023 oct 2 doi 101111tan15239 onlin ahead print',\n 'adapt hla test character cynomolgu macaqu mhc polymorph alloantibodi signatur',\n 'agarw d1 liu c2 bhoj v3 kearn j4 bharani t5 choe i4 vivek k6 oconnor dh78 wiseman rw78 duquesnoy rj9 naji a2 kamoun m4',\n 'author inform 1depart surgeri massachusett gener hospit boston massachusett usa 2divis transplant depart surgeri hospit univers pennsylvania philadelphia pennsylvania usa 3center cellular immunotherapi parker institut cancer immunotherapi perelman school medicin univers pennsylvania philadelphia pennsylvania usa 4depart patholog laboratori medicin perelman school medicin univers pennsylvania philadelphia pennsylvania usa 5thoma jefferson univers hospit sidney kimmel medic colleg philadelphia pennsylvania usa 6depart anesthesiolog montefior medic center albert einstein colleg medicin bronx new york usa 7depart patholog laboratori medicin univers wisconsinmadison madison wisconsin usa 8wisconsin nation primat research center univers wisconsinmadison madison wisconsin usa 9univers pittsburgh medic center pittsburgh pennsylvania usa',\n 'nonhuman primat closest anim model human respect genet physiolog consequ critic compon immunogenet research reli draw infer cynomolgu macaqu inform human trial despit conserv organ major histocompat complex mhc cynomolgu macaqu human mhc genotyp cynomolgu macaqu challeng due high rate copi number variant duplic rearrang particularli mhc class loci furthermor limit avail commerci reagent specif cynomolgu macaqu use character antimhc class class ii antibodi ab specif cynomolgu macaqu present major bottleneck translat research success character cynomolgu macaqu mafa class class ii serolog specif 86 anim origin variou geograph region use complement depend cytotox cdc assay human hla class class ii monoclon antibodi mab type tray success induc character antimafa class class ii alloantibodi specif use hla singl antigen bead assay also subsequ track alloab burden anim treatment antib lymphocyt stimul bli treatment altogeth method easili use translat research serotyp mhc class class ii specif macaqu character alloab specif evalu efficaci novel therapeut modal deplet circul alloab anim',\n '2023 john wiley son publish john wiley son ltd',\n 'doi 101111tan15239 pmid 37784210',\n '120 j transl med 2023 oct 2211686 doi 101186s12967023045759',\n 'explor dynam interplay cancer stem cell tumor microenviron implic novel therapeut strategi',\n 'li yr1 fang y2 lyu z2 zhu y2 yang l3456',\n 'author inform 1depart microbiolog immunolog molecular genet univers california lo angel lo angel ca 90095 usa charlieliuclaedu 2depart microbiolog immunolog molecular genet univers california lo angel lo angel ca 90095 usa 3depart microbiolog immunolog molecular genet univers california lo angel lo angel ca 90095 usa liliyanguclaedu 4eli edyth broad center regen medicin stem cell research univers california lo angel lo angel ca 90095 usa liliyanguclaedu 5jonsson comprehens cancer center david geffen school medicin univers california lo angel lo angel ca 90095 usa liliyanguclaedu 6molecular biolog institut univers california lo angel lo angel ca 90095 usa liliyanguclaedu contribut equal',\n 'cancer stem cell csc emerg key contributor tumor initi growth metastasi addit csc play signific role induc immun evas therebi compromis effect cancer treatment reciproc commun csc tumor microenviron tme observ tme provid support nich csc surviv selfrenew csc turn influenc polar persist tme promot immunosuppress state consequ interact hinder efficaci current cancer therapi necessit explor novel therapeut approach modul tme target csc review highlight intric strategi employ csc evad immun surveil develop resist therapi furthermor examin dynam interplay csc tme shed light interact impact cancer progress moreov provid overview advanc therapeut strategi specif target csc tme hold promis futur clinic translat studi cancer treatment',\n '2023 biom central ltd part springer natur',\n 'doi 101186s12967023045759 pmid 37784157121 bmc med genom 2023 oct 2161228 doi 101186s1292002301664i',\n 'cyp19a1 promot gastric cancer part lipid metabolismrel gene signatur relat respons immunotherapi prognosi',\n 'zhou x1 meng f2 xiao l1 shen h3',\n 'author inform 1nanj benq medic center affili benq hospit nanj medic univers nanjingjiangsu provinc 210019 china 2depart gener surgeri first affili hospit nanj medic univers 300 guangzhou road nanj 210029 jiangsu china 3depart gener surgeri first affili hospit nanj medic univers 300 guangzhou road nanj 210029 jiangsu china shnjmuhotmailcom contribut equal',\n 'background increas evid suggest metabol lipid play crucial role progress gastric cancer howev express lipid metabolismrel gene lmg still serv prognost biomark gastric cancer method obtain transcriptom data 751 lmg divid stad patient two subtyp base differ lmg express analyz genet chang two subtyp well immun featur determin differ also construct prognost risk model relat lmg individu comprehens evalu result studi two lipid metabol lm subtyp identifi anchor express profil lmg clinic inform genom alter immun featur immunotherapi respons vari significantli two lm subtyp risk model base lmg also develop assess prognosi distinguish patient high risk low risk prognosi differ significantli two risk group patient stad patient risk score strongli correl genom alter immun profil score also risk score excel predictor immun checkpoint inhibitor ici respons anchor preliminari result deriv aforement bioinformat analysi chose cyp19a1 target gene express cyp19a1 verifi sever common gastric cancer cell line carri western blot cck8 assay coloni format assay wound heal assay transwel assay explor effect cyp19a1 malign biolog behavior posit consequ obtain conclus studi stad patient divid two subtyp base lmg express possibl assess prognosi patient respons immunotherapi use establish prognost risk model seri basic laboratori experi also verifi function role cyp19a1 gastric cancer',\n '2023 biom central ltd part springer natur',\n 'doi 101186s1292002301664i pmid 37784135',\n '122 mol cancer 2023 oct 2221159 doi 101186s12943023018605',\n 'defin cancerassoci fibroblast caf tumor microenviron new opportun cancer immunotherapi advanc clinic trial',\n 'zhang h1 yue x12 chen z1 liu c3 wu w4 zhang n5 liu z6 yang l7 jiang q2 cheng q89 luo p1011 liu g12',\n 'author inform 1depart neurosurgeri second affili hospit chongq medic univers chongq china 2depart urolog second affili hospit chongq medic univers chongq china 3depart neurosurgeri central hospit zhuzhou zhuzhou china 4depart oncolog xiangya hospit central south univers changsha china 5colleg life scienc technolog huazhong univers scienc technolog wuhan china 6depart intervent radiolog first affili hospit zhengzhou univers zhengzhou china 7depart laboratori medicin second affili hospit chongq medic univers chongq china 8depart neurosurgeri xiangya hospit central south univers changsha china chengquancsueducn 9nation clinic research center geriatr disord xiangya hospit central south univers changsha china chengquancsueducn 10depart neurosurgeri second affili hospit chongq medic univers chongq china luopengsmueducn 11depart oncolog zhujiang hospit southern medic univers guangzhou china luopengsmueducn 12depart neurosurgeri second affili hospit chongq medic univers chongq china 304678hospitalcqmueducn contribut equal',\n 'despit centuri sinc discoveri studi cancer cancer still lethal intract health issu worldwid cancerassoci fibroblast caf gain much attent pivot compon tumor microenviron versatil sophist mechan caf facilit cancer progress elucid extens includ promot cancer angiogenesi metastasi induc drug resist reshap extracellular matrix develop immunosuppress microenviron owe robust tumorpromot function caf consid promis target oncotherapi howev caf highli heterogen group cell subpopul exert inhibitori role tumor growth impli caftarget approach must precis individu review comprehens summar origin phenotyp function heterogen caf importantli underscor advanc strategi clinic trial target caf variou cancer also summar progress caf cancer immunotherapi',\n '2023 biom central ltd part springer natur',\n 'doi 101186s12943023018605 pmid 37784082',\n '123 bmc med genom 2023 oct 2161230 doi 101186s1292002301671z',\n 'macrophag relat signatur predict prognosi drug sensit ovarian cancer base integr machin learn',\n 'zhao b1 pei l2',\n 'author inform 1depart obstetr gynecolog gener hospit northern theater command shenyang 110016 china 2depart obstetr gynecolog gener hospit northern theater command shenyang 110016 china 64271174qqcom',\n 'background ovarian cancer rank lead caus gynecolog cancerrel death unit state fifth common caus cancerrel mortal among american women increas evid highlight vital role macrophag m2m1 proport tumor progress prognosi immunotherapi method weight gene coexpress network analysi wgcna perform identifi macrophag relat marker integr procedur includ 10 machin learn algorithm perform develop prognost macrophag relat signatur mr tcga gse14764 gse140082 dataset role mr tumor microenviron tme therapi respons evalu data cibersort mcpcounter quantiseq xcell cibersortab timer epic gse91061 imvigor210 dataset result optim mr develop combin coxboost stepcoxforward algorithm serv independ risk factor ovarian cancer compar stage grade establish prognost signatur current mr better perform predict overal surviv rate ovarian cancer patient low risk score indic higher tme score higher level immun cell higher immunophenoscor higher tumor mutat burden lower tide score lower ic50 valu ovarian cancer surviv predict nomogram good potenti clinic applic predict 1 3 5year overal surviv rate ovarian cancer patient conclus current studi construct power prognost mr ovarian cancer patient use 10 machin learn algorithm mr could predict prognosi drug sensit ovarian cancer',\n '2023 biom central ltd part springer natur',\n 'doi 101186s1292002301671z pmid 37784081',\n '124 bmc cancer 2023 oct 2231925 doi 101186s12885023113080',\n 'gbp2 prognost biomark associ immunotherapeut respons gastric cancer',\n 'wang y1 pan j2 f1 chen k1 chen j1 nie h1 zhu y3 qian z4 zhan q5',\n 'author inform 1depart gastroenterolog wuxi peopl hospit wuxi medic center affili wuxi peopl hospit nanj medic univers nanj medic univers wuxi jiangsu 214023 china 2depart gastroenterolog third peopl hospit kunshan suzhou 215300 china 3depart clinic laboratori changshu medicin examin institut changshu 215500 china 4depart clinic laboratori changshu medicin examin institut changshu 215500 china csbaizj93163com 5depart gastroenterolog wuxi peopl hospit wuxi medic center affili wuxi peopl hospit nanj medic univers nanj medic univers wuxi jiangsu 214023 china ryzhanqiang163com contribut equal',\n 'background interferoninduc protein known guanylatebind protein 2 gbp2 link multipl differ cancer type oncogen gene although role gbp2 cancer preliminarili explor unclear protein interact tumor immun gastric cancer method express prognost valu immunecorrel gbp2 gastric cancer explor multipl public inhous cohort addit pancanc analysi perform investig immunolog role gbp2 base cancer genom atla tcga dataset predict valu gbp2 immunotherapi also examin multipl public cohort result gbp2 highli express tumor tissu associ poor prognosi gastric cancer addit gbp2 associ immunehot phenotyp specif gbp2 posit relat immunomodul tumorinfiltr immun cell tiic immunotherapi biomark even well immunotherapeut respons addit gastric cancer gbp2 expect indic high immunogen cancer type importantli gbp2 could predict immunotherapeut respons least four differ cancer type includ melanoma urotheli carcinoma nonsmal cell lung cancer breast cancer conclus sum gbp2 express promis pancanc biomark estim immunolog characterist tumor may util detect immunohot tumor gastric cancer',\n '2023 biom central ltd part springer natur',\n 'doi 101186s12885023113080 pmid 37784054',\n '125 nat rev immunol 2023 oct 2 doi 101038s4157702300937i onlin ahead print',\n 'challeng develop person neoantigen cancer vaccin',\n 'katsiki pd1 ishii kj23 schlieh c4',\n 'author inform 1depart immunolog erasmu univers medic center rotterdam netherland pkatsikiserasmusmcnl 2divis vaccin scienc depart microbiolog immunolog institut medic scienc univers tokyo imsut tokyo japan 3intern vaccin design center vdesc institut medic scienc univers tokyo imsut tokyo japan 4depart immunolog erasmu univers medic center rotterdam netherland',\n 'recent success cancer immunotherapi highlight benefit har immun system cancer treatment vaccin long histori promot immun pathogen consequ vaccin target cancer neoantigen champion tool direct amplifi immun respons tumour spare healthi tissu recent year extens preclin research one hundr clinic trial test differ strategi neoantigen discoveri vaccin formul howev despit enthusiasm neoantigen vaccin proof unequivoc efficaci remain beyond reach major clinic trial review focu key obstacl pertain vaccin design tumour environ remain overcom order unleash true potenti neoantigen vaccin cancer therapi',\n '2023 springer natur limit',\n 'doi 101038s4157702300937i pmid 37783860',\n '126 nat cancer 2023 oct 2 doi 101038s43018023006428 onlin ahead print',\n 'cell receptor target recurr driver mutat flt3 mediat elimin primari human acut myeloid leukemia vivo',\n 'giannakopoul e12 lehand m3 vird culleton s3 yang w12 li y12 karpanen t124 yoshizato t3 rustad eh12 nielsen mm12 bollineni rc12 tran tt5 delicsarac m12 gjerdingen tj12 douvlatanioti k12 lao m12 ali m12 hillen a6 mazzi s3 chin dwl3 mehta a7 holm js8 bentzen ak8 bill m9 griffioen m10 geddedahl t11 lehmann s31213 jacobsen sew14151617 woll ps18 olweu j1920',\n 'author inform 1depart cancer immunolog oslo univers hospit radiumhospitalet oslo norway 2institut clinic medicin univers oslo oslo norway 3depart medicin hudding center hematolog regen medicin karolinska institutet stockholm sweden 4genom group faculti bioscienc aquacultur nord univers bod norway 5depart immunolog oslo univers hospit oslo norway 6depart cell molecular biolog karolinska institutet stockholm sweden 7depart immunolog univers oslo oslo univers hospit oslo norway 8section experiment translat immunolog depart health technolog technic univers denmark kongen lyngbi denmark 9depart hematolog aarhu univers hospit aarhu denmark 10depart hematolog leiden univers medic center leiden netherland 11hematolog depart section stem cell transplant oslo univers hospit rikshospitalet clinic cancer medicin oslo norway 12karolinska univers hospit stockholm sweden 13depart medic scienc uppsala univers uppsala sweden 14depart medicin hudding center hematolog regen medicin karolinska institutet stockholm sweden steneirikjacobsenkis 15depart cell molecular biolog karolinska institutet stockholm sweden steneirikjacobsenkis 16karolinska univers hospit stockholm sweden steneirikjacobsenkis 17mrc molecular haematolog unit mrc weatheral institut molecular medicin univers oxford oxford uk steneirikjacobsenkis 18depart medicin hudding center hematolog regen medicin karolinska institutet stockholm sweden petterwollkis 19depart cancer immunolog oslo univers hospit radiumhospitalet oslo norway johannaolweusmedisinuiono 20institut clinic medicin univers oslo oslo norway johannaolweusmedisinuiono contribut equal',\n 'acut myeloid leukemia aml frequent leukemia adult driven recurr somat acquir genet lesion restrict number gene treatment tyrosin kinas inhibitor demonstr target preval fmsrelat receptor tyrosin kinas 3 flt3 gainoffunct mutat provid signific surviv benefit patient although efficaci flt3 inhibitor elimin flt3mutat clone variabl identifi cell receptor tcr reactiv recurr d835i driver mutat flt3 tyrosin kinas domain tcrflt3di tcrflt3dyredirect cell select elimin primari human aml cell harbor flt3d835i mutat vitro vivo tcrflt3di cell reject cd34 cd34 aml mice engraft primari leukemia patient reach minim residu diseaseneg level elimin primari cd34 aml leukemiapropag cell vivo thu cell target singl share mutat provid effici immunotherapi toward select elimin clonal involv primari aml cell vivo',\n '2023 author',\n 'doi 101038s43018023006428 pmid 37783807',\n '127 sci rep 2023 oct 213116554 doi 101038s41598023437953',\n 'comprehens analysi cuproptosi copper homeostasi genotyp relat immun land scape lung adenocarcinoma',\n 'luo d1 wang x1 feng w2',\n 'author inform 1depart thorac surgeri second xiangya hospit central south univers changsha 410013 hunan china 2depart cardiothorac surgeri third xiangya hospit central south univers changsha 410013 hunan china fweimail163com',\n 'cuproptosi manner cell death relat homeostasi copper ion cellular environ expect open new direct antitumor therapi howev studi cuproptosi copper homeostasi lung adenocarcinoma luad still limit studi identifi new cuproptosi copper homeostasi relat gene chrg effect stratifi genotyp cluster surviv differ base transcriptom data obtain cancer genom atla tcga gene express omnibu geo weight gene coexpress network analysi wgcna expand screen boundari chrg final establish 10chrgsbase prognost signatur use lassopen cox regress method valid gse30219 comprehens bioinformat analysi reveal gene potenti regul modul immunotherapi efficaci drug resist tumor microenviron infiltr tumor mutat pattern lastli scrnaseq dataset gse183219 gse203360 offer evid chrg signatur mainli distribut cancer epitheli cell real time quantit polymeras chain reaction rtqpcr also confirm differenti express gene normal lung cell line lung adenocarcinoma cell line collect find reveal new cuproptosi copper homeostasi relat genotyp cluster gene may play import role predict prognosi influenc tumor microenviron drug efficaci luad patient',\n '2023 springer natur limit',\n 'doi 101038s41598023437953 pmid 37783723',\n '128 trend cancer 2023 sep 30s2405803323001917 doi 101016jtrecan202309007 onlin ahead print',\n 'enhanc dendrit cell inhibit bcl2',\n 'booth cag1 lane aa2',\n 'author inform 1depart medic oncolog danafarb cancer institut boston usa 2depart medic oncolog danafarb cancer institut boston usa electron address andrewlanedfciharvardedu',\n 'dendrit cell play import role anticanc immun expos cell tumorassoci antigen recent studi zhao et al show bcl2 inhibit improv abil dendrit cell present antigen cell activ antitumor cytotox',\n 'copyright 2023 elsevi inc right reserv',\n 'doi 101016jtrecan202309007 pmid 37783616',\n 'conflict interest statement declar interest aal receiv research support abbvi stemlin therapeut aal receiv consult fee cimeio therapeut idrx jnana therapeut proteinqur qiagen equiti advisor medzown interest declar cagb',\n '129 cancer lett 2023 sep 30216410 doi 101016jcanlet2023216410 onlin ahead print',\n 'gastric cancer deriv exosom thbs1 enhanc v9v2 tcell function activ rigilik receptor signal pathway n6methyladenosin methyl depend manner',\n 'li j1 feng h2 zhu j3 yang k2 zhang g4 gu y5 shi t6 chen w7',\n 'author inform 1jiangsu institut clinic immunolog first affili hospit soochow univers suzhou china jiangsu key laboratori clinic immunolog soochow univers suzhou china depart gastroenterolog first affili hospit soochow univers suzhou china 2depart gastroenterolog first affili hospit soochow univers suzhou china 3jiangsu institut clinic immunolog first affili hospit soochow univers suzhou china depart gastroenterolog first affili hospit soochow univers suzhou china 4jiangsu institut clinic immunolog first affili hospit soochow univers suzhou china jiangsu key laboratori clinic immunolog soochow univers suzhou china 5jiangsu key laboratori clinic immunolog soochow univers suzhou china electron address gyz1982yeahnet 6jiangsu institut clinic immunolog first affili hospit soochow univers suzhou china jiangsu key laboratori clinic immunolog soochow univers suzhou china electron address shitgsudaeducn 7jiangsu key laboratori clinic immunolog soochow univers suzhou china depart gastroenterolog first affili hospit soochow univers suzhou china electron address weichangchen126com',\n 'gamma delta tcellbas immunotherapi shown favor safeti clinic respons patient multipl type cancer howev effici treat patient solid tumor remain limit current studi investig function molecular mechan underli gastric cancer gc cellderiv exosom thbs1 regul v9v2 cell found gc cellderiv exosom thbs1 markedli enhanc cytotox v9v2 cell gc cell product ifn tnf perforin granzym b vitro elev kill effect v9v2 cell gc cell vivo mechanist exosom thbs1 could regul mettl3or igf2bp2medi m6a modif activ rigilik receptor signal pathway v9v2 cell moreov block rigilik receptor signal pathway revers effect exosom thbs1 function v9v2 cell addit thbs1 express low level gc tissu associ unfavor prognosi gc patient sum find indic exosom thbs1 deriv gc cell enhanc function v9v2 cell activ rigilik signal pathway m6a methylationdepend manner target exosom thbs1m6arigi axi may import implic gc immunotherapi base v9v2 cell',\n 'copyright 2023 publish elsevi bv',\n 'doi 101016jcanlet2023216410 pmid 37783390',\n 'conflict interest statement declar compet interest author declar known compet financi interest person relationship could appear influenc work report paper',\n '130 radioth oncol 2023 sep 30109934 doi 101016jradonc2023109934 onlin ahead print',\n 'risk ontreat lymphopenia associ treatment outcom efficaci consolid immunotherapi patient nonsmal cell lung cancer treat concurr chemoradiotherapi',\n 'yang g1 yoon h1 lee j1 kim j2 kim h1 cho j1 geol lee c1 suk chang j1 cho y2 kim j1 hwan kim k3',\n 'author inform 1depart radiat oncolog yonsei cancer center heavi ion therapi research institut yonsei univers colleg medicin 501 yonseiro seodaemungu seoul 03722 republ korea 2depart radiat oncolog gangnam sever hospit yonsei univers colleg medicin 211 eonjuro gangnamgu seoul 06273 republ korea 3depart radiat oncolog yonsei cancer center heavi ion therapi research institut yonsei univers colleg medicin 501 yonseiro seodaemungu seoul 03722 republ korea electron address kyunghkimyuhsac',\n 'background purpos abil effect dose immun cell edic preradiotherapi rt absolut lymphocyt count alc predict lymphopenia rt treatment outcom efficaci consolid immunotherapi patient local advanc nonsmal cell lung cancer investig method materi among 517 patient treat concurr chemoradiotherapi edic calcul use mean dose lung heart total bodi patient group accord high low edic prert alc correl radiationinduc lymphopenia surviv outcom determin result altogeth 195 patient 377 receiv consolid immunotherapi cutoff valu edic prert alc predict sever lymphopenia 289 gy 203109 cellsl respect highrisk group defin edic 289 gy prert alc 203109 cellsl lowrisk group edic 289 gy prert alc 203109 cellsl rest patient intermediaterisk group incid sever lymphopenia rt high intermedi lowrisk group 901 771 523 respect p 0001 risk group could independ predict progressionfre p 0001 overal surviv p 0001 highrisk group show higher incid locoregion distant recurr p 0001 consolid immunotherapi show signific surviv benefit low intermediaterisk group highrisk group conclus combin edic prert alc predict sever lymphopenia recurr surviv may potenti serv biomark consolid immunotherapi',\n 'copyright 2023 elsevi bv right reserv',\n 'doi 101016jradonc2023109934 pmid 37783291',\n '131 biom pharmacoth 2023 sep 30167115622 doi 101016jbiopha2023115622 onlin ahead print',\n 'microenvironment regul tumor progress interact cancerassoci fibroblast immun cell',\n 'gao d1 fang l2 liu c1 yang m1 yu x1 wang l3 zhang w3 sun c4 zhuang j5',\n 'author inform 1colleg tradit chines medicin weifang medic univers weifang 261000 china 2colleg tradit chines medicin shandong univers tradit chines medicin jinan 250355 china 3state key laboratori qualiti research chines medicin faculti chines medicin macau univers scienc technolog 999078 macao special administr region china 4colleg tradit chines medicin weifang medic univers weifang 261000 china depart oncolog weifang tradit chines hospit weifang 261000 china electron address scgdoctor126com 5depart oncolog weifang tradit chines hospit weifang 261000 china electron address 13963676719163com',\n 'tumor microenviron tme soil tumor cell grow import role regul prolifer metastasi tumor cell well respons treatment cancerassoci fibroblast caf abund stromal cell tme directli alter immunosuppress effect tme metabol also influenc aggreg function immun cell secret larg number cytokin chemokin reduc bodi immun surveil tumor cell make prone immun escap studi provid comprehens review fibroblast chemotaxi malign transform metabol characterist interact immun cell addit current small molecul drug target caf summar includ natur small molecul target drug current clinic therapeut applic complet review role fibroblast tme immun perspect present import implic improv effici immunotherapi target fibroblast',\n 'copyright 2023 author publish elsevi masson sa right reserv',\n 'doi 101016jbiopha2023115622 pmid 37783155',\n 'conflict interest statement declar compet interest author declar known compet financi interest person relationship could appear influenc work report paper',\n '132 biom pharmacoth 2023 sep 30167115597 doi 101016jbiopha2023115597 onlin ahead print',\n 'nanovaccin game chang approach fight infecti diseas',\n 'priyanka1 abusalah mah2 chopra h3 sharma a4 mustafa sa5 choudhari op6 sharma m7 dhawan m8 khosla r9 loshali a10 sundriy a11 saini j12',\n 'author inform 1depart veterinari microbiolog colleg veterinari scienc guru angad dev veterinari anim scienc univers gadvasu rampura phul bathinda 151103 punjab india 2depart medic laboratori scienc faculti alli medic scienc zarqa univers alzarqa 13132 jordan 3depart bioscienc saveetha school engin saveetha institut medic technic scienc chennai tamil nadu india 4depart life scienc gujarat univers univers school scienc gujarat univers ahmedabad 380009 gujarat india 5scientif research center salahaddin universityerbil erbil kurdistan region iraq 6depart veterinari anatomi colleg veterinari scienc guru angad dev veterinari anim scienc univers gadvasu rampura phul bathinda 151103 punjab india electron address dromchoudharygmailcom 7univers institut biotechnolog depart biotechnolog chandigarh univers mohali 140413 punjab india 8depart microbiolog punjab agricultur univers ludhiana 141004 punjab india trafford colleg altrincham manchest wa14 5pq uk electron address dhawanmanish501gmailcom 9depart biotechnolog doaba colleg jalandhar 144004 punjab india 10depart pharmacognosi phytochemistri school pharmaceut educ research jamia hamdard new delhi 110062 india 11school pharmaceut scienc research sardar bhagwan singh univers balawala dehradun 248001 india 12depart veterinari anatomi colleg veterinari scienc guru angad dev veterinari anim scienc univers gadvasu rampura phul bathinda 151103 punjab india',\n 'field nanotechnolog revolutionis global attempt prevent treat erad infecti diseas foreseen futur nanovaccin proven valuabl pawn novel technolog nanovaccin made nanoparticl associ prepar compon stimul host immun system addit deliveri capabl nanocarri demonstr possess intrins adjuv properti work immun cell stimul thu nanovaccin potenti promot rapid well longlast humor cellular immun nanovaccin sever possibl benefit includ sitespecif antigen deliveri increas antigen bioavail diminish advers effect profil avail benefit sever nanoparticlebas vaccin develop includ viruslik particl liposom polymer nanoparticl nanogel lipid nanoparticl emuls vaccin exom inorgan nanoparticl inspir distinct properti research work develop nanovaccin varieti applic cancer immunotherapi infecti diseas although challeng still need overcom modul nanoparticl pharmacokinet avoid rapid elimin bloodstream reticuloendotheli system futur prospect technolog also assur multipl option personalis vaccin needlefre formul combin nanovaccin sever promis candid',\n 'copyright 2023 author publish elsevi masson sa right reserv',\n 'doi 101016jbiopha2023115597 pmid 37783148',\n 'conflict interest statement declar compet interest author declar known compet financi interest person relationship could appear influenc work report paper',\n '133 cell reprogram 2023 sep 29 doi 101089cell20230041 onlin ahead print',\n 'induc pluripot stem cellderiv chimer antigen receptor cell intersect stem cell immunotherapi',\n 'lahimchi mr1 maroufi f2 maali a34',\n 'author inform 1depart immunolog semnan univers medic scienc semnan iran 2depart medic laboratori scienc faculti alli medicin qazvin univers medic scienc qazvin iran 3depart immunolog pasteur institut iran tehran iran 4depart medic biotechnolog faculti alli medicin qazvin univers medic scienc qazvin iran',\n 'chimer antigen receptor car cell therapi promis cellbas immunotherapi applic variou cancer high cost product immun reject heterogen cell product limit cell sourc limit expand rel long product time creat need achiev univers allogen cart cell product offtheshelf applic sinc innov induc pluripot stem cell ipsc yamanaka et al extens effort made prepar unlimit cell sourc regen medicin immunotherapi autolog graft approach ipsc prepar desir cell sourc gener autolog cart cell access avail sourc addit gener ipscderiv cart cell promis approach achiev suitabl sourc produc allogen cart cell product brief first step reprogram somat cell access peripher blood skin etc ipsc next step car express cell lineag differenti appli differ arrang addit allogen manner human leukocyt antig cell receptor tcr defici appli ipsc coloni allogen ipscderiv cart cell experi show simultan perform hlatcr defici car express cell lineag differenti could bring product highest efficaci gener allogen ipscderiv cart cell',\n 'doi 101089cell20230041 pmid 37782910',\n '134 proc natl acad sci u 2023 oct 1012041e2221985120 doi 101073pnas2221985120 epub 2023 oct 2',\n 'characterist anatom locat pd1tcf1 stemlik cd8 cell chronic viral infect cancer',\n 'im sj123 obeng rc1245 nasti th12 mcmanu d12 kamphorst ao67 gunisetti s12 prokhnevska n18 carlisl jw910 yu k4 sica gl41011 cardozo le12 gonalv ana12 kissick ht18 nakaya hi12 ramalingam ss910 ahm r12',\n 'author inform 1emori vaccin center emori univers school medicin atlanta ga 30322 2depart microbiolog immunolog emori univers school medicin atlanta ga 30322 3depart immunolog sungkyunkwan univers school medicin suwon 16419 republ korea 4depart patholog laboratori medicin emori univers school medicin atlanta ga 30322 5depart patholog case western reserv univers school medicin cleveland oh 44106 6depart immunolog immunotherapi lipschultz precis immunolog institut tisch cancer institut icahn school medicin mount sinai new york ny 10029 7depart oncolog scienc lipschultz precis immunolog institut tisch cancer institut icahn school medicin mount sinai new york ny 10029 8depart urolog emori univers school medicin atlanta ga 30322 9depart hematolog medic oncolog emori univers school medicin atlanta ga 30322 10winship cancer institut emori univers school medicin atlanta ga 30322 11depart patholog univers pittsburgh school medicin pittsburgh pa 15213 12hospit israelita albert eisnstein sao paulo 05652 brazil contribut equal',\n 'cd8 cell play essenti role antitumor immun chronic viral infect recent find delin differenti pathway cd8 cell accord progenitorprogeni relationship tcf1 stemlik tim3tcf1 differenti cell investig characterist stemlik differenti cd8 cell isol sever murin tumor model human lung cancer sampl term phenotyp transcript featur well locat compar virusspecif cd8 cell chronic lymphocyt choriomening viru lcmvinfect mice found cd8 tumorinfiltr lymphocyt til murin human tumor exhibit overal similar phenotyp transcript characterist compar correspond subset spleen chronic infect mice moreov stemlik cd8 til exclus respond produc effectorlik progeni cd8 cell vivo antigen restimul confirm lineag relationship prolif potenti stemlik cd8 til importantli similar preferenti local pd1 stemlik cd8 cell cell zone spleen chronic lcmv infect found pd1 stemlik cd8 til lung cancer sampl preferenti locat tumor parenchyma tertiari lymphoid structur tlss stemlik cd8 cell present tlss locat within peripheri tumor well tlss close adjac tumor parenchyma find suggest tlss provid protect nich support quiescenc mainten stemlik cd8 cell tumor',\n 'doi 101073pnas2221985120 pmid 37782797',\n '135 hepatol commun 2023 oct 2710e0288 doi 101097hc90000000000000288 ecollect 2023 oct 1',\n 'contemporari applic y90 treatment hepatocellular carcinoma',\n 'yu q1 khanjyan m2 fidelman n2 pillai a3',\n 'author inform 1depart radiolog univers chicago medic center univers chicago chicago illinoi usa 2depart radiolog biomed imag univers california san francisco california usa 3depart medicin divis gastroenterolog hepatolog nutrit univers chicago medic center univers chicago chicago illinoi usa',\n 'transarteri radioembol tare yttrium90 90i microspher wide adopt treatment hcc recent advanc yttrium90 90i dosimetri led durabl local respons radiat segmentectomi becom viabl altern thermal ablat earlystag hcc barcelona clinic liver cancer 0 commonli use bridg transplant tare also commonli use downstag transplant use tradit lobar dosimetri radiat segmentectomi techniqu radiat lobectomi dual role local tumor control induct contralater liver lobe hypertrophi bridg resect patient inadequ futur liver remnant tare continu provid diseas control patient limit vascular invas may altern system therapi patient local advanc diseas potenti synergi tare immunotherapi recogn prospect studi evalu combin need patient barcelona clinic liver cancer b c hcc',\n 'copyright 2023 author publish wolter kluwer health inc behalf american associ studi liver diseas',\n 'doi 101097hc90000000000000288 pmcid pmc10545406 pmid 37782464 index medlin',\n 'conflict interest statement nichola fidelman report grant boston scientif merck sirtex medic paid ucsf anjana pillai medic advisori board eisai inc exelixi genentech astrazeneca replimun remain author conflict report',\n '136 curr oncol rep 2023 oct 2 doi 101007s1191202301462w onlin ahead print',\n 'immunerel advers event patient lung cancer',\n 'sacchi de camargo correia g1 pai t1 li s1 connor d1 zhao y1 lou y1 manochakian r2',\n 'author inform 1divis hematolog medic oncolog mayo clinic 4500 san pablo rd jacksonvil fl 32224 usa 2divis hematolog medic oncolog mayo clinic 4500 san pablo rd jacksonvil fl 32224 usa manochakianramimayoedu',\n 'purpos review immun checkpoint inhibitor ici wide adopt treatment lung cancer sinc receiv first us food drug administr fda approv 2015 howev along use occurr immunerel advers event ira present challeng patient oncolog provid manuscript review clinic trial led approv ici fda treatment lung cancer 2015 2023 establish frequenc ira patient popul among advers event associ ici focus common relev one includ hypothyroid pneumon diarrheacol skin rash hepat recent find thoroughli examin avail literatur includ societi guidelin concern complic discuss variou aspect pathophysiolog epidemiolog diagnost process grade system clinic manag addit explor associ ira diseas respons manag ira crucial aspect oncolog care particularli due potenti caus sever lifethreaten clinic manifest present pertin aspect concis organ manner provid guidanc assist oncolog provid manag patient outpati inpati set',\n '2023 author exclus licenc springer sciencebusi media llc part springer natur',\n 'doi 101007s1191202301462w pmid 37782426',\n '137 embo mol med 2023 oct 2e17804 doi 1015252emmm202317804 onlin ahead print',\n 'intratumor coinject nk cell nkg2aneutr monoclon antibodi',\n 'melero i1234 ochoa mc123 molina c12 sanchezgregorio s12 garasa s12 lurirey c12 hervasstubb s12 casar n12 elizald e12 gomi g12 cirella a12 berraondo p123 teijeira a123 alvarez m12356',\n 'author inform 1program immunolog immunotherapi cima universidad de navarra pamplona spain 2navarra institut health research idisna pamplona spain 3centro de investigacin biomdica en red de cncer ciberonc madrid spain 4depart immunolog oncolog clnica universidad de navarra pamplona spain 5cell therapi stem cell tissu group biocruc bizkaia health research institut barakaldo spain 6research unit basqu center blood transfus human tissu osakidetza galdakao spain',\n 'nkcell reactiv cancer conceiv suppress tumor microenviron interact inhibitori receptor nkg2a nonclass mhci molecul hlae human qa1b mice found intratumor deliveri nk cell attain signific therapeut effect coinject antinkg2a antiqa1b block monoclon antibodi solid mous tumor model therapeut activ conting endogen cd8 cell type1 convent dendrit cell cdc1 moreov antitumor effect enhanc upon combin system antipd1 mab treatment achiev partial abscop efficaci distant noninject tumor xenograft mice bear hlaeexpress human cancer cell intratumor coinject activ allogen human nk cell clinicalgrad antinkg2a mab monalizumab synergist achiev therapeut effect conclus studi provid evid clinic potenti intratumor nk cellbas immunotherapi exert antitumor efficaci result elicit endogen tcell respons',\n '2023 author publish term cc 40 licens',\n 'doi 1015252emmm202317804 pmid 37782273',\n '138 ac nano 2023 oct 2 doi 101021acsnano3c01912 onlin ahead print',\n 'redirect antigen engin photosynthet bacteria deriv outer membran vesicl enhanc cancer immunotherapi',\n 'han d123 wang f23 y1 zhao y4 zhang w5 zhang z4 liu h4 yang x1 zhang c5 zhang j1 li z23',\n 'author inform 1colleg chemistri materi scienc key laboratori medicin chemistri molecular diagnosi ministri educ state key laboratori new pharmaceut prepar excipi chemic biolog key laboratori hebei provinc hebei univers baod 071002 china 2the tenth affili hospit southern medic univers dongguan guangdong 523059 china 3guangdong provinci key laboratori cardiac function microcircul guangdong 510515 china 4colleg pharmaceut scienc key laboratori pharmaceut qualiti control hebei provinc hebei univers baod 071002 china 5depart orthoped shanghai jiao tong univers affili sixth peopl hospit 600 yishan road shanghai 200233 china',\n 'signific stride made develop cancer vaccin combat malign tumor howev natur immunosuppress environ within tumor known tumor microenviron tme hamper uptak present antigen antigenpres cell apc within tumor limit result inadequ activ immun respons cancer contrast immun cell peritumor tissu maintain normal function context present interest approach enhanc cancer immunotherapi util engin photosynthet bacteria psb outer membran vesicl omvpsb captur transport antigen outer region tumor modifi psb maleimid psbmal expos nearinfrar nir lasermedi phototherm therapi ptt induc extens cancer cell death releas tumor antigen subsequ nirphototact psbmal transport tumor antigen peripher region tumor nir laser exposur even intriguingli psbmalderiv omvpsbmal effect captur deliv antigen tumordrain lymph node tdln facilit enhanc antigen present matur fulli function apc tdln intric commun network psbmal omvpsbmal apc promot effici present tumor antigen tumor peripheri tdln consequ notabl increas infiltr cytotox lymphocyt ctl tumor trigger potent antitumor immun respons melanoma breast cancer model cascad event result enhanc suppress tumor metastasi recurr underscor robust efficaci approach interest studi har potenti bacteria omv redirect tumor antigen enhanc cancer immunotherapi provid promis path toward develop person cancer vaccin strategi',\n 'doi 101021acsnano3c01912 pmid 37782086',\n '139 ideggyogi sz 2023 sep 3076910339347 doi 1018071isz760339',\n 'prognost valu indoleamin 2 3dioxygenase1 express glial tumor',\n 'articl english',\n 'kaya m1 aksoy a2 arta g3 kaplan m4',\n 'author inform 1depart intern medicin medic faculti firat univers turkey 2depart medic oncolog healthi scienc univers elazig fethi sekin citi hospit suam turkey 3depart patholog medic faculti firat univers turkey 4depart neurosurgeri medic faculti firat univers turkey',\n 'background purpos pglioma common primari malign central nervou system tumor adult exhibit poor prognosi indoleamin 2 3dioxygenase1 ido1 import function cancer immunotherapi due role escap cancer cell immun system studi purpos evalu correl ido1 express clinicopatholog paramet glioma whether ido1 prognost markerp method pn75 patient total n25 patient low grade glial tumor lgg grade 12 n25 patient high grade glial tumor hgg grade 34 n25 person normal brain tissu control group includ studi ido1 express categor use immunohistochem stain biopsi specimen high h low l group among patient glioma use 95 percent confid interv p lt005 analyz associ degre ido1 express clinicopatholog characterist surviv rate glioma patientsnbspp result pin hgg ido1 level higher control brain tissu lgg plt 0001 mean overal surviv os longer lido1 group 6453 plusmn 334 month 95 ci 5796971098 compar hido1 group 4374 plusmn 436 month 95 ci 3521852330 plt 005p conclus pido1 express inshydeshypend prognost biomark predictnbspbro progress hgg ido1 benbspevalu altern instrument precis medicin treatment gliomasp',\n 'publish background purpos pa gliomaacutek leggyakoribb rossz prognoacuteziss rendelkez primer rosszindulatuacut koumlzponti idegrendszeri daganatok felnttekneacutel az indolamin 2 3dioxigenaacutez1 ido1 fonto funkcioacutev rendelkezik raacutek immunteraacutepiaacutejaacuteban mivel raacuteko sejtek immunrendsz ell valoacut elmenekuumlleacuteseacuteben jaacutetszik szerepet ebben tanulmaacutenyban az volt ceacutelunk hogi felmeacuterjuumlk az ido1expresszioacut eacut klinikopatoloacutegiai parameacuteterek koumlzoumltti oumlsszefuumlggeacutest gliomaacutekban eacut hogi az ido1 hasznaacutelhatoacute prognosztikai markerkeacutentp method poumlsszesen n 75 beteg n 25 beteg alacsoni fokuacut gliadaganatt lgg 1ndash2 fokozat n 25 beteg maga fokuacut gliadaganatt hgg 3ndash4 fokozat eacut n 25 szemeacut normaacutel agyszoumlvet kontrollcsoportkeacut keruumllt vizsgaacutelatba biopsziaacut mintaacutek immunhisztokeacutemiai festeacutes reacuteveacuten az ido1 expresszioacuteja alapjaacuten gliomaacut betegeket maga h eacut alacsoni l csoportba soroltuk 95o konfidenciaintervallumot eacut p lt 005 eacuterteacuteket hasznaacuteltunk az ido1expresszioacut meacuterteacutek klinikopatoloacutegiai jellemzk eacut gliomaacut betegek tuacuteleacuteleacutesi araacutenya koumlzoumltti oumlsszefuumlggeacut elemzeacuteseacuterenbspp result phggben az ido1 szintj magasabb volt mint kontrol agyszoumlvetben eacut lggben p lt 0001 telj tuacuteleacuteleacut os koumlzeacutepeacuterteacutek hosszabb volt az lido1 csoportban 6453 plusmn 334 hoacutenap 95o ci 57969ndash71098 mint hido1 csoportban 4374 plusmn 436 hoacutenap 95o ci 35218ndash52330 p lt 005p conclus paz ido1expresszioacut fuumlggetlen prognosztikai biomark ami hgg eseteacuten elr jelzi az ost eacut progresszioacutet az ido1 preczioacut orvoslaacut alternatv eszkoumlz lehet gliomaacutek kezeleacutes soraacutenp',\n 'doi 1018071isz760339 pmid 37782060 index medlin',\n '140 expert rev anticanc ther 2023 oct 2 doi 1010801473714020232265570 onlin ahead print',\n '2023 asco genitourinari cancer symposium focu urotheli carcinoma',\n 'cigliola a1 beccia v1 anghelon a1 panebianco m1 ciccares c2 iacovelli r2',\n 'author inform 1medic oncolog unit universit cattolica del sacro cuor rome itali 2medic oncolog unit fondazion policlinico gemelli ircc rome itali',\n 'articl describ main acquisit urotheli carcinoma uc manag report 2023 american societi clinic oncolog genitourinari cancer symposium major develop year character confirm diseasefre surviv advantag adjuv nivolumab highrisk muscleinvas urotheli carcinoma radic resect longer followup metastat set updat analysi imvigor130 studi confirm failur strategi ad immunotherapi ie atezolizumab fistlin chemotherapi analog atezolizumab monotherapi improv overal surviv compar chemotherapi untreat metastat urotheli carcinoma muc furthermor interest data present concern futur treatment option particular immunotherapi io pembrolizumab show promis activ patient highrisk non muscleinvas bladder cancer unrespons bacillu calmett gurin keynote057 antibodydrug conjug sacituzumab govitecan demonstr relev activ platinum ptinelig muc patient progress prior io certainli lack predict biomark respons specif therapi highlight urgent need comprehens character uc person therapeut approach improv patient outcom',\n 'doi 1010801473714020232265570 pmid 37781991',\n '141 angew chem int ed engl 2023 oct 2e202309744 doi 101002anie202309744 onlin ahead print',\n 'stereoselect synthesi sialyl lewisa antigen effect anticanc activ bacteriophag q conjug anticanc vaccin',\n 'rashidijahanabad z1 ramadan s1 obrien n2 nakisa a1 lang s1 crawford h3 gildersleev j2 huang x4',\n 'author inform 1michigan state univers chemistri unit state 2nation cancer institut frederick chemic biolog laboratori unit state 3henri ford health system surgeri unit state 4michigan state univers chemistri 578 shaw lane michigan state univers 48824 east lans unit state',\n 'sialyl lewisa slea also known cancer antigen 199 ca199 tumor associ carbohydr antigen overexpress slea surfac varieti cancer cell make attract target anticanc immunotherapi howev slea base anticanc vaccin underexplor develop new vaccin effici stereoselect synthesi slea amin bear linker achiev subsequ conjug power carrier bacteriophag q mous immun qslea conjug gener strong longlast antislea igg antibodi respons superior induc correspond conjug slea benchmark carrier keyhol limpet hemocyanin antibodi elicit qslea highli select toward slea structur could bind strongli slea express cancer cell human pancreat cancer tissu kill tumor cell via complement mediat cytotox furthermor vaccin qslea significantli reduc tumor develop metastat cancer model mice demonstr tumor protect first time slea base vaccin highlight signific potenti slea promis cancer antigen',\n '2023 wileyvch gmbh',\n 'doi 101002anie202309744 pmid 37781858',\n '142 cancer biomark 2023382143159 doi 103233cbm230028',\n 'chrdl1 nefh tagln synm novel diagnost biomark benign prostat hyperplasia prostat cancer',\n 'su z1 wang g2 li l3',\n 'author inform 1depart urolog affili hospit guizhou medic univers guiyang guizhou china 2depart breast surgeri guizhou provinci peopl hospit guiyang guizhou china 3depart patholog kunm medic univers kunm yunnan china',\n 'background prostat cancer pca benign prostat hyperplasia bph common male diseas whose incid rate gradual increas age serious affect men physic health qualiti life studi aim identifi new biomark diagnosi bph pca method two dataset gse28204 gse134051 includ human pca bph download geo databas batch effect remov merg differenti gene express analysi conduct identifi bph pca case diagnost biomark bph pca screen use machin learn bioinformat roc curv drawn evalu diagnost accuraci select biomark onlin websit qpcr use preliminarili explor express level pca biomark correl express biomark tumor microenviron tumor mutat load immunotherapi drug evalu result identifi fifteen gene chrdl1 de flnc gstp1 myl9 tgfb3 nefh tagln sparcl1 synm trpm8 hpn pla2g7 entpd5 gpr160 critic diagnost biomark review literatur select biomark found studi four gene chrdl1 nefh tagln synm bph pca defin four gene new potenti diagnost biomark npdb bph pca npdb downregul pca patient pca cell line upregul bph patient cell line immun landscap mutat frequenc analyz result show tumor microenviron tme immun landscap tumor mutat burden drug respons significantli correl npdb express conclus found four new diagnost marker bph pca may facilit earli diagnosi treatment immunotherapeut respons assess may major valu guid clinic practic',\n 'doi 103233cbm230028 pmid 37781794',\n '143 front pharmacol 2023 sep 15141240736 doi 103389fphar20231240736 ecollect 2023',\n 'comprehens analysi cuproplasia immun microenviron lung adenocarcinoma',\n 'kuang j1 zheng z2 w3 zeng s4 wu d5 weng x6 chen y1',\n 'author inform 1dongguan institut clinic cancer research dongguan key laboratori precis diagnosi treatment tumor affili dongguan hospit southern medic univers dongguan guangdong china 2depart respiratori critic care medicin nanfang hospit southern medic univers guangzhou guangdong china 3depart medic oncolog affili cancer hospit institut guangzhou medic univers guangzhou guangdong china 4shenzhen hospit futian guangzhou univers chines medicin shenzhen guangdong china 5depart radiat oncolog nanfang hospit southern medic univers guangzhou guangdong china 6cancer center integr hospit tradit chines medicin southern medicin univers guangzhou guangdong china',\n 'background trace element copper essenti human health recent journal nat rev cancer put forward concept cuproplasia way promot tumor growth relianc copper attempt conduct comprehens analysi cuproplasiarel gene lung adenocarcinoma luad explor mechan action cuproplasiarel gene luad method transcriptom data clinic inform luad obtain tcgaluad gse31210 prognost model cuproplasiarel gene construct verifi regress analysi gsva wgcna univari cox lasso signal pathway affect cuproplasiarel gene analyz go kegg hallmark pathway enrich method five immunocel infiltr algorithm imvigor210 data use analyz immun cell content immunotherapi outcom highlow risk group result result wgcna brown turquois identifi modul close relat cuproplasia score end lasso regress analysi establish cuproplasiarel signatur cr base 24 gene prognosi highrisk popul wors tcgaluad gse31210 dataset enrich analysi show copper prolifer mainli chromosom cell cycl dna replic g2m checkpoint pathway immunoinfiltr analysi show differ content macrophag among four algorithm imvigor210 found lower score effect immunotherapi conclus cuproplasia relat gene use predict prognosi immunotherapi outcom luad patient may exert effect affect chromosomerel pathway macrophag',\n 'copyright 2023 kuang zheng zeng wu weng chen',\n 'doi 103389fphar20231240736 pmcid pmc10540310 pmid 37781711',\n 'conflict interest statement author declar research conduct absenc commerci financi relationship could constru potenti conflict interest',\n '144 biorxiv 2023 sep 2220230919558262 doi 10110120230919558262 preprint',\n ...]"
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "abstracts_no_meta = remove_metadata(abstracts)\n",
    "cleaned_abstracts = [preprocess_text(abstract) for abstract in abstracts_no_meta]\n",
    "cleaned_abstracts"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-10-03T11:38:42.619311020Z",
     "start_time": "2023-10-03T11:37:54.420331221Z"
    }
   }
  },
  {
   "cell_type": "markdown",
   "source": [
    "## Advanced NLP analysis\n",
    "1.General Keyword Extraction\n",
    "2.Topic Modeling and Keyword Extraction\n",
    "\n",
    "### General Keyword Extraction"
   ],
   "metadata": {
    "collapsed": false
   }
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "outputs": [],
   "source": [
    "# import necessary lib\n",
    "from sklearn.feature_extraction.text import TfidfVectorizer\n"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-10-03T11:38:42.620123090Z",
     "start_time": "2023-10-03T11:38:42.604473609Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "outputs": [],
   "source": [
    "# General Keyword Extraction\n",
    "\n",
    "# for getting keywords only introduction of each research will be checked\n",
    "intro_abstracts = select_introduction(abstracts)\n",
    "cleaned_intro_abstracts = [preprocess_text(abstract) for abstract in intro_abstracts]\n",
    "\n",
    "\n",
    "# convert the clean abstracts \"Introduction into TF-IDF feature vectors\"\n",
    "# Initialize TF-IDF vectorizer\n",
    "tfidf_vectorizer = TfidfVectorizer(max_features=20, min_df=2, stop_words='english')\n",
    "# Create TF-IDF matrix\n",
    "tfidf_matrix = tfidf_vectorizer.fit_transform(cleaned_intro_abstracts)\n",
    "# Get feature names (terms)\n",
    "feature_names = tfidf_vectorizer.get_feature_names_out()\n",
    "tfidf_scores = tfidf_matrix.toarray()\n",
    "top_keywords_per_abstract = []\n",
    "\n",
    "\n",
    "for i, abstract in enumerate(cleaned_intro_abstracts):\n",
    "    tfidf_scores_for_abstract = tfidf_scores[i]\n",
    "    top_keywords_indices = tfidf_scores_for_abstract.argsort()[-5:][::-1]  # Get the top 5 keywords\n",
    "    top_keywords = [feature_names[idx] for idx in top_keywords_indices]\n",
    "    top_keywords_per_abstract.append(top_keywords)"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-10-03T11:50:47.528062289Z",
     "start_time": "2023-10-03T11:50:46.248837472Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Abstract 1 Keywords: tumor, cell, therapi, express, immunotherapi\n",
      "Abstract 2 Keywords: therapi, cancer, treatment, patient, result\n",
      "Abstract 3 Keywords: surviv, analysi, tumor, cell, express\n",
      "Abstract 4 Keywords: patient, cancer, associ, respons, therapi\n",
      "Abstract 5 Keywords: studi, patient, treatment, use, therapi\n",
      "Abstract 6 Keywords: respons, tumor, clinic, immun, therapi\n",
      "Abstract 7 Keywords: cancer, treatment, patient, tumor, therapi\n",
      "Abstract 8 Keywords: cell, tumor, express, treatment, clinic\n",
      "Abstract 9 Keywords: clinic, treatment, therapi, immunotherapi, patient\n",
      "Abstract 10 Keywords: cell, express, use, studi, treatment\n",
      "Abstract 11 Keywords: therapi, respons, studi, treatment, immunotherapi\n",
      "Abstract 12 Keywords: treatment, studi, patient, cancer, analysi\n",
      "Abstract 13 Keywords: respons, studi, analysi, therapi, clinic\n",
      "Abstract 14 Keywords: cell, therapi, immun, treatment, tumor\n",
      "Abstract 15 Keywords: tumor, analysi, cell, cancer, use\n",
      "Abstract 16 Keywords: patient, associ, analysi, studi, use\n",
      "Abstract 17 Keywords: immun, cancer, tumor, patient, use\n",
      "Abstract 18 Keywords: therapi, cancer, patient, treatment, immun\n",
      "Abstract 19 Keywords: immun, result, patient, analysi, studi\n",
      "Abstract 20 Keywords: cancer, immunotherapi, patient, analysi, therapi\n",
      "Abstract 21 Keywords: patient, use, method, result, surviv\n",
      "Abstract 22 Keywords: tumor, cancer, therapi, immunotherapi, clinic\n",
      "Abstract 23 Keywords: immunotherapi, cancer, therapi, studi, immun\n",
      "Abstract 24 Keywords: cell, treatment, express, studi, patient\n",
      "Abstract 25 Keywords: cell, express, result, use, immunotherapi\n",
      "Abstract 26 Keywords: patient, treatment, therapi, clinic, use\n",
      "Abstract 27 Keywords: patient, treatment, surviv, respons, therapi\n",
      "Abstract 28 Keywords: tumor, cell, immun, respons, clinic\n",
      "Abstract 29 Keywords: patient, cancer, associ, studi, use\n",
      "Abstract 30 Keywords: cancer, tumor, clinic, cell, use\n",
      "Abstract 31 Keywords: cell, tumor, patient, studi, use\n",
      "Abstract 32 Keywords: express, tumor, clinic, immun, cell\n",
      "Abstract 33 Keywords: treatment, studi, surviv, patient, result\n",
      "Abstract 34 Keywords: cancer, patient, use, immunotherapi, method\n",
      "Abstract 35 Keywords: clinic, respons, patient, cancer, associ\n",
      "Abstract 36 Keywords: respons, immun, cell, tumor, method\n",
      "Abstract 37 Keywords: cancer, respons, tumor, clinic, immun\n",
      "Abstract 38 Keywords: cell, immun, patient, tumor, analysi\n",
      "Abstract 39 Keywords: tumor, use, express, analysi, respons\n",
      "Abstract 40 Keywords: respons, tumor, patient, treatment, therapi\n",
      "Abstract 41 Keywords: cancer, therapi, tumor, immun, studi\n",
      "Abstract 42 Keywords: cell, respons, express, tumor, result\n",
      "Abstract 43 Keywords: cell, cancer, immunotherapi, studi, use\n",
      "Abstract 44 Keywords: immunotherapi, patient, cancer, clinic, respons\n",
      "Abstract 45 Keywords: therapi, treatment, immunotherapi, patient, surviv\n",
      "Abstract 46 Keywords: cell, patient, therapi, studi, surviv\n",
      "Abstract 47 Keywords: use, tumor, cell, studi, treatment\n",
      "Abstract 48 Keywords: immun, express, tumor, use, analysi\n",
      "Abstract 49 Keywords: patient, tumor, analysi, cancer, therapi\n",
      "Abstract 50 Keywords: patient, tumor, cell, studi, immun\n",
      "Abstract 51 Keywords: immunotherapi, patient, tumor, express, associ\n",
      "Abstract 52 Keywords: patient, treatment, express, tumor, respons\n",
      "Abstract 53 Keywords: patient, immunotherapi, use, treatment, studi\n",
      "Abstract 54 Keywords: patient, tumor, surviv, immun, studi\n",
      "Abstract 55 Keywords: cell, respons, patient, associ, immun\n",
      "Abstract 56 Keywords: treatment, patient, studi, use, surviv\n",
      "Abstract 57 Keywords: patient, therapi, cancer, immunotherapi, respons\n",
      "Abstract 58 Keywords: cell, tumor, immun, result, therapi\n",
      "Abstract 59 Keywords: cell, immun, tumor, cancer, use\n",
      "Abstract 60 Keywords: patient, treatment, cancer, analysi, associ\n",
      "Abstract 61 Keywords: cell, tumor, clinic, studi, conclus\n",
      "Abstract 62 Keywords: tumor, cell, patient, immunotherapi, analysi\n",
      "Abstract 63 Keywords: patient, treatment, surviv, analysi, respons\n",
      "Abstract 64 Keywords: express, patient, surviv, tumor, immun\n",
      "Abstract 65 Keywords: cell, tumor, treatment, respons, immun\n",
      "Abstract 66 Keywords: patient, tumor, cancer, respons, therapi\n",
      "Abstract 67 Keywords: patient, therapi, surviv, treatment, result\n",
      "Abstract 68 Keywords: respons, patient, treatment, clinic, use\n",
      "Abstract 69 Keywords: express, patient, associ, use, result\n",
      "Abstract 70 Keywords: patient, therapi, immun, associ, respons\n",
      "Abstract 71 Keywords: tumor, cell, respons, immun, treatment\n",
      "Abstract 72 Keywords: treatment, tumor, respons, patient, analysi\n",
      "Abstract 73 Keywords: therapi, patient, surviv, clinic, immunotherapi\n",
      "Abstract 74 Keywords: analysi, cell, immun, respons, tumor\n",
      "Abstract 75 Keywords: patient, associ, surviv, use, therapi\n",
      "Abstract 76 Keywords: immunotherapi, respons, immun, method, patient\n",
      "Abstract 77 Keywords: cancer, immun, treatment, immunotherapi, analysi\n",
      "Abstract 78 Keywords: surviv, cancer, studi, patient, cell\n",
      "Abstract 79 Keywords: cell, therapi, studi, immunotherapi, result\n",
      "Abstract 80 Keywords: patient, express, surviv, tumor, use\n",
      "Abstract 81 Keywords: immunotherapi, therapi, express, respons, clinic\n",
      "Abstract 82 Keywords: analysi, cancer, tumor, surviv, immun\n",
      "Abstract 83 Keywords: result, treatment, patient, surviv, cell\n",
      "Abstract 84 Keywords: therapi, immunotherapi, associ, clinic, introduct\n",
      "Abstract 85 Keywords: patient, treatment, cancer, tumor, conclus\n",
      "Abstract 86 Keywords: immun, express, cell, surviv, analysi\n",
      "Abstract 87 Keywords: clinic, patient, surviv, introduct, associ\n",
      "Abstract 88 Keywords: patient, tumor, clinic, cancer, method\n",
      "Abstract 89 Keywords: cell, use, tumor, therapi, treatment\n",
      "Abstract 90 Keywords: associ, patient, respons, surviv, cell\n",
      "Abstract 91 Keywords: cancer, surviv, treatment, result, tumor\n",
      "Abstract 92 Keywords: cell, immun, express, therapi, use\n",
      "Abstract 93 Keywords: associ, cancer, express, therapi, use\n",
      "Abstract 94 Keywords: studi, clinic, result, treatment, therapi\n",
      "Abstract 95 Keywords: surviv, studi, use, treatment, patient\n",
      "Abstract 96 Keywords: clinic, immunotherapi, immun, express, surviv\n",
      "Abstract 97 Keywords: cancer, clinic, immun, cell, respons\n",
      "Abstract 98 Keywords: patient, express, respons, clinic, cell\n",
      "Abstract 99 Keywords: treatment, patient, result, immun, cell\n",
      "Abstract 100 Keywords: therapi, respons, immun, immunotherapi, patient\n",
      "Abstract 101 Keywords: associ, treatment, result, therapi, clinic\n",
      "Abstract 102 Keywords: clinic, studi, result, immun, use\n",
      "Abstract 103 Keywords: clinic, express, patient, use, cancer\n",
      "Abstract 104 Keywords: respons, surviv, immun, treatment, analysi\n",
      "Abstract 105 Keywords: immunotherapi, respons, method, tumor, clinic\n",
      "Abstract 106 Keywords: studi, use, cancer, patient, result\n",
      "Abstract 107 Keywords: therapi, immunotherapi, patient, associ, surviv\n",
      "Abstract 108 Keywords: patient, use, conclus, cancer, result\n",
      "Abstract 109 Keywords: patient, surviv, studi, associ, cancer\n",
      "Abstract 110 Keywords: therapi, patient, treatment, immunotherapi, introduct\n",
      "Abstract 111 Keywords: therapi, respons, surviv, tumor, cell\n",
      "Abstract 112 Keywords: patient, surviv, result, clinic, studi\n",
      "Abstract 113 Keywords: method, tumor, analysi, cell, use\n",
      "Abstract 114 Keywords: cell, immun, tumor, studi, method\n",
      "Abstract 115 Keywords: cell, tumor, immun, analysi, respons\n",
      "Abstract 116 Keywords: cell, express, associ, surviv, immunotherapi\n",
      "Abstract 117 Keywords: cancer, treatment, patient, therapi, surviv\n",
      "Abstract 118 Keywords: respons, studi, use, conclus, cancer\n",
      "Abstract 119 Keywords: associ, patient, respons, surviv, clinic\n",
      "Abstract 120 Keywords: cancer, immunotherapi, therapi, use, associ\n",
      "Abstract 121 Keywords: patient, treatment, therapi, clinic, immun\n",
      "Abstract 122 Keywords: cancer, analysi, therapi, studi, treatment\n",
      "Abstract 123 Keywords: immun, use, tumor, express, analysi\n",
      "Abstract 124 Keywords: surviv, express, associ, tumor, immun\n",
      "Abstract 125 Keywords: cell, cancer, respons, patient, result\n",
      "Abstract 126 Keywords: cell, express, associ, cancer, respons\n",
      "Abstract 127 Keywords: respons, immun, studi, use, result\n",
      "Abstract 128 Keywords: patient, studi, clinic, immun, express\n",
      "Abstract 129 Keywords: patient, therapi, analysi, surviv, treatment\n",
      "Abstract 130 Keywords: tumor, cell, cancer, immun, use\n",
      "Abstract 131 Keywords: use, associ, clinic, immun, cell\n",
      "Abstract 132 Keywords: associ, studi, cancer, method, result\n",
      "Abstract 133 Keywords: tumor, associ, surviv, immun, cell\n",
      "Abstract 134 Keywords: surviv, treatment, associ, therapi, cell\n",
      "Abstract 135 Keywords: patient, respons, use, immunotherapi, method\n",
      "Abstract 136 Keywords: clinic, use, method, patient, tumor\n",
      "Abstract 137 Keywords: therapi, treatment, patient, clinic, use\n",
      "Abstract 138 Keywords: patient, treatment, studi, associ, clinic\n",
      "Abstract 139 Keywords: immun, cell, use, analysi, tumor\n",
      "Abstract 140 Keywords: express, immun, cancer, tumor, studi\n",
      "Abstract 141 Keywords: express, immun, analysi, cancer, immunotherapi\n",
      "Abstract 142 Keywords: patient, clinic, surviv, studi, immunotherapi\n",
      "Abstract 143 Keywords: tumor, immun, cell, cancer, surviv\n",
      "Abstract 144 Keywords: respons, associ, patient, treatment, immunotherapi\n",
      "Abstract 145 Keywords: cell, cancer, patient, use, analysi\n",
      "Abstract 146 Keywords: analysi, surviv, patient, cell, use\n",
      "Abstract 147 Keywords: tumor, cell, immun, associ, surviv\n",
      "Abstract 148 Keywords: patient, studi, cell, treatment, immunotherapi\n",
      "Abstract 149 Keywords: tumor, therapi, immun, treatment, cell\n",
      "Abstract 150 Keywords: cell, cancer, tumor, therapi, clinic\n",
      "Abstract 151 Keywords: cell, method, use, tumor, therapi\n",
      "Abstract 152 Keywords: patient, therapi, studi, immunotherapi, result\n",
      "Abstract 153 Keywords: patient, tumor, respons, surviv, cancer\n",
      "Abstract 154 Keywords: patient, tumor, associ, therapi, conclus\n",
      "Abstract 155 Keywords: clinic, studi, cancer, therapi, immunotherapi\n",
      "Abstract 156 Keywords: express, tumor, immun, use, patient\n",
      "Abstract 157 Keywords: cell, tumor, respons, immun, treatment\n",
      "Abstract 158 Keywords: therapi, patient, treatment, surviv, studi\n",
      "Abstract 159 Keywords: patient, use, treatment, cancer, result\n",
      "Abstract 160 Keywords: patient, result, surviv, tumor, cell\n",
      "Abstract 161 Keywords: therapi, patient, cell, clinic, treatment\n",
      "Abstract 162 Keywords: express, tumor, cell, patient, surviv\n",
      "Abstract 163 Keywords: cell, tumor, respons, therapi, patient\n",
      "Abstract 164 Keywords: treatment, associ, result, cell, patient\n",
      "Abstract 165 Keywords: studi, associ, patient, cancer, immunotherapi\n",
      "Abstract 166 Keywords: patient, associ, tumor, conclus, immunotherapi\n",
      "Abstract 167 Keywords: respons, immunotherapi, associ, use, patient\n",
      "Abstract 168 Keywords: patient, treatment, use, surviv, studi\n",
      "Abstract 169 Keywords: associ, patient, express, analysi, surviv\n",
      "Abstract 170 Keywords: patient, use, treatment, therapi, associ\n",
      "Abstract 171 Keywords: result, use, analysi, studi, conclus\n",
      "Abstract 172 Keywords: cell, patient, tumor, immun, use\n",
      "Abstract 173 Keywords: associ, studi, conclus, cancer, method\n",
      "Abstract 174 Keywords: tumor, cell, immun, treatment, studi\n",
      "Abstract 175 Keywords: cell, cancer, respons, tumor, patient\n",
      "Abstract 176 Keywords: immunotherapi, cell, patient, surviv, express\n",
      "Abstract 177 Keywords: studi, patient, use, immunotherapi, surviv\n",
      "Abstract 178 Keywords: tumor, immun, result, therapi, cell\n",
      "Abstract 179 Keywords: therapi, immun, treatment, clinic, tumor\n",
      "Abstract 180 Keywords: patient, immun, analysi, associ, tumor\n",
      "Abstract 181 Keywords: therapi, tumor, patient, respons, associ\n",
      "Abstract 182 Keywords: patient, therapi, surviv, treatment, immunotherapi\n",
      "Abstract 183 Keywords: cell, immun, cancer, analysi, respons\n",
      "Abstract 184 Keywords: surviv, patient, therapi, result, analysi\n",
      "Abstract 185 Keywords: express, patient, clinic, cell, result\n",
      "Abstract 186 Keywords: cancer, use, therapi, clinic, cell\n",
      "Abstract 187 Keywords: cell, express, tumor, analysi, associ\n",
      "Abstract 188 Keywords: patient, immunotherapi, cancer, surviv, cell\n",
      "Abstract 189 Keywords: patient, therapi, surviv, clinic, result\n",
      "Abstract 190 Keywords: patient, therapi, surviv, treatment, associ\n",
      "Abstract 191 Keywords: cell, immun, immunotherapi, respons, patient\n",
      "Abstract 192 Keywords: cell, immun, use, patient, express\n",
      "Abstract 193 Keywords: treatment, respons, tumor, therapi, analysi\n",
      "Abstract 194 Keywords: therapi, patient, associ, treatment, use\n",
      "Abstract 195 Keywords: cell, patient, clinic, studi, use\n",
      "Abstract 196 Keywords: studi, patient, cancer, respons, immunotherapi\n",
      "Abstract 197 Keywords: patient, associ, surviv, immunotherapi, analysi\n",
      "Abstract 198 Keywords: cell, tumor, immun, respons, therapi\n",
      "Abstract 199 Keywords: patient, treatment, immunotherapi, cancer, clinic\n",
      "Abstract 200 Keywords: respons, cell, associ, surviv, express\n",
      "Abstract 201 Keywords: use, result, associ, therapi, clinic\n",
      "Abstract 202 Keywords: patient, studi, conclus, treatment, cancer\n",
      "Abstract 203 Keywords: clinic, treatment, tumor, studi, use\n",
      "Abstract 204 Keywords: respons, immun, cell, studi, immunotherapi\n",
      "Abstract 205 Keywords: patient, surviv, immunotherapi, result, studi\n",
      "Abstract 206 Keywords: surviv, associ, immunotherapi, treatment, studi\n",
      "Abstract 207 Keywords: tumor, cell, associ, respons, result\n",
      "Abstract 208 Keywords: therapi, immun, respons, introduct, treatment\n",
      "Abstract 209 Keywords: therapi, clinic, respons, immun, use\n",
      "Abstract 210 Keywords: cell, cancer, immun, result, express\n",
      "Abstract 211 Keywords: respons, cell, clinic, immunotherapi, patient\n",
      "Abstract 212 Keywords: treatment, clinic, cell, use, patient\n",
      "Abstract 213 Keywords: patient, tumor, therapi, respons, clinic\n",
      "Abstract 214 Keywords: immunotherapi, cancer, respons, surviv, tumor\n",
      "Abstract 215 Keywords: patient, analysi, associ, surviv, respons\n",
      "Abstract 216 Keywords: therapi, cancer, treatment, immunotherapi, analysi\n",
      "Abstract 217 Keywords: cancer, express, tumor, immun, conclus\n",
      "Abstract 218 Keywords: patient, clinic, use, cancer, immunotherapi\n",
      "Abstract 219 Keywords: use, method, result, conclus, patient\n",
      "Abstract 220 Keywords: patient, immunotherapi, cancer, analysi, studi\n",
      "Abstract 221 Keywords: tumor, immun, cell, express, analysi\n",
      "Abstract 222 Keywords: patient, treatment, studi, cancer, analysi\n",
      "Abstract 223 Keywords: respons, patient, cancer, analysi, tumor\n",
      "Abstract 224 Keywords: cell, express, tumor, therapi, studi\n",
      "Abstract 225 Keywords: express, cell, immunotherapi, cancer, clinic\n",
      "Abstract 226 Keywords: tumor, cell, associ, therapi, immun\n",
      "Abstract 227 Keywords: respons, surviv, patient, analysi, therapi\n",
      "Abstract 228 Keywords: patient, immun, use, associ, therapi\n",
      "Abstract 229 Keywords: express, immun, cell, use, cancer\n",
      "Abstract 230 Keywords: analysi, cell, cancer, method, express\n",
      "Abstract 231 Keywords: express, cell, tumor, therapi, cancer\n",
      "Abstract 232 Keywords: patient, respons, surviv, clinic, result\n",
      "Abstract 233 Keywords: express, tumor, immun, cell, cancer\n",
      "Abstract 234 Keywords: patient, cell, immun, use, surviv\n",
      "Abstract 235 Keywords: cancer, patient, surviv, method, express\n",
      "Abstract 236 Keywords: patient, associ, use, surviv, clinic\n",
      "Abstract 237 Keywords: respons, immunotherapi, surviv, treatment, result\n",
      "Abstract 238 Keywords: patient, treatment, surviv, therapi, studi\n",
      "Abstract 239 Keywords: cell, cancer, tumor, patient, result\n",
      "Abstract 240 Keywords: immunotherapi, cancer, patient, therapi, use\n",
      "Abstract 241 Keywords: tumor, patient, express, associ, immun\n",
      "Abstract 242 Keywords: result, studi, use, treatment, immun\n",
      "Abstract 243 Keywords: express, cell, patient, analysi, cancer\n",
      "Abstract 244 Keywords: immun, analysi, respons, tumor, studi\n",
      "Abstract 245 Keywords: studi, patient, therapi, cancer, immunotherapi\n",
      "Abstract 246 Keywords: cell, therapi, use, treatment, immunotherapi\n",
      "Abstract 247 Keywords: respons, studi, patient, surviv, therapi\n",
      "Abstract 248 Keywords: express, analysi, immun, use, associ\n",
      "Abstract 249 Keywords: clinic, immun, immunotherapi, respons, tumor\n",
      "Abstract 250 Keywords: patient, surviv, immun, cancer, result\n",
      "Abstract 251 Keywords: treatment, clinic, cell, method, therapi\n",
      "Abstract 252 Keywords: tumor, immun, immunotherapi, analysi, surviv\n",
      "Abstract 253 Keywords: immun, patient, cell, treatment, therapi\n",
      "Abstract 254 Keywords: respons, clinic, patient, tumor, immun\n",
      "Abstract 255 Keywords: cell, cancer, tumor, express, therapi\n",
      "Abstract 256 Keywords: treatment, patient, studi, use, respons\n",
      "Abstract 257 Keywords: surviv, tumor, therapi, cancer, clinic\n",
      "Abstract 258 Keywords: studi, respons, clinic, immunotherapi, immun\n",
      "Abstract 259 Keywords: clinic, immun, method, studi, conclus\n",
      "Abstract 260 Keywords: tumor, therapi, immun, cell, studi\n",
      "Abstract 261 Keywords: patient, cancer, therapi, studi, clinic\n",
      "Abstract 262 Keywords: associ, use, method, tumor, patient\n",
      "Abstract 263 Keywords: patient, surviv, associ, studi, express\n",
      "Abstract 264 Keywords: treatment, patient, immun, studi, immunotherapi\n",
      "Abstract 265 Keywords: tumor, immun, cell, method, associ\n",
      "Abstract 266 Keywords: cancer, treatment, immunotherapi, immun, patient\n",
      "Abstract 267 Keywords: patient, respons, immun, analysi, associ\n",
      "Abstract 268 Keywords: immunotherapi, patient, clinic, cancer, respons\n",
      "Abstract 269 Keywords: patient, treatment, immunotherapi, surviv, clinic\n",
      "Abstract 270 Keywords: tumor, immun, treatment, associ, use\n",
      "Abstract 271 Keywords: cell, tumor, express, use, immun\n",
      "Abstract 272 Keywords: use, patient, surviv, therapi, immun\n",
      "Abstract 273 Keywords: respons, studi, treatment, cancer, patient\n",
      "Abstract 274 Keywords: surviv, patient, use, analysi, studi\n",
      "Abstract 275 Keywords: treatment, patient, clinic, associ, surviv\n",
      "Abstract 276 Keywords: tumor, cell, immunotherapi, cancer, method\n",
      "Abstract 277 Keywords: therapi, patient, cancer, associ, conclus\n",
      "Abstract 278 Keywords: cell, associ, clinic, use, analysi\n",
      "Abstract 279 Keywords: therapi, patient, surviv, result, immun\n",
      "Abstract 280 Keywords: treatment, studi, cancer, patient, associ\n",
      "Abstract 281 Keywords: cancer, immun, express, treatment, surviv\n",
      "Abstract 282 Keywords: express, immun, cell, immunotherapi, tumor\n",
      "Abstract 283 Keywords: treatment, use, patient, therapi, clinic\n",
      "Abstract 284 Keywords: treatment, patient, clinic, studi, use\n",
      "Abstract 285 Keywords: cancer, patient, therapi, immunotherapi, tumor\n",
      "Abstract 286 Keywords: cell, cancer, studi, treatment, therapi\n",
      "Abstract 287 Keywords: therapi, patient, treatment, analysi, clinic\n",
      "Abstract 288 Keywords: patient, respons, surviv, result, associ\n",
      "Abstract 289 Keywords: therapi, patient, surviv, tumor, studi\n",
      "Abstract 290 Keywords: express, cell, associ, patient, analysi\n",
      "Abstract 291 Keywords: express, patient, analysi, cell, studi\n",
      "Abstract 292 Keywords: patient, surviv, tumor, result, express\n",
      "Abstract 293 Keywords: patient, respons, surviv, cell, treatment\n",
      "Abstract 294 Keywords: patient, respons, treatment, cancer, clinic\n",
      "Abstract 295 Keywords: patient, surviv, respons, tumor, express\n",
      "Abstract 296 Keywords: express, cell, tumor, immunotherapi, result\n",
      "Abstract 297 Keywords: patient, cell, surviv, associ, conclus\n",
      "Abstract 298 Keywords: clinic, patient, immun, use, treatment\n",
      "Abstract 299 Keywords: patient, clinic, use, immunotherapi, cancer\n",
      "Abstract 300 Keywords: therapi, patient, treatment, clinic, immun\n",
      "Abstract 301 Keywords: analysi, use, tumor, cancer, express\n",
      "Abstract 302 Keywords: treatment, studi, patient, surviv, cell\n",
      "Abstract 303 Keywords: use, studi, associ, clinic, cell\n",
      "Abstract 304 Keywords: use, patient, clinic, conclus, treatment\n",
      "Abstract 305 Keywords: express, cell, tumor, immun, cancer\n",
      "Abstract 306 Keywords: cell, tumor, respons, therapi, studi\n",
      "Abstract 307 Keywords: patient, immun, cell, immunotherapi, associ\n",
      "Abstract 308 Keywords: tumor, immun, therapi, cell, immunotherapi\n",
      "Abstract 309 Keywords: therapi, patient, cancer, tumor, immun\n",
      "Abstract 310 Keywords: therapi, use, cancer, associ, surviv\n",
      "Abstract 311 Keywords: immunotherapi, patient, therapi, immun, treatment\n",
      "Abstract 312 Keywords: immunotherapi, method, patient, result, introduct\n",
      "Abstract 313 Keywords: patient, immunotherapi, clinic, studi, cancer\n",
      "Abstract 314 Keywords: clinic, therapi, treatment, immun, associ\n",
      "Abstract 315 Keywords: associ, patient, surviv, use, analysi\n",
      "Abstract 316 Keywords: treatment, immunotherapi, patient, surviv, therapi\n",
      "Abstract 317 Keywords: therapi, treatment, cancer, surviv, use\n",
      "Abstract 318 Keywords: clinic, cell, patient, surviv, therapi\n",
      "Abstract 319 Keywords: treatment, immunotherapi, patient, associ, use\n",
      "Abstract 320 Keywords: express, immunotherapi, respons, patient, tumor\n",
      "Abstract 321 Keywords: cell, patient, clinic, use, result\n",
      "Abstract 322 Keywords: patient, surviv, clinic, immun, use\n",
      "Abstract 323 Keywords: patient, studi, respons, express, treatment\n",
      "Abstract 324 Keywords: patient, studi, result, conclus, method\n",
      "Abstract 325 Keywords: cancer, cell, express, analysi, patient\n",
      "Abstract 326 Keywords: cancer, clinic, express, analysi, immun\n",
      "Abstract 327 Keywords: cell, express, tumor, immun, use\n",
      "Abstract 328 Keywords: cancer, patient, therapi, result, clinic\n",
      "Abstract 329 Keywords: patient, respons, surviv, immunotherapi, tumor\n",
      "Abstract 330 Keywords: cell, respons, studi, analysi, immun\n",
      "Abstract 331 Keywords: patient, surviv, tumor, clinic, respons\n",
      "Abstract 332 Keywords: cell, patient, immun, immunotherapi, use\n",
      "Abstract 333 Keywords: cancer, express, immun, analysi, associ\n",
      "Abstract 334 Keywords: patient, therapi, respons, immun, use\n",
      "Abstract 335 Keywords: surviv, treatment, therapi, express, patient\n",
      "Abstract 336 Keywords: associ, cancer, patient, immunotherapi, result\n",
      "Abstract 337 Keywords: express, use, tumor, cell, surviv\n",
      "Abstract 338 Keywords: patient, analysi, clinic, surviv, therapi\n",
      "Abstract 339 Keywords: patient, treatment, cancer, associ, surviv\n",
      "Abstract 340 Keywords: express, patient, associ, cell, use\n",
      "Abstract 341 Keywords: patient, cancer, respons, immun, treatment\n",
      "Abstract 342 Keywords: conclus, method, patient, result, introduct\n",
      "Abstract 343 Keywords: clinic, patient, treatment, therapi, use\n",
      "Abstract 344 Keywords: therapi, clinic, cell, treatment, patient\n",
      "Abstract 345 Keywords: cell, tumor, express, immun, respons\n",
      "Abstract 346 Keywords: treatment, cancer, clinic, result, analysi\n",
      "Abstract 347 Keywords: respons, surviv, tumor, studi, result\n",
      "Abstract 348 Keywords: respons, patient, surviv, clinic, studi\n",
      "Abstract 349 Keywords: tumor, express, therapi, studi, analysi\n",
      "Abstract 350 Keywords: clinic, therapi, immun, cell, immunotherapi\n",
      "Abstract 351 Keywords: therapi, analysi, patient, use, associ\n",
      "Abstract 352 Keywords: cell, patient, tumor, clinic, studi\n",
      "Abstract 353 Keywords: treatment, patient, therapi, introduct, use\n",
      "Abstract 354 Keywords: patient, use, cancer, associ, result\n",
      "Abstract 355 Keywords: immunotherapi, patient, respons, analysi, tumor\n",
      "Abstract 356 Keywords: cancer, cell, treatment, result, immun\n",
      "Abstract 357 Keywords: therapi, clinic, result, use, patient\n",
      "Abstract 358 Keywords: cell, use, express, patient, clinic\n",
      "Abstract 359 Keywords: express, use, patient, surviv, result\n",
      "Abstract 360 Keywords: surviv, patient, studi, cancer, analysi\n",
      "Abstract 361 Keywords: surviv, analysi, respons, patient, studi\n",
      "Abstract 362 Keywords: analysi, surviv, patient, cancer, immunotherapi\n",
      "Abstract 363 Keywords: analysi, patient, immunotherapi, cancer, therapi\n",
      "Abstract 364 Keywords: cancer, cell, associ, analysi, patient\n",
      "Abstract 365 Keywords: use, clinic, immun, studi, conclus\n",
      "Abstract 366 Keywords: cancer, clinic, cell, immun, patient\n",
      "Abstract 367 Keywords: patient, studi, result, cell, conclus\n",
      "Abstract 368 Keywords: respons, patient, express, associ, immun\n",
      "Abstract 369 Keywords: use, result, analysi, studi, conclus\n",
      "Abstract 370 Keywords: cell, result, express, respons, immun\n",
      "Abstract 371 Keywords: patient, respons, cell, studi, tumor\n",
      "Abstract 372 Keywords: analysi, patient, surviv, immun, use\n",
      "Abstract 373 Keywords: result, immun, studi, immunotherapi, cancer\n",
      "Abstract 374 Keywords: cancer, respons, studi, method, analysi\n",
      "Abstract 375 Keywords: cancer, express, tumor, analysi, treatment\n",
      "Abstract 376 Keywords: cell, tumor, immun, therapi, express\n",
      "Abstract 377 Keywords: treatment, cancer, therapi, patient, immunotherapi\n",
      "Abstract 378 Keywords: patient, studi, use, treatment, therapi\n",
      "Abstract 379 Keywords: patient, associ, cancer, therapi, use\n",
      "Abstract 380 Keywords: cancer, patient, respons, cell, treatment\n",
      "Abstract 381 Keywords: immun, surviv, express, immunotherapi, associ\n",
      "Abstract 382 Keywords: surviv, use, therapi, method, result\n",
      "Abstract 383 Keywords: studi, patient, surviv, tumor, cancer\n",
      "Abstract 384 Keywords: therapi, patient, surviv, result, studi\n"
     ]
    }
   ],
   "source": [
    "for i, keywords in enumerate(top_keywords_per_abstract):\n",
    "    print(f\"Abstract {i+1} Keywords: {', '.join(keywords)}\")"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-10-03T11:49:56.174812709Z",
     "start_time": "2023-10-03T11:49:56.128794451Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "tumor: 128\n",
      "cell: 137\n",
      "therapi: 125\n",
      "express: 80\n",
      "immunotherapi: 89\n",
      "cancer: 121\n",
      "treatment: 112\n",
      "patient: 231\n",
      "result: 63\n",
      "surviv: 106\n",
      "analysi: 75\n",
      "associ: 81\n",
      "respons: 96\n",
      "studi: 99\n",
      "use: 109\n",
      "clinic: 94\n",
      "immun: 121\n",
      "method: 26\n",
      "conclus: 20\n",
      "introduct: 7\n"
     ]
    }
   ],
   "source": [
    "# Create an empty dictionary to store word counts\n",
    "flattened_list = [item for sublist in top_keywords_per_abstract for item in sublist]\n",
    "word_count = {}\n",
    "\n",
    "# Loop through the words and count their occurrences\n",
    "for word in flattened_list:\n",
    "    if word in word_count:\n",
    "        word_count[word] += 1\n",
    "    else:\n",
    "        word_count[word] = 1\n",
    "\n",
    "# Print the word counts\n",
    "for word, count in word_count.items():\n",
    "    print(f'{word}: {count}')"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-10-03T11:51:33.668367650Z",
     "start_time": "2023-10-03T11:51:33.662038803Z"
    }
   }
  },
  {
   "cell_type": "markdown",
   "source": [
    "# Topic Modeling and Keyword Extraction"
   ],
   "metadata": {
    "collapsed": false
   }
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "outputs": [],
   "source": [
    "# Apply Topic Modeling LDA:\n",
    "\n",
    "from sklearn.decomposition import LatentDirichletAllocation\n",
    "\n",
    "# Initialize LDA model\n",
    "num_topics = 10  # adjust this number \n",
    "lda_model = LatentDirichletAllocation(n_components=num_topics, random_state=42)\n",
    "\n",
    "# Fit LDA model to TF-IDF matrix\n",
    "lda_model.fit(tfidf_matrix)\n",
    "\n",
    "# Get the document-topic matrix\n",
    "doc_topic_matrix = lda_model.transform(tfidf_matrix)\n",
    "\n",
    "# Get the topic-term matrix\n",
    "topic_term_matrix = lda_model.components_"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-10-03T11:53:49.028000209Z",
     "start_time": "2023-10-03T11:53:48.242399105Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Topic 1: respons, patient, immunotherapi, tumor, immun, clinic, treatment, studi, surviv, result\n",
      "Topic 2: cell, tumor, immun, cancer, express, result, respons, use, therapi, patient\n",
      "Topic 3: patient, surviv, associ, studi, cancer, result, analysi, conclus, use, treatment\n",
      "Topic 4: express, conclus, therapi, associ, introduct, respons, method, clinic, result, tumor\n",
      "Topic 5: therapi, patient, treatment, immunotherapi, clinic, immun, cancer, surviv, use, introduct\n",
      "Topic 6: express, tumor, immun, analysi, cell, patient, cancer, use, immunotherapi, surviv\n",
      "Topic 7: patient, treatment, studi, use, clinic, result, cancer, method, introduct, conclus\n",
      "Topic 8: express, conclus, therapi, associ, introduct, respons, method, clinic, result, tumor\n",
      "Topic 9: cancer, patient, treatment, immunotherapi, therapi, tumor, clinic, respons, cell, use\n",
      "Topic 10: express, conclus, therapi, associ, introduct, respons, method, clinic, result, tumor\n"
     ]
    }
   ],
   "source": [
    "num_top_words = 10  # Adjust the number of top words as needed\n",
    "for topic_idx, topic in enumerate(topic_term_matrix):\n",
    "    top_words_idx = topic.argsort()[:-num_top_words - 1:-1]\n",
    "    top_words = [feature_names[i] for i in top_words_idx]\n",
    "    print(f\"Topic {topic_idx + 1}: {', '.join(top_words)}\")"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-10-03T11:53:59.411570856Z",
     "start_time": "2023-10-03T11:53:59.390187473Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "outputs": [],
   "source": [],
   "metadata": {
    "collapsed": false
   }
  }
 ],
 "metadata": {
  "language_info": {
   "name": "python"
  },
  "orig_nbformat": 4,
  "kernelspec": {
   "name": "python3",
   "language": "python",
   "display_name": "Python 3 (ipykernel)"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
